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ABSTRACT IN ENGLISH 
Disturbances in mitochondrial energy metabolism lead to severe effects on human health. To fulfill 
their important functions, mitochondria are organized in an interconnected network, providing energy 
and biosynthetic intermediates necessary for cellular homoeostasis and tissue function.  
Methylmalonic aciduria (MMA) is a rare inborn error of metabolism due to the mutation of the 
mitochondrial enzyme methylmalonyl-CoA mutase (MUT) catalyzing the conversion of 
methylmalonyl-CoA to succinyl-CoA requiring vitamin B12 as an essential co-factor. The reaction 
fuels metabolites from the break-down of branched chain amino acids, odd chain fatty acids, 
cholesterol and propionic acid into the Krebs cycle (TCA). Mutations in the recessively inherited 
MUT-gene lead to a partial mut(-) or complete mut(0) loss of MUT function. MMA clinically results 
in severe metabolic acidosis due to accumulation of organic acids (predominantly methylmalonic 
acid), hyper-ammonaemia and an acute, life-threatening metabolic crisis usually manifesting in the 
neonatal period. 
MUT is expressed in all tissue organs; high expression levels are found in the kidney, where 
mitochondria provide energy for transport processes mediated by renal tubular cells. Renal tubular 
dysfunction and chronic kidney disease (CKD) due to tubulo-interstitial lesions are the main long-term 
consequence in MMA patients. The pathomechanisms linking mitochondrial enzyme deficiency to 
renal epithelial dysfunction in basically all MMA patients remains largely unknown. Onset and 
progression of CKD seems to be linked to the severity of the mutation and is most pronounced in 
mut(0) patients, showing the highest levels of methylmalonic acid. Main hypothesis for CKD in MMA 
are abnormal mitochondrial function due to energetic depletion of the TCA, oxidative stress and 
potentially toxic effects of accumulating methylmalonic acid. 
On top of suffering from a life-threatening disease, CKD imposes a high morbidity and mortality risk 
on MMA patients. The identification of kidney-protective measures and the in-depth understanding of 
the underlying pathomechanisms inducing CKD is crucial to slow down or even prevent severe kidney 
damage in a next step. Therefore, the aim of the thesis was to 1) investigate the stabilizing effect of co-
factor application for renal protection in a mildly affected MMA patient and 2) to provide a 
(potentially targetable) link between MUT deficiency, mitochondrial dysfunction and renal epithelial 
cell damage in different in vitro and in vivo models. 
The obtained data provide evidence, that even mild forms of MMA inevitably lead to CKD and 
underline the importance of early and adequate co-factor supplementation in vitamin B12-responsive 
MMA patients. Maintenance of mitochondrial integrity is a key requirement to preserve cellular 
homeostasis and function particularly in highly specialized renal epithelial cells. Using different 
MMA-models we provide evidence, that MUT deficiency leads to severe disturbance of the 
mitochondrial network in terms of morphology, function and homeostasis. Dysregulation of the 
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organelle-specific mitochondrial quality control (MQC) system initiated by PINK1 and parkin induces 
impaired autophagy-mediated clearance of dysfunctional mitochondria. As a consequence, the cells 
accumulate autophagic proteins and mitochondrial reactive oxygen species potentiating cellular and 
tissue damage. Mitochondria-targeted treatment with the anti-oxidant Mito-TEMPO restores 
mitochondrial integrity and homeostasis, improves organelle-specific targeting by PINK1 and induces 
autophagic degradation of dysfunctional mitochondria. These changes lead to a reduction of the 
cellular damage process. 
The results provide a link between mitochondrial dysfunction and kidney damage in MMA and 
highlight the importance of the MQS for mitochondrial integrity and homeostasis. Mitochondrial-
targeted treatment offers new therapeutic options to address renal epithelial damage down-stream to 
primary mitochondrial diseases. 
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ABSTRACT IN GERMAN 
Störungen des mitochondrialen Energiestoffwechsels führen beim Menschen zu schwerwiegenden 
gesundheitlichen Komplikationen. Um wichtige Funktionen wie Energiebereitstellung und 
Generierung von intrazellulären Botenstoffen ausführen zu können, sind Mitochondrien in eng 
verknüpften Netzwerken organisiert, welche Homöostase und Gewebsfunktion aufrechterhalten. 
Methylmalonazidurie (MMA) ist eine seltene, angeborene Stoffwechselkrankheit, welche durch 
Mutationen des mitochondrialen Enzyms Methylmalonyl-CoA Mutase (MUT) verursacht wird. MUT 
ist unter Verwendung des essentiellen Co-Faktors Vitamin B12 für die Umwandlung von 
Methylmalonyl-CoA in Succinyl-CoA verantwortlich. Durch die Reaktion werden Metabolite, welche 
aus dem Abbau verzweigtkettiger Aminosäuren, ungeradzahliger Fettsäuren, Cholesterol und 
Propionsäure entstanden sind, in den Krebs-Zyklus eingespeist. Mutationen im autosomal-rezessiv 
vererbten MUT-Gen führen entweder zu einem partiellen mut(-) oder kompletten Verlust mut(0) der 
MUT-Enzymaktivität. Klinisch manifestiert sich MMA klassischerweise in der neonatalen Periode mit 
einer schwerwiegenden metabolischen Azidose (bedingt durch die Akkumulation organischer Säuren, 
vorwiegend Methylmalonsäure), sowie Hyperammonämie und einer akuten, lebensbedrohlichen 
metabolischen Krise.  
MUT ist in allen Geweben des menschlichen Körpers exprimiert. Hohe Konzentrationen finden sich 
insbesondere in der Niere, wo Mitochondrien Energie für Transportprozesse liefern, welche von den 
renalen Tubulusepithelzellen ausgeführt werden. Renale tubuläre Dysfunkion und chronische 
Niereninsuffizienz (CNI) bedingt durch tubulo-interstitielle Läsionen sind die hauptsächlich 
beobachteten Langzeitkomplikationen bei MMA-Patienten. Der Pathomechanismus, welcher für die 
Verknüpfung des mitochondrialen Enzymmangels mit der renalen, epithelialen Dysfunktion bei 
faktisch allen MMA-Patienten verantwortlich ist, ist weitgehend unbekannt. Beginn und Progression 
der CNI scheinen mit der Schwere der Mutation verknüpft zu sein und werden daher am häufigsten bei 
Mut(0) Patienten gefunden, welche auch die höchste Konzentration an Methylmalonsäure aufweisen. 
Als Hauptursache für CNI bei MMA wird eine mitochondriale Dysfunktion angesehen, welche durch 
energetische Verarmung des Krebs-Zyklus, akkumulierenden oxidativen Stress sowie potentiell 
toxische Effekte der anflutenden Methylmalonsäure verursacht und unterhalten wird. 
Das ohnehin erhöhte Morbiditäts- und Mortalitätsrisiko erfährt durch die CNI bei MMA-Patienten 
eine zusätzliche Steigerung. Die Identifizierung von Nieren-protektiven Maßnahmen und das 
eingehende Verständnis der der CNI zugrundeliegenden Pathomechanismen sind daher essentiell, um 
in einem nächsten Schritt eine Nierenschädigung zu verlangsamen oder sogar zu verhindern. Das Ziel 
der vorliegenden Arbeit war daher 1) die stabilisierende Wirkung der Co-Faktor Applikation auf die 
Nierenfunktion bei einem mild betroffenen, Vitamin B12-responsiven MMA-Patienten zu evaluieren 
sowie 2) zu untersuchen, ob eine (potentiell behandelbare) Verbindung zwischen der Defizienz von 
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MUT, mitochondrialer Dysfunktion und Nierenepithelzellschädigung in verschiedenen in vitro- und in 
vivo- Modellen herzustellen ist. 
Die erhobenen Daten belegen, dass auch milde Formen von MMA unweigerlich zu CNI führen und 
unterstreichen die Bedeutung einer frühen und adäquaten Co-Faktor Supplementierung in Vitamin 
B12-responsiven MMA-Patienten. Die Aufrechterhaltung mitochondrialer Integrität ist -insbesondere 
in hoch spezialisierten Nierenepithelzellen- eine wesentliche Voraussetzung für die Erhaltung von 
zellulärer Homöostase und Funktion. Unsere Daten belegen, dass MUT-Defizienz zu einer erheblichen 
Störung des mitochondrialen Netzwerkes in Bezug auf Morphologie, Funktion und Homöostase führt. 
Eine Dysregulation der Organell-spezifischen mitochondrialen Qualitätskontrolle (MQK), welche 
durch PINK1 und Parkin mediiert wird, führt zu einem reduzierten Abbau dysfunktionaler 
Mitochondrien über Autophagie. Infolgedessen kommt es zu einer Akkumulation von Autophagie-
spezifischen Proteinen und mitochondrialem oxidativen Stress, welche zu Zell- und Gewebeschäden 
führen. Eine zielgerichtete Behandlung der Mitochondrien mit dem Anti-Oxidans MitoTEMPO stellt 
die mitochondriale Integrität und Homöostase wieder her, verbessert das Organell-spezifische 
Targeting durch PINK1 und induziert den Abbau dysfunktioneller Mitochondrien durch Autophagie. 
Die beschriebenen Effekte führen zu einer Reduktion der zellulären Schädigung. 
Die Ergebnisse weisen auf einen kausalen Zusammenhang zwischen mitochondrialer Dysfunktion und 
Nierenschäden bei MMA-Patienten hin und heben die Bedeutung der MQK für mitochondriale 
Integrität und Homöostase hervor. Eine zielgerichtete Behandlung der Mitochondrien mit einem Anti-
Oxidans bietet neue therapeutische Optionen, um renale epitheliale Schäden zu vermindern, welche 
durch primäre mitochondriale Erkrankungen verursacht werden.  
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I. INTRODUCTION 
I.1 Inborn errors of metabolism 
I.1.1 Rare diseases  
A disease is considered as “rare” in Europe, when it affects less than 1:2000 individuals. More than 
7000 rare diseases, most of them of genetic origin, are currently identified. If the total patient number 
for each rare disease is marginal, taken together more than 30 million subjects are presenting with a 
rare disease. More than half of rare diseases affect children of which 35% will not celebrate their 5th 
birthday (EU commission for rare diseases, 2008).  
Diagnoses of rare diseases are often delayed and complicated by variable prevalence between different 
populations and clinical heterogeneity: The age of onset, severity and progression of symptoms may 
be very different in patients and even siblings suffering from the same disease caused by identic 
mutations (Devuyst, 2014). Insufficient knowledge on ontology may also complicate prognosis and 
diagnosis. Diﬀerent mutations may influence the same biological pathways and give rise to similar 
clinical, biochemical, and histopathological features, like e.g. in Fanconi’s syndrome. Another 
complicating aspect is the absence of valid biomarkers for diagnosis and follow-up (Devuyst, 2014). 
Even if treatment is available a monitoring of effects (and conclusions from the observations) is made 
impossible. This may not only delay treatment of potentially treatable diseases but also hampers the 
patients’ quality of live due to chronic, progressive and often live-threatening aspects of the disease 
(EU commission for rare diseases, 2008).  
To improve the patients’ situation, a combination of multi-level approaches has to be applied: 
Networks and registries need to collect patient-related information and disease courses. Omics 
technologies are needed to screen patient’s samples for novel biomarkers which can be used for 
diagnosis and follow-up. Next-generation sequencing will help to simultaneously investigate all 
relevant genes for a phenotype. To link disease genes and clinical phenotypes, efficient model 
organisms (e.g. mouse, zebrafish) and appropriate cellular systems to study disease-related 
mechanisms are needed. The combination of different approaches will lead to a broader understanding 
of the underlying defects, a better understanding of the disease causing pathomechanisms and 
hopefully to identification of potential new treatment options. 
 
I.1.2 Classification of inborn errors of metabolism  
Inborn errors of metabolism (IEM) cause hereditary metabolic diseases and belong to the group of rare 
diseases. The overall incidence of patients affected by a metabolic disease is around 40/100.000 
(Applegarth, 2000). Sub-groups may go down to 1:100.000 and lower.  
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IEM classically are monogenic diseases leading to insufficiency or complete loss of enzymatic activity 
in the affected pathway. As consequence, metabolites up-stream of the deficient enzyme accumulate 
and may cause disease manifestations whereas down-stream depletion of important substrates and 
intermediary products may also lead to deleterious effects. Most IEMs are inherited in an autosomal-
recessive mode which explains why they are particularly common in societies with a high percentage 
of consanguinity (Al Jasmi, 2015). Few of them are X-linked affecting exclusively males or few 
females due to unfavorable X-inactivation. De novo mutations in the affected patient can occur. IEM 
are structurally caused by small scale (e.g. missense and nonsense mutations) and large-scale 
mutations (particularly large deletions). Ethnic predomination may be observed in sub-groups like e.g. 
Ashkenazi Jews and Finns (Jimenez-Sanchez, 2014). 
The pattern of tissue-specific gene expression is different for each IEM. Some affected genes might be 
widely expressed (“-house-keeping genes-”) while others fulfill specific tasks in highly specified 
tissues (e.g. rhodopsin in photoreceptors in the eye). 70% of the genes altered in IEM lead to a multi-
systemic disease reflecting how tightly integrated and interconnected metabolic pathways are 
(Jimenez-Sanchez, 2014). 
 
I.1.2.1 Presentation of inborn errors of metabolism 
Inborn errors of metabolism can present at any age and often show multi-system involvement. That is 
why they are often divided into acute onset (within the neonatal period), chronic intermittent form 
(“on-/off”-phenomenon at any age) and chronic progressive form (onset and progression at any age). 
However, there are characteristic diagnostic criteria and typical time points of manifestation for IEMs 
and that is why they are often grouped in into 5 categories according to their manifestation (Fig. 1) 
(Hoffmann, 2010):  
a) Intoxication type (aminoacidopathies, organic acidurias, urea cycle defects, galactosaemia, 
hereditary fructose intolerance)  
Patients are usually born after an uneventful pregnancy usually without any specific stigmas. They are 
typically asymptomatic within the first hours or days of life. After exposure to the substrate that 
cannot be processed due to the IEM (certain amino acids, proteins and sugars), affected children start 
to accumulate toxic molecules and metabolites which they cannot break down therefore leading to 
“intoxication”. Down-stream of the enzymatic block the system gets depleted and substrates for 
important intermediary pathways involved in energy production lack substrate. This leads to 
catabolism, further deterioration of the system and progression to a live-threatening metabolic crisis. 
Any condition resulting in catabolism (e.g. prolonged fasting, infections, fever, vaccination and 
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hormonal changes (growth, puberty, steroid therapy)) as well as overload with the un-metabolizable 
substrates (e.g. proteins, certain sugars) can induce another crisis. 
b) Reduced fasting tolerance (fatty acid oxidation, disorders of ketogenesis, glycogen storage disease 
type I, disorders of glyconeogenesis)  
These disorders usually present in fasting states or conditions with high energy demands. They may 
present initially as intoxication type diseases but more likely emerge in the second half of infancy (6-
12 months) during infections with severe hypoglycaemia and acidosis.  
c) Disturbed energy metabolism (mitochondrial disorders, long-chain fatty acid oxidation defects) 
Disorders of disturbed energy metabolism usually present at birth but may present at any life time, in 
dependence of the organ involvement, the defect and the mode of X-inactivation. Mitochondrial 
disorders characteristically show multi-organ involvement which are classically triggered by changes 
in the carbohydrate intake or infections (e.g. certain viruses). Marked and rapid deterioration with 
irreversible loss of capabilities are frequent in such episodes. Highly energy dependent organ systems 
(e.g. brain, heart, kidneys, liver) are affected in particular. 
d) Disturbed metabolism of complex molecules (peroxisomal disorders, lysosomal disorders, disorders 
of glycosylation)  
Disorders of complex molecules usually have a creeping course often starting at birth with increasing 
signs and symptoms (e.g. organ enlargement and loss of organ function) as time goes by. In contrary 
to the before mentioned, there are no metabolic crisis or acute derailments. 
e) Disturbed neurotransmission (non-ketotic hyperglycinaemia, sulfite oxidase deficiency, vitamin B6 
and pyridoxal-phosphate dependent seizures, GABA transaminase deficiency)  
Patients suffering from disturbed neurotransmission usually present immediately after birth or even 
ante-partum showing intra-uterine seizures. The symptoms are the expression of disturbed 
neurotransmitter production, up-take, recycling or processing and receptor/transporter expression. 
There is no external trigger promoting or provoking the symptoms.  
 
Figure 1: Typical age of disease manifestation and course in IEM. (Adapted from Hoffmann, 2010). 
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Among the above, the intoxication type diseases manifest with acute life-threatening metabolic crisis 
due to severe disturbance of metabolic energy metabolism and are causally treatable by fast 
intervention, if diagnosed in time. Defects in the break-down of branched chain amino acids causing 
organic acidurias are of particular interest, since they affect the mitochondrion as compartment and 
have a direct impact on cellular energy production. 
 
I.2 Disorders of branched chain amino acid metabolism 
I.2.1 Organic acidurias 
Disorders of branched chain amino acid metabolism are caused by mutations of the enzymes involved 
in the breakdown of the branched chain amino acids (BCAA) leucine, isoleucine and valine leading to 
the disturbance of intermediary metabolism. The accumulation of characteristic organic acids leads to 
the diagnosis and that is why they are also called organic acidurias (OA).  
The breakdown of the BCAAs begins with the degradation of essential amino acids to non-essential 
amino acids by transamination (Fig. 2). The process results in the generation of the corresponding 2-
oxo-branched chain organic acids which are processed to branched chain acyl coenzyme A (CoA) 
products by oxidative decarboxylation. The second step is similar in the process of breakdown of all 
BCAAs and catalyzed by the branched-chain 2-ketoacid dehydrogenase complex (BCKDH). 
Afterwards, the pathways diverge: Leucine is cleaved down to isovaleryl-CoA, finally entering the 
TCA as acetyl-CoA. Isoleucine is processed to 2-methylbutyryl-CoA and can be converted to both 
acetyl- and succinyl-CoA. Valine forms isobutyryl-CoA finally leading to propionyl-CoA and 
succinyl-CoA providing substrate for the tricarboxylic acid cycle (TCA). Propionyl-CoA is also 
produced from the breakdown of the amino acids methionine and threonine as well as from fatty acids 
with an odd number of carbons and resident bacteria from the gut. (Vockley, 2014). 
Defects in this pathway cause the 13 different organic acidurias known today. The most frequent OAs 
(maple sirup urine disease (MSUD), isovaleric aciduria (IVA), propionic aciduria (PA) and 
methylmalonic aciduria (MMA) are caused by disturbance of the intra-mitochondrial breakdown of 
BCAA and lead to accumulation of characteristic CoA derivatives and organic acids.  
Other rare disorders of BCAA metabolism are 3-methylcrotonyl-glycinuria, 3-methylglutaconic 
aciduria, short-/branched chain acyl CoA dehydrogenase deficiency, 2-methyl-3-hydroxybutyryl-CoA 
dehydrogenase deficiency, isobutyryl-CoA dehydrogenase deficiency, 3-hydroxy-isobutyric aciduria 
and malonic aciduria (Vockley, 2014), which will not be discussed in this thesis. 
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Figure 2: Summary of branched chain amino acid metabolism. Enzymes involved in the catabolism of leucine, isoleucine, and valine are 
shown in blue boxes. The 13 different organic acidurias known today are numbered and start at the level of the branched chain acyl-CoA 
dehydrogenases (1, isovaleryl-CoA dehydrogenase; 2, short/branched chain acyl-CoA dehydrogenase; and 3, isobutyryl-CoA 
dehydrogenase). The remaining enzymes in the pathway are 4, 3-methylcrotanyl-CoA carboxylase; 5, tiglyl-CoA hydratase; 6, 
methacrylyl-CoA hydratase; 7, 3-methylglutaconyl-CoA hydratase; 8, 2-mthyl-3-hydroxybutyryl-CoA dehydrogenase; 9, 3-
hydroxyisobutyryl-CoA deacylase; 10, 3-hydroxy-3-methylglutaryl-CoA lyase; 11, 2-methyl-acetoacetyl-CoA thiolase; 12, 3-
hydroxyisobutyryl-CoA dehydrogenase; 13, methylmalonate semialdehyde dehydrogenase. (Adapted from Valle, 2014).  
 
I.2.1.1 Presentation of organic acidurias 
The clinical presentation of the so called “classical” organic acidurias are somehow similar and can be 
divided into three main forms: i) an acute, severe neonatal onset with metabolic decompensation and 
neurological symptoms, ii) an acute-intermittent form with recurrent severe metabolic crisis, and iii) a 
chronic-progressive form presenting with rather unspecific signs like hypotonia, developmental delay 
and failure to thrive. (Saudybray, 2016) 
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Patients with the acute neonatal onset form usually have an unremarkable history with a normal 
pregnancy and delivery at full-term. After a symptom-free period there is a rapid decline of well-
being: All OAs except MSUD present with a dramatic clinical picture including dehydration, 
ketoacidosis, lactate elevation and hyperammonaemia. Hyper- and hypoglycaemia can be found. 
Blood count alterations (neutropenia, thrombocytopenia, pancytopenia) might be suggestive for a 
sepsis. Respiratory distress because of ketoacidosis may develop. Patients may present with 
hypertonic, ophistotonic episodes or axial hypotonia with limb hypertonia and myoclonic jerks. 
Seizures may develop. Cerebral oedema may lead to a bulging fontanelle and may be misinterpreted as 
a sign of a neonatal cerebral infection. If treatment is delayed (or too late) children will depict a picture 
of metabolic encephalopathy progressing to metabolic coma and death. (Baumgartner, 2014) 
The acute intermittent form is with 25% less frequent. Patients may develop normally during the first 
year(s) of live and only present in catabolic states (e.g. infections, fasting, fever) with acute metabolic 
deterioration. In-between, the episodes the patients may return to normal. Slightly elevated ammonia 
levels can be found. The development might be normal or delayed with unspecific signs like failure to 
thrive, recurrent vomiting attacks or episodic, abnormal behavior.  
Chronic progressive forms are even less specific in their manifestations. Patients may have a long 
history of muscular weakness and hypotonia in combination with progressive developmental delay and 
movements disorders. A history of gastro-intestinal problems including malnutrition and gastro-
intestinal reflux may accompany the neurological problems. Classically, patients have an aversion 
against protein rich food (Saudybray, 2016). 
 
I.2.1.2 Diagnosis of organic acidurias 
Although sharing similarities in disease presentation, each OA has its own, metabolic pattern, 
characterized by the elevation of specific metabolites in patients’ body fluids (urine and plasma). 
These metabolic fingerprints can be detected by the accumulation of characteristic organic acids in 
patients’ urine using gas chromatography mass spectrometry (GC-MS) and by tandem mass 
spectrometry (MS/MS) which is a complementary technique detecting alterations of the acylcarnitine 
profile. The latter technique exploits the fact that most acyl-CoA esters are in equilibrium with their 
corresponding acylcarnitines. A defective single enzyme leads to characteristic elevations of certain 
products of the acyl-CoA intermediary metabolism (Millington, 2000; Rashed, 1997). Both methods 
(GC-MS / MS/MS) detect metabolites and intermediary products normally found in healthy 
individuals but also elevations of metabolites which are usually absent in normal conditions 
(Chalmers, 1982; Sweetman, 1991). Metabolic deterioration may aggravate the metabolic pattern in 
the patient while it might be not very pronounced while the patient is well. The diagnosis of organic 
17 
acidurias is confirmed by enzymatic assays in patients’ cultured cell fibroblasts and finally by 
molecular genetic analysis. 
I.2.1.3 Current opinion on alterations in metabolic flux in organic acidurias 
Organic acidurias are caused by monogenic, single enzyme defects leading to an enzymatic block. 
This leads primarily to the accumulation of specific, potentially toxic products of the intermediary 
metabolism and to depletion of pathways down-stream the enzymatic block. Mechanistically, this 
results in impairment of metabolic pathways, activation of by-pass mechanisms, substrate competition 
for specific transporters and inhibition of enzymes, explaining the clinical and biochemical 
abnormalities observed in organic acidurias (Fig. 3): In order to compensate for energetic substrates 
not provided by a blocked gluconeogenic pathway, ketone body formation is up-regulated to fuel beta-
oxidation leading to ketoacidosis. Acyl-CoAs are piling up, depleting free Acetyl-CoA in the 
mitochondria. Accumulating Acyl-CoAs furthermore inhibit the N-Acetyl glutamate synthase, a 
mitochondrial enzyme catalyzing the first step of the urea cycle essential for the detoxification of 
ammonia thus leading to hyperammonaemia. Lack of free CoA inhibits the CoA-carnitine exchange 
mechanism and prevents correct oxidation of substrates from fatty and amino acid oxidation. 
As a consequence, disturbances in energy metabolism lead to mitochondrial stress expressed in 
hyperlactatemia, reduced energy production and oxidative stress (Vockley, 2014). 
 
Figure 3: Summary of altered metabolic flux in organic acidurias. CACT, carnitine acylcarnitine translocase; CoA, coenzyme A; CPT, 
carnitine palmitoyltranferase; CT, carnitine transporter; MTP, mitochondrial trifunctional protein, NAGS N-acetyl-glutamate synthase. 
PM, plasma membrane; OMM, outer mitochondrial membrane; IMM, inner mitochondrial membrane; MM, mitochondrial matrix. 
Depletion of Acetyl-CoA leads to impaired energy production from beta-oxidation and inhibition of NAGS activity resulting in 
hyperammonaemia. CoA depletion hinders beta-oxidation from fatty acid and amino acid substrates. Consequently, beta-oxidation is 
fueled by ketone bodies leading to ketoacidosis and respiratory chain dysfunction. (Adapted from: Saudubray, 2016).  
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I.2.1.4 General treatment principles of organic acidurias  
A major therapeutic goal in the management of OAs is to reduce the metabolic flux trough the affected 
pathways and restore/sustain anabolism: The protein amount is reduced by limitation of natural protein 
intake and supplementation of amino acid mixtures selectively depleted of BCAAs. A balance 
between provision of sufficient amounts of protein for development/growth and reduction of metabolic 
flux via defective pathways has to be found. Furthermore, sufficient energy intake (carbohydrates, fat) 
is required and has to be increased in situations prone to lead to catabolism (e.g. infections, fever, 
vaccinations, etc.) which can provoke a live-threatening metabolic crisis. Fasting has to be avoided by 
all means. Patients’ diets are enriched with levocarnitine to support acetyl-CoA formation and 
facilitate mitochondrial energy metabolism. Oral antibiotics can be used to reduce the propionic acid 
load produced by gut bacteria. Some enzymes (e.g. propionyl-CoA carboxylase and methylmalonyl-
CoA mutase) have an essential co-factor (biotin, adenosylcobalamin (=vitamin B12)). In the case of 
MMA, co-factor responsive patients have been described and administration of hydroxocobalamin 
(pharmacological form of adenosylcobalmin) improves their metabolic stability and outcome. In acute 
crisis, scavenger drugs (sodium benzoate, arginine hydrochloride, N-carbamylglutamate) or 
hemodialysis are needed to counteract hyperammonaemia and prevent cerebral oedema leading to 
death. In certain organic acidurias, organ transplantation can give metabolic stability (Brassier, 2013; 
Kashahahara, 2006). There is no causal cure for any of the OAs. Gene or cellular therapy are still 
pending. 
 
I.2.2 Isolated and combined forms of methylmalonic aciduria  
I.2.2.1 Isolated form of MMA 
Methylmalonic aciduria (MMA) was first described by the group of Oberholzer (Oberholzer, 1967) in 
1967. The prevalence of isolated MMA is about 1:50.000-100.000 (Sniderman 1999; Chace 2001; 
Shigematsu 2002). Isolated MMA is either caused by mutations of the mitochondrial apoenzyme 
methylmalonyl-CoA mutase (MUT) encoded by the MUT gene (60%), deficiency of the enzyme 
methylmalonyl-CoA epimerase (MCEE, very rare, few cases) or by defects in the processing of 5’-
deoxyadenosylcobalamin (AdoCbl), the essential co-factor of MUT (37%). Mutations in AdoCbl 
processing leading to isolated MMA are due to alterations in the cblA (MMAA, 25%), cblB (MMAB, 
12%) and cblD2 (MMADHC, very rare, few cases) complementation group involved in AdoCbl 
synthesis. The above changes lead to a complete loss (Mut0) or reduced function (Mut-) of MUT 
activity (Fowler, 2008; Coelho, 2008; Banerjee, 2009) hindering the conversion of D-/L-
methylmalonyl-CoA to succinyl-CoA therefore depleting the TCA cycle from anaplerotic substrate 
(Fig. 4). Biochemically, the disease is characterized by the accumulation of potentially toxic organic 
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acids (methylmalonic acid, propionate, 3-OH-propionate and 3-methylcitrate) in tissues and body 
fluids. The most abundant is methylmalonic acid which is pathognomonic and name giving for MMA 
(Kölker, 2013) (Fig. 4). Elevated propionyl carnitine (C3) levels reflecting the disturbance in 
acylcarnitine flux are found as well. Disturbed acylcarnitine flux leads to acetyl-CoA depletion of the 
TCA cycle. The accumulation of diverse monocarboxylic and dicarboxylic short-chain acyl-CoAs (C3 
in particular) lead inhibition of the N-acetyl-glutamate-synthase, the first and therefore rate limiting 
enzyme of the urea cycle (Fig. 4), explaining why secondary hyperammonaemia occurs in MMA 
patients (Wanders, R, 2014). Hydroxocobalamin responsiveness is frequently found in cblA patients, 
less frequently in cblB and Mut(-) patients and almost never in Mut(0) patients. It should be carefully 
evaluated though the prognosis is improved in responsive, treated patients. 
 
Figure 4: Consequence of mitochondrial MUT deficiency leading to accumulation of specific organic acids, energy depletion of the tricylic 
acid cycle and hyperammonaemia. (Adapted from Fowler, 2008). 
 
I.2.2.2 Combined forms of MMA 
The isolated forms of MMA have to be distinguished from a disease group presenting with combined 
methylmalonic acidemia and homocystinuria or homocystinuria alone. Isolated and combined MMAs 
are linked via cobalamin (cbl), an essential cofactor for various reactions. Cbl is taken up by a highly 
specialized mechanism in the gastrointestinal system and disturbances in the cbl metabolism can affect 
extra- and intracellular cbl trafficking and processing:  
After dietary up-take, cbl is bound to intrinsic factor and absorbed in the ileum via the cubam receptor. 
Entering the blood stream, cbl is transferred to transcobalamin and taken up by the cell via 
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endocytosis. Intrinsic factor deficiency (GIF gene) and mutations in the subunits of the cubam 
receptor (CUBN, AMN gene) as well as transcobalamin deficiency lead to methylmalonic acidemia 
and homocystinuria caused by disturbance of extracellular trafficking (Allen, 1978 (47); Allen, 1978 
(1628); Marcoullis, (1980)). After endocytic up-take in the hepatocyte, cbl is released from transferrin 
by lysosomal cleavage and exported by the cblJ complementation group with ATP-ase function 
(ABCD4) (Coelho, 2012) and the cblF complementation group (LMBRD1) (Rutsch, 2009) in a joined 
effort (Deme et al, 2014) to the cytoplasm where it undergoes cblC (MMACHC) mediated reduction. 
The processing is continued by the cblD complementation group (MMACHD), a multifunctional 
protein. From this step, 2 pathways diverge: CblD is either processed via mitochondrial synthesis and 
the cblD2, cblA and cblB complementation group to adenosylcobalamin, the essential cofactor for 
MUT (leading to isolated MMA if steps are deficient), or to methylcobalalmin, the essential cofactor 
for methionine synthase (MS) and therefore for methylation reactions. Mutations in the cblF, cblJ, 
cblC and cblD complementation groups lead to combined methylmalonic acidemia and 
homocystinuria caused by disturbance of intracellular cobalamin trafficking. 
Isolated homocystinuria is caused by mutations in the cblD1 complementation group catalyzing the 
first step of methylcobalamin synthesis needed for MS function. MS, encoded by the MTR gene (cblG 
complementation group), catalyzes the re-methylation of homocysteine to the essential amino acid 
methionine and plays a major role in the synthesis of creatine, choline and adrenaline as well as in 
desoxyribonucleic acid (DNA) methylation (Poloscheck, 2005; Hill, 2004). The transfer of methyl-
groups is carried out via S-adenosylmethionine (SAM). The product of demethylation is homocysteine 
again. With time the cob(I)alamin cofactor becomes oxidized to cob(II)alamin rendering MS inactive. 
Regeneration of MS activity requires methionine synthase reductase (MTRR, cblE complementation 
group) (Zadakova, 2002) in which SAM is used as a methyl-group donor (Leclerc, 1998; Zavadoka, 
2002). Deficiencies in CblD1, cblG and cblE complementation groups lead to isolated homocystinuria 
and low methionine concentrations.  
Disturbances affecting homocysteine and methionine metabolism clinically result in bone marrow 
deficiency, various neurological complications including hypotonia, seizures, severe mental disability 
and retinopathies. 
 
I.2.2.3 Clinical presentation of isolated MMA 
Patients with isolated MMA typically present in the neonatal period after protein intake with 
hyperammonaemia and severe ketoacidosis leading to an acute, life-threatening metabolic crisis 
(Ciani, 2000). Moderate lactic acidosis and as well as high glycine levels are frequently found. Neutro- 
and thrombopenia in combination with vomiting and abdominal distension may lead to confusion with 
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a sepsis like clinical pattern. Poor weight gain in the postnatal period is usually observed. Acute 
hemorrhages have been described in a few cases probably due to inappropriate correction of metabolic 
acidosis. Hypotonia and seizures progressing to lethargy, coma and death evoke if treatment is 
insufficient or delayed (Saudubray, 2016). 
Classical major long-term consequences are “metabolic-stroke”-like episodes causing choreo-athetotic 
movement disorders and dystonia due to basal ganglia damage (Heidenreich, 1988; Korf, 1986) and 
tubule-interstitial nephritis (Dudley, 1998; Coman, 2006) leading inevitably to end-stage renal disease. 
Chronic vomiting and aversion to protein-rich food frequently lead to failure to thrive. Patients may 
present with severe hypotonia, seizures and movement disorders accompanied by severe intellectual 
disability. Late-onset optic nerve neuropathy with impaired vision is another insidious complication. 
Various immunological abnormalities including recurrent infections and pancytopenia have been 
described. Some patients will present skin disorders resembling acrodermatitis enteropathica-like 
syndrome (Lane, 2007). 
Metabolic crisis can be triggered at any time by catabolism due to e.g. fasting, infections, vaccinations 
or protein overload. Predictions of the clinical outcome are very difficult to make. There seems to be a 
correlation between the severity of the mutation and the general disease course. Patients suffering from 
MMA due to Mut(0) or cblB deficiency have the lowest (or no) MUT activity and the highest MMA 
levels and are usually more severely affected than Mut(-) or CblA patients. Especially in the kidney 
disease progression is dependent on the severity of the defect and MMA concentrations (Hörster, 
2007). Hydroxocobalamin responsiveness is known to be a protective factor (Haarmann, 2013). For 
the neurological outcome the frequency of metabolic crisis, early, sufficient management and the 
damage caused by the previous crises can be used as a prognostic factor (Hörster, 2009).  
 
I.2.2.4 Diagnostic testing in MMA 
The clinical pattern described above leads to the suspicion of MMA. Isolated MMA is diagnosed using 
tandem mass spectrometry (MS/MS) which reveals an abnormal acylcarnitine profile showing 
elevated levels of propionyl-carnitine (C3). C3 detection alone will not allow the diagnosis of MMA, 
since it is also elevated in PA due to propionyl-CoA carboxylase deficiency just one step up-stream of 
MUT. A characteristic pattern for MMA can be identified performing urinary organic acid analysis 
with gas chromatography–mass spectrometry (GC-MS) which will reveal the pathognomonic 
metabolite methylmalonic acid as well as 3-methylcitric acid and 3-OH propionic acid besides others. 
Amino acid chromatography will display non-specific abnormalities such as hyperglycinaemia and 
hyperalaninaemia. Glutamine levels tend to be low due to metabolic acidosis (Nissim, 1998). The 
findings need to be further classified either by molecular genetic or enzymatic studies in patients’ skin 
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fibroblasts in order to group the findings into MUT deficiency or complementation group deficiency 
by propionate incorporation assay (Willard, 1976) and MUT enzyme assay in the presence or absence 
of the essential cofactor adenosylcobalamin (Baumgartner, 1983). Complementation analyses are 
needed for exact assignment to a complementation group (Gravel, 1976). The final diagnosis is 
confirmed by genetic testing in the proband with subsequent confirmation of the mutation in the 
parents. 
I.2.2.5 Treatment options in isolated MMA 
Treatment principles in MMA have to be divided into acute and chronic interventions.  
Acute metabolic crisis requires the complete stop of protein-intake for maximal 24 (-48h). High 
dosage of i.v. glucose if necessary in combination with insulin is required to induce anabolism. 
Application of i.v. lipids can be used to support anabolism. Hyperammonaemia is a potentially life-
threatening complication accounting for a high percentage of mental disability in the patients and 
ammonia levels have to be reduced as fast and effective as possible. This can be achieved by the use of 
scavenger drugs (sodium benzoate, L-arginine hydrochloride) and N-carbamylglutamate antagonizing 
propionyl-CoA induced hyperammonaemia. Hyerammonaemia is most efficiently reduced by 
hemodialysis, -filtration or peritoneal dialysis. However, in certain circumstances due to circulation 
issues in babies and little experience for this age group, novel therapies using peritoneal dialysis and 
small nanoparticles highly specific binding ammonia without causing peritoneal damage might soon 
become novel therapeutic options (Devuyst, 2015). 
The principles of long-term treatment are sufficient calorie intake to avoid catabolism and a protein 
restricted diet especially limited for the intake of the precursor amino acids which cannot be broken 
down. Carnitine is supplemented at 100 mg/kg/d to fuel mitochondrial energy metabolism. Co-factor 
responsive patients will profit from hydroxocobalamin supplementation.  
These measures, however, do not prevent metabolic derailments and long-term complications. Chronic 
kidney disease is inevitably diagnosed in every MMA patient earlier or later in dependency of the 
severity of the mutation and methylmalonic acid concentrations. Hemo- and peritoneal dialysis are 
needed to bridge the time until kidney transplantation. 
Since liver and kidney are the organs with the highest MUT expression (Wilkemeyer, 1993) and 
people running on 20% residual enzyme activity can lead a normal live, it was believed that organ 
transplantation might cure MMA. However, it turned out that transplantation of either combined liver 
and kidney or liver and kidney alone gives increased metabolic stability in many cases, but still does 
not prevent patients from metabolic stroke like events and long-term complications (Brassier, 2006; 
Kasahara, 2013). Therefore, new treatment options are needed to slow down or even stop disease 
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progression. To gain new insights into disease mechanism, cellular models to investigate subcellular 
effects and animal models to investigate whole organ(ism) effects of the disease are required.  
I.2.2.6 Pathophysiology of kidney disease in MMA  
Patients suffering from MMA, even when mildly affected, are known to be at risk of developing CDK. 
The severity of the mutation is directly related to the concentration of accumulating methylmalonic 
acid, a well-known risk factor for onset and progression of CKD (Hörster, 2007). 
MUT is expressed in all human tissues, high concentrations are found in the kidney, where renal 
epithelial cells depent on mitochondrial energy production for various important transport processes 
(Emma, 2016). Renal tubular dysfunction and tubulointerstitial lesions are frequently found in MMA 
patients (Baumgartner, 2014; Hörster, 2007). The cellular mechanisms linking MUT deficiency and 
renal epithelial dysfunction have not been elucidated to date. Several mechanisms have been proposed 
to explain the pathophysiology. First, disturbances of the TCA cycle and the respiratory chain as well 
as alterations in the transport of the anti-oxidant glutathione have been thought to be involved in 
cellular damage (Morath, 2008). As a consequence of mitochondrial dysfunction oxidative stress and 
mitochondrial DNA depletion might lead to disturbed cellular homeostasis and function (De Keyzer, 
2009; Kölker, 2006; 2013). Second, accumulating organic acids (methylmalonic acid in particular) 
might exert toxic effects on cellular function. According to the “trapping-hypothesis”, impaired 
organic acid transport across the blood-brain barrier as well as de novo synthesis has been associated 
to brain damage in MMA (Kölker, 2006; 2013). Sauer et al. (2009) suspect a similar pathomechanism 
for mitochondrial dysfunction in the kidney. Finally, the detection of tubulo-interstitial nephritis in 
kidney biopsies of MMA patients led to the suspicion of an underlying inflammatory stimulus 
(Lubrano, 2007; Ruppert, 2015).  
The generation of Mut knock-out mouse models was hampered by the fact of neonatal lethality (Peters 
H, 2008). Following mouse models were dependent on AAV-based gene therapy (Chandler, 2010) or 
transgenic expression (Mut- -/- ; TgINS-Alb-Mut) for survival (Manoli, 2013). Protein load was able to 
induce a renal phenotype in Mut- -/- ; TgINS-Alb-Mut mice with reduced glomerular filtration rate, 
tubulointerstitial damage and increased renal damage markers. Aditionally, abnormal mitochondrial 
morphology and function was detected. The use of a constitutive Mut knock-in allele derived from a 
patient’s mutation recently allowed the generation of mouse models recapitulating phenotypic traits 
with a genetic-dosage effect presenting with progressive CKD and oxidative stress over time (Forny, 
2016).  
However, it remains unclear, how MUT deficiency influences mitochondrial integrity and homeostasis 
and how mitochondrial fate is linked to renal epithelial cell damage. 
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I.3. Impact of mitochondrial function on human health and disease 
I.3.1 Mitochondrial energy metabolism 
Mitochondria, cytoplasmic organelles derived from the engulfment of an eukaryotic progenitor by an 
alpha-proteobacterium are the only organelles to have their own genome (mtDNA), which is organized 
in a single double-stranded loop, lacking introns and using a different genetic code as compared to 
nuclear encoded genes. MtDNA codes for 37 genes and includes 13 subunits of respiratory chain 
proteins. The inheritance is exclusively maternal. More than 6% of the active genome contributes to 
function and homeostasis of mitochondria emphasizing their key role for the organism (Suomalainen, 
2015). 
Based on their specific structure with strictly separated outer (OMM), inter (IMS) and inner (IMM) 
mitochondrial membrane spaces, mitochondria are enabled to generate adenosine triphosphate (ATP) 
via oxidative phosphorylation along the respiratory chain. The respiratory chain consists of 5 
enzymatic complexes (complex I-V) and 2 electron carriers (CoQ10, cytochrome c) residing along the 
christae of the IMM (Nunnari, 2012). Acetyl-CoA derived from the breakdown of carbohydrate and 
lipid metabolism enters the TCA cycle producing NADH and FADH2 which are reduced by complex I 
and complex II. The electrons are transported via electron transporters and complex III to complex IV, 
where they reduce O2 to H2O. The energy produced is used to pump protons across the IMM leading 
to an electrochemical gradient needed by complex V for ATP production (Fig. 5). Other important 
tasks in cellular metabolism include the production of redox substrates, regulation of cell signaling and 
apoptosis as well as biosynthetic functions. This sum of tasks makes mitochondria important sensors 
of cellular metabolic stress and allows for cellular adaptation to environmental factors (Vyas, 2016). 
 
 
Figure 5: Mitochondrial morphology and structure allows a unique form of energy production via the respiratory chain. Acetyl-CoA is an 
important product of carbohydrate and lipid metabolism. ATP is produced via oxygene reduction along the highly specialized respiratory 
chain. (OMM=outer mitochondrial membrane, IMS=intermembrane space, IMM=inner mitochondrial membrane, CoQ=Coenzyme Q10). 
(Adapted from Emma F, 2016, Sheng ZH, 2012). 
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I.3.1.1 Disorders in mitochondrial energy metabolism 
Disorders of mitochondrial energy metabolism caused by mutations in mitochondrial and/or nuclear 
DNA are a genetically highly heterogeneous group of different diseases (Suomalainen, 2015). They 
display both tissue specific manifestations and clinical diversity (Nunnari, 2012) and may present at 
any age. The overall prevalence of mitochondrial disorders is probably greater than 1:5000.  
Primary mitochondrial disorder syndromes frequently present with optic nerve atrophy, sensorineural 
deafness, cardiomyopathy, muscular weakness and encephalopathy and many show various degrees of 
renal tubular dysfunction. Renal Fanconi syndrome is frequently present in patients with Pearson 
syndrome (Niaudet, 1994) or patients with CoQ10 deficiency (Niaudet, 1997; Emma 2012). Only a few 
primary mitochondrial diseases present with isolated symptoms (e.g. Leber hereditary optic nerve 
neuropathy) causing isolated blindness. Secondary (acquired) mitochondrial dysfunction is caused by 
many different hereditary diseases leading to impairment of mitochondrial function without affecting 
genes encoding for structural or functional mitochondrial proteins (Nunnari, 2012). Acquired 
mitochondrial dysfunction has been described e.g. in kidney disease. Studies provide evidence for 
increased ROS levels in common causes for CKD like diabetes mellitus, arterial hypertension and 
glomerulonephritis leading to initiation and aggravation of kidney damage (Che, 2013).  
Mitochondrial well-being is considered essential for tissue functionality and excessively elevated ROS 
levels have been identified as a major disease-driving burden. However, recent studies provide 
evidence ROS signaling is a selective, dosage-dependent and target-specific process (Schieber, 2014) 
playing an important role in cell signaling, proliferation and cell survival. Mitochondrial ROS 
signaling is an essential second messenger for an efficient immune system (West, 2011) (Kamminski, 
2013). Inflammation on the contrary, is associated with high ROS levels, resulting in tissue damage. 
This highlights the narrow border between physiological and pathophysiological effects of ROS and 
explains why mitochondria, important sources of ROS themselves, need a dynamic defense to 
maintain integrity and homeostasis. 
I.3.1.2 Mitochondrial dynamics and homoeostasis 
Mitochondria play a fundamental role in regulating cellular metabolism. Tight control of 
mitochondrial functions and dynamics is crucial to maintain an adequate energy balance. Adaption to 
different stressors (ROS) is critical for the maintenance of mitochondrial integrity and homeostasis. 
Functionally, the underlying process refers to mitochondrial fission and fusion, a process in which 
morphological changes of the mitochondrial network allow the separation of dysfunctional from 
healthy mitochondria. The process is mediated by Mitofusin 1 and 2 (Mfn1, Mfn2) required for outer 
membrane fusion, while inner membrane fusion is promoted by the dynamin like protein encoded by 
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OPA1. Fission is tightly regulated by Dynamin related protein 1 (Drp1). Disturbances in these 
delicate, well balanced processes have been associated with mitochondrial diseases (Chen H, 2009). 
In dependency on the extent of ROS induced damage several lines of defense have been developed. 
Mitochondria have an intrinsic proteolytic system to eliminate misfolded proteins (Matsushima 2012) 
(Fig. 6a). Dysfunctional outer mitochondrial membrane proteins can be removed by proteosomal 
degradation (Karbowski, 2011) (Fig. 6b). Furthermore, oxidized products can “bud” of mitochondria 
for lysosomal degradation (McLelland, 2014), (Fig. 6c). The diversity of this disposal pathway 
underlines the importance of mitochondrial integrity for energy supply and highlights ROS as a major 
disease-causing burden.  
 
 
Figure 6: Mitochondrial quality control. In dependency of the severity of damage mitochondria can use different strategies to protect 
themselves from ROS. a) Degradation of misfolded proteins by proteases of the intermembrane space or mitochondrial matrix; b) 
Degradation of misfolded protein on the outer mitochondrial membrane by proteasomal degradation or c) budding of outer mitochondrial 
membrane compounds for lysosomal degradation. (Adapted from Sugiura, 2014). 
Mitochondrial degradation is counter acted by mitochondrial biogenesis under the control of numerous 
nuclear transcription factors and co-activators (Liang H, 2006). The most extensively studied is 
peroxisome proliferator-activated receptor-gamma coactivator (PGC)-1-α. PGC-1-α is modulated by 
extracellular signals controlling metabolism, cellular growth and differentiation (Scarpulla, 2011) as 
well as by the important intracellular nutrient and energy sensors adenosine monophosphate-activated 
protein kinase (AMPK) and sirtuin1 (SIRT1) (Scarpulla, 2011). Highly expressed in metabolically 
active organs, PGC-1-α expression can be linked to the mitochondrial distribution pattern in the 
kidney with highest levels in the renal cortex and tubular epithelial cells and lowest in the glomerulus 
(Tran, 2007). In acute kidney injury, PGC-1-α expression is down regulated followed by return to 
normal levels when organ function recovers (Tran, 2007).  
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Taken together, these findings point at a complex interplay of mitochondrial separation and 
degradation on the one hand and biogenesis on the other hand rendering possible mitochondrial 
homeostasis and integrity. Both systems are tightly connected to cellular metabolic needs and 
impairment will lead to severe disturbance of cellular energy metabolism. 
 
I.3.1.3 Mitochondrial dysfunction in renal disease 
Different studies have pointed at the special relationship between mitochondrial energy production 
(generation of ATP), mitochondrial well-being and kidney function (Verdin 2015; Tran, 2016). 
Although the kidneys only account for 0.5% of body mass, they consume 10% of the total oxygen 
production (Berg 2002). Especially the proximal tubule (PT) and the thick ascending limb (TAL) of 
the kidney are rich in mitochondria and therefore vulnerable to mitochondrial dysfunction. This is due 
to active reabsorption and excretion processes against concentration gradients at high energy costs: 
The proximal tubule of the kidney is involved in specialized transport processes that are critical to 
maintain homeostasis, reabsorbing two thirds of filtered solutes and water. The energy driving these 
processes is mainly generated by the basolateral Na+/K+-ATP-ase. Various co- and counter 
transporters are dependent on gradients produced by active, ATP-consuming, transport mechanisms. 
Multi-ligand receptors lining PT-cells are responsible for the endocytic up-take of various ligands. 
Further processing along the endolysosmal pathway requires vesicular acidification by -ATP-ase 
before re-distribution of the recycled substances can occur (Prange, 2016). In the thick ascending limb 
urine is concentrated again requiring active transport processes by Na+/K+-ATP-ases. Electrolytes 
(Ca2+, Mg2+) are reabsorbed by Ca2+/Mg2+- sensing receptors (Ferre, 2012). Mitochondria are 
increasingly recognized to be the key organelles for proper kidney function and mitochondrial 
dysfunction plays a leading role in the pathophysiology of kidney disease (Emma, 2016). 
Unsurprisingly, many mitochondrial disorders are characterized by various degrees of renal tubular 
dysfunction. Complete Fanconi syndrome, presenting with low-molecular weight proteinuria and 
glucose loss represents global dysfunction of PT cells (Emma, 2012). Partial defects including renal 
tubular acidosis, isolated glycosuria or aminoaciduria are frequently observed. Patients presenting with 
a Bartter-like phenotype and hypermagnesuria pointing at involvement of the distal nephron and the 
TAL have also been reported (Emma, 2011; 2006). Mitochondrial impairment in podocytes leads to 
disruption of the filtration barrier and protein loss. Two major entities have been identified: 
Glomerulopathies due to defects in the CoQ10 biosynthesis, an important shuttle of electrons and anti-
oxidants, and due to the mtDNA mutation 3243 A>G in the tRNALeu(UUR) gene (Emma, 2016). 
In most cases, mitochondrial damage is acquired. As renal tubules are highly active in terms of 
transport and metabolism, acute kidney injury (of toxic, septic or ischemic etiology) causes early 
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changes the epithelial-lining mitochondrial population. Excessive ROS production leads to 
morphological and functional changes. Loss of the characteristic christae structure, mitochondrial 
swelling, disruption and loss of mitochondrial mass have been observed predominantly in the PT but 
also in the TAL and the distal tubule (Brooks, 2009; Manny, 1980). These defects in mitochondria of 
the renal tubular epithelium underline the fact, that high energy consumption and vulnerability are 
closely related and that mitochondrial dysfunction is accompanied by ultrastructural damage.  
Common diseases like diabetes mellitus and arterial hypertension are known to induce chronic kidney 
injury. Studies have shown increased ROS production and inactivation of complex IV pointing at 
mitochondrial dysfunction in these patients. (Che, 2013). It appears that there is a correlation between 
degradation of renal function and increasing ROS levels. ROS in turn is believed to stimulate CKD 
progression (Cachofeiro, 2008). In this context, different mediators and markers of inflammation 
(interleukin-6, tumor necrosis factor-α, cyclooxygenase I) were found to be elevated suggesting an 
inflammatory process which is triggered by ROS. Persistent inflammation might be another factor 
leading to progression of CKD (Landray, 2004).  
The current opinion on kidney injury caused by mitochondrial dysfunction states, that impairment of 
mitochondrial function not only leads to decreased ATP but also increased ROS production (Fig. 7). 
ROS released from damaged kidney cells furthermore amplifies ROS levels. Structural mitochondrial 
alterations lead to release a of mtDNA working as a pro-inflammatory signal and cytochrome c, a 
trigger for apoptosis (Zhang, 2010), thereby possibly driving renal epithelial dysfunction and CKD. 
Tran et al. recently showed that substitution with nicotinamide adenine dinucleotide, an important 
player of the respiratory chain, improves kidney function after ischemic insult, providing evidence that 
control of ROS levels and mitochondrial health is not only important for the maintenance of kidney 
function but also plays an important role in tissue repair (Tran, 2016).  
In the last years, mitochondria have been identified as the key organelles for onset and progression of 
kidney damage and ROS has been identified to be a major disease driving burden. The use of 
mitochondria targeted anti-oxidants has been shown to have beneficial effects by ROS reduction and 
improvement of kidney damage (Szeto, 2011). Targeting pathways which effect mitochondrial 
dynamics, mitophagy and biogenesis might offer other, novel approaches to ameliorate progression of 
kidney damage and sustain kidney function. 
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Figure 7: Mitochondrial injury and recovery in renal epithelial cells. Renal epithelial cells are highly active in terms of transport 
processes and rich in mitochondria providing ATP. Multiple stimuli induce mitochondrial injury leading to organellar swelling, 
fragmentation and dysfunction. Dysfunctional mitochondria release a cocktail of harmful molecules such as ROS and cytochrome c 
potentiating mitochondrial injury and promoting cell-death if uncontrolled. Recent studies suggest that clearance of dysfunctional 
mitochondria by mitophagy/autophagy and reconstitution of mitochondrial mass by mitochondrial biogenesis, a process mediated via 
proliferator-activated receptor-γ co-activator 1-α (PGC-1-α), are involved in the recovery process. (Adapted from Emma F, 2016). 
 
I.3.2 Autophagy and mitophagy  
Mitochondria are essential organelles that regulate cellular homeostasis and concomitantly tissue 
function. The removal of dysfunctional mitochondria is critical to maintain proper cellular function. 
Elimination of defective mitochondria either occurs via autophagy, a non-selective cellular recycling 
process or via mitophagy, an organelle-specific break-down pathway. Both pathways are essential for 
mitochondrial quality control (MQC). 
Autophagy, also known as self-digestion, is a crucial cellular degradation process. Its main function is 
to provide metabolites in times of shortage and to serve as quality control by clearing misfolded 
proteins and dysfunctional organelles. Recent evidence suggests that autophagy can not only be 
induced by starvation but also in nutrient-rich conditions pointing at a key role for autophagy in 
catabolic and anabolic metabolism (Kaur, 2015).  
Defects in the autophagic pathway result in the accumulation of dysfunctional products (e.g. 
organelles, proteins) and have been associated with severe infectious, malignant, renal, 
immunological, cardiovascular and neurodegenerative chronic diseases (Sureshbabu, 2015). 
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Autophagy is a tightly orchestrated multi-step process starting with the formation of an isolation 
membrane (phagophore), elongation of this membrane and cargo recruitment, formation of a double-
layer membrane (autophagosome), fusion with the lysosome (autolysosome) and finally degradation 
(Fig. 8). 
Dysfunctional cargo gets ubiquitinated (e.g. by ubiquitin ligase) which allows selective recognition of 
dysfunctional products by the autophagic receptor p62/SQSTM1. p62/SQSTM1 labelled cargo attracts 
microtubule associated protein light chain 3 (LC3) for autophagosome formation (Lenoir, 2016). 
Autolysosome formation is mediated by RAB7, an important regulator of late endocytic membrane 
trafficking. After complete fusion of the autolysosome and the lysosome the cargo is degraded by 
different enzymes in the acidic lysosomal environment. Nutrients are recycled and transported into the 
cytoplasm (Nixon, 2013).  
Autophagy itself is tightly controlled by the mammalian target of rapamycin complex (mTORC1), 
adenosine monophosphate-activated protein kinase (AMPK) and sirtuin1 (SIRT1), important sensors 
for nutrient state, oxygen consumption and energy status of a cell. Activation of mTORC1 leads to 
inhibition of autophagy. AMPK and SIRT1 on the other hand, are autophagy inducers (Lenoir, 2016) 
as is the catabolic state induced by starvation.  
While degradation via autophagy is rather unspecific, mitophagy exclusively removes damaged 
mitochondria via this organelle specific pathway (Fig. 8). The process is initiated after separation by 
mitochondrial fission. Major players are the mitochondrial serine/threonine-protein kinase PINK1 and 
the E3 ubiquitin ligase parkin. PINK1 is rapidly turned over by proteolysis in healthy mitochondria. 
During mitochondrial dysfunction PINK1 is no longer cleaved from the OMM thereby attracting 
parkin. Parkin recruitment leads to ubiquitination of OMM structures. The ubiquitin binding-adaptor 
p62/SQSTM1 binds to parkin-ubiquitinated mitochondria mediating the binding of LC3 which allows 
degradation via the lysosomal pathway (Youle, 2011). 
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Figure 8: Mitochondrial quality control. (A) Non-selective autophagy degrades cytosolic compounds and different organelles. After 
ubiquitination, recruitment of p62/SQSTM1 and LC3 induce autophago-lysosomal fusion and lysosomal digestion. (B) Mitophagy 
selectively eliminates defective mitochondria. Dysfunctional mitochondria express PINK1 on the OMM attracting parkin. Parkin-
ubiquitinated mitochondria attract the autophagic machinery for lysosomal degradation. (Adapted from Youle, 2011). 
 
It is generally accepted, that ROS induces autophagy and activation of autophagy counteracts ROS 
(Scherz-Shouval, 2011) in return. Mitochondrial dysfunction, ROS and activation of autophagy are 
therefore tightly related. Disturbance in this key system for cellular homoeostasis can be monitored 
e.g. by studies of autophagic flux, trafficking of cargo between different compartments or by 
measurement of lysosomal enzymatic activity. P62/SQSTM1 or LC3 are often used to monitor 
autophagic processes. It has to be kept in mind, that accumulation of autophagic proteins can be 
induced by any step down-stream in the autophagic process and either due to increased autophagic 
flux, inhibition of autophogo-lysosomal fusion as well as inhibition of lysosomal function. To 
correctly evaluate the status of autophagic flux, co-localization studies of different subcellular 
compartments to visualize correct targeting, inhibition of certain processes (e.g. lysosomal degradation 
with Bafilomycin) to reveal changes in autophagosome synthesis and investigation of lysosomal 
dynamics (content of lysosomal proteins, activity of lysosomal enzymes) have to be performed 
(Klionsky, 2016; Mizushima, 2004). 
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I.3.2.1 The role of autophagy in kidney disease 
Autophagy is a tightly controlled lysosomal degradation pathway removing damaged organelles and 
aggregated proteins to preserve cellular homeostasis and integrity. Defective autophagic clearance is 
involved in the pathogenesis of a variety of systemic and metabolic diseases. Autophagy plays a 
crucial role in metabolically active, mitochondria-rich organs like the kidney (Lenoir, 2016). Recent 
studies link renal cellular damage in the tubulo-interstitial and glomerular compartment (Fig. 9) to 
dysregulated autophagic processes (Ding, 2015; Lee, 2014; Fougeray, 2015; Liu, 2014).  
Renal epithelial cells are rich in mitochondria to perform active transport processes and are extremely 
vulnerable to ROS. Recent studies suggest that autophagy is important to preserve mitochondrial 
integrity and homeostasis in proximal (Namba, 2014; Kimura, 2011) and distal tubular cells (Pallet, 
2008). Disturbance of the autophagic process induced by genetic manipulation resulted in elevated 
ROS levels, accumulation of autophagic proteins and kidney damage.  
The importance of autophagic clearance has also been demonstrated in different models for acute 
kidney injury like ischemia-reperfusion (Jiang, 2010) and cisplatin treatment (Periyasamy-Thandavan, 
2008). Acute damage led to autophagy induction while inhibition of the process worsened tissue 
damage. Chronic metabolic acidosis is a severe complication of CKD and frequently found in patients 
with organic acidurias leading to mitochondrial stress and dysfunction. Namba et al. (Namba, 2014) 
recently provided evidence, that metabolic acidosis induces autophagy in renal tubule cells and that 
activation of autophagy is crucial for the maintenance of mitochondrial homeostasis in these 
conditions. Activation of the autophagic pathway is also observed in other chronic (Lenoir, 2015; Lim, 
SW) kidney disease conditions and believed to be renal-protective. 
Interestingly, disturbances of the autophagic pathway have been linked to progressive renal fibrosis. In 
several mouse models for fibrosis induction, autophagic markers were increased. Pharmacological 
inhibition of autophagy worsened tubule-interstitial fibrosis progression (Kim, 2012; Ding, 2014). In 
line with that, autophagy was found to foster degradation of transforming growth factor beta (TGF-), 
which is known to promote fibrosis progression and aggravate kidney disease (Ding, 2014).  
The role of autophagy in the glomerular compartment has been extensively studied in diabetes mellitus 
characterized by causing progressive podocyte destruction over time (Najafian, 2011). Robust 
evidence suggests, that high glucose levels lead to ROS production followed by activation of the 
autophagy machinery in podocytes. High glucose concentrations furthermore induce autophagy 
directly (Lenoir, 2016). Long term exposure to high glucose levels induces a down-regulation of the 
autophagy machinery which seems to sustain podocyte damage (Fang, 2013). The group of Gödel et al 
(Gödel, 2011) provides evidence, that this is due to mTORC1 activation, which might provide some 
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short-term benefits but ultimately leads to glomerulosclerosis and podocyte destruction. These data 
sustain the renal-protective effect of autophagy induction for the glomerular compartment. 
It is commonly believed, that autophagy has a reno-protective role and that impairment of the 
autophagy pathway leads to kidney disease progression. The mechanism by which autophagy protects 
renal tubular cells is currently unclear (Huber, 2012). Novel insights from this thesis suggest, that 
inter-connected mechanisms like general and organelle specific degradation of dysfunctional 
organelles might be part of that complex pathway. Further investigations are needed to unravel the 
precise role of autophagy in different disease entities and cell types. A comprehensive understanding 
of the underlying network will facilitate the discovery of novel therapeutics to prevent CKD. 
 
 
Figure 9: Putative cyto-protective functions of autophagy in tubular cells and podocytes (A) Protection of renal tubular cells from acute 
and chronic damage by clearance of defective mitochondria, protein aggregates and ROS reduction. (B) Defects in the autophagic 
pathway induce podocyte loss and glomerular damage. Activation of autophagy removes defective mitochondria and protein clusters 
restoring podocyte function. (Adapted from Pallet, 2015). 
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II. AIMS OF THE THESIS 
The PhD Thesis consist of 2 main parts aiming to shed new light on how the deficiency of the 
monogenic enzyme MUT leads to systemic and subcellular changes driving onset and progression of 
CKD in MMA in a multilevel approach. 
 
1I.1 Characterization of the classical disease course and possible influence of adenosylcobalamin 
(vitamin B12) on the progression of CKD in Methylmalonic aciduria (MMA) 
The first section deals with the long-term follow up of a patient suffering from a vitamin B12 
responsive CblA type MMA-uria due to the relatively common p.R145X STOP mutation. Despite 
metabolic stability and normal development and growth, the patient developed chronic kidney disease 
(CKD) at the age of 12 years. Of note, kidney function could be stabilized by the administration of 
vitamin B12 for a period of 13 years before the patient had to undergo renal replacement therapy.  
This case report illustrates: 
i) The long-term follow-up of a patient with MMA-uria due to cblA deficiency; 
ii) The involvement of the kidney as a target organ despite a relatively mild metabolic phenotype; 
iii) The importance of early and adequate vitamin B12 substitution in responsive patients; 
 
II.2 Mechanistic studies in the different mouse and human models reveal mitochondrial 
dysfunction and impaired autophagy to drive kidney damage in Methylmalonic aciduria 
The MUT enzyme is ubiquitously expressed in tissues of mouse and humans. However, long-term 
consequences in MMA predominantly affect the brain (basal ganglia damage) and the kidney (CKD), 
which are highly energy dependent organs and therefore rich in mitochondria. For this reason, the 
mitochondrion has been suspected to be the key organelle related to CKD in MMA.  
We used a multi-level approach in human derived samples (tissue, renal epithelial cell lines) and 
different animal models (Mutki/ko mouse model, Mutflox/flox mouse model) to:  
i) Characterize MUT expression in mouse tissues and human renal cells; 
ii) Investigate mitochondrial morphology and function in MMA; 
iii) Evaluate the role of the autophagy and mitophagy in MMA; 
iv) Recapitulate findings in the novel MMA mouse model (Mutki/ko); 
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v) Exploit Cre mediated Mut deletion in mPTC to investigate the causal role of MUT; 
vi) Investigate the possible impact of anti-oxidants in human MMA cells 
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Abstract 
 Chronic renal failure is a well-known long-term complication of methylmalonic aciduria 
(MMA-uria), occurring even under apparently optimal metabolic management. The onset of renal 
dysfunction seems to be dependent on the type of defect and vitamin B12-responsiveness. We report on 
a patient with a vitamin B12-responsive cobalamin A type (cblA) MMA-uria caused by a homozygous 
stop mutation (p.R145X) in the cobalamin A gene (MMAA). She was diagnosed with chronic kidney 
disease (CKD) stage III at the age of 12 years. Following re-evaluation, the patient received vitamin 
B12 (hydroxocobalamin) treatment, resulting in a significant decrease in the concentration of 
methylmalonic acid (MMA) in urine and plasma. Until age 29 years glomerular filtration rate 
remained stable probably due to hydroxocobalamin treatment slowing down progression to end-stage 
renal failure. Kidney biopsies showed non-specific manifestations of chronic interstitial inflammation. 
The patient received a renal transplant at age 35 years. Under continuous treatment with 
hydroxocobalamin there is no evidence of kidney damage due to MMA-uria until the last follow-up 6 
years after transplantation.  
This case report illustrates (i) a long-term follow-up of a patient with MMA-uria due to cblA 
deficiency, (ii) the involvement of the kidney as a target organ and (iii) the importance of early and 
adequate vitamin B12 substitution in responsive patients. Further investigation will be necessary to 
prove the protective effect of hydroxocobalamin on the kidney in vitamin B12-responsive patients.  
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Abbreviations 
AdoCbl adenosylcobalamin 
cblA methylmalonic aciduria cblA type OMIM 251100 
cblB methylmalonic aciduria cblB type OMIM 251110 
cblD-variant 2 methylmalonic aciduria and homocystinuria cblD type OMIM 277410 
CKD chronic kidney disease 
 
 
 
 
eGFR estimated GFR 
MMA methylmalonic acid 
 
MMA-uria methylmalonic aciduria 
 
MC 2-methylcitric acid 
MUT methylmalonyl-CoAmutase OMIM 609058 
mut- partial defect of methylmalonyl-CoA mutase activity OMIM 251000 
mut0 complete defect of methylmalonyl-CoA mutase activity OMIM 251000 
3-OH-PA 3-OH-propionic acid 
PA propionic acid 
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1. Introduction 
Methylmalonic aciduria (MMA-uria), first described by the group of Oberholzer et al. in 1967 
(1), belongs to the group of organic acidurias. It is biochemically characterized by the accumulation of 
specific organic acids such as methylmalonic acid (MMA), propionate (PA), 3-OH-propionic acid (3-
OH-PA) and 2-methylcitric acid (MC). The disease is caused either by mutations (mut0, mut-) in the 
enzyme methylmalonyl-CoA mutase (MUT) which is involved in the break-down of branched chain 
amino acids, odd-numbered chain fatty acids, cholesterol side chains and other metabolites or by 
mutations in the genes MMAA (cblA), MMAB (cblB) and MMADHC (cblD-variant2) encoding 
proteins important for the synthesis of its cofactor adenosylcobalamin (AdoCbl) (2). According to the 
type of mutation and resulting residual enzymatic activity, there is a wide clinical spectrum of the 
disease. Typically, patients manifest with acute metabolic crisis during the first days of life or in 
catabolic states due to infectious diseases or prolonged fasting. The metabolic crises are characterized 
by lactic acidosis, hyperketonaemia, hypo- or hyperglycaemia and hyperammonaemia and may result 
in metabolic encephalopathy and multi-organ failure. Complications include failure to thrive, 
developmental delay, mental retardation, muscular hypotonia, metabolic stroke like episodes with 
basal ganglia damage and renal failure (3). 
The pathophysiology of chronic kidney disease (CKD) in MMA-uria is poorly understood. 
There is evidence that the severity of the defect and therefore the concentration of MMA might play an 
important role (3). The nature of the disease in the kidney is unclear for the lack of specific biomarkers 
and investigations of kidney biopsies at an early stage of the disease. Careful clinical descriptions 
combined with detailed studies of kidney biopsies are necessary to yield insights into the origin of 
kidney destruction. Here we present the 42-year history of renal involvement as well as analysis of 
several kidney biopsies in a female patient with vitamin B12-responsive MMA-uria due to a 
homozygous stop mutation in the MMAA gene (cblA). 
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2. Case report 
The patient was born after uneventful pregnancy as the first child to a non-consanguineous 
Caucasian couple. She presented at 3 days of life with icterus (bilirubin 340 µmol/l), muscular 
hypotonia, vomiting, weight loss and lethargy. There was no acidosis present (plasma bicarbonate 25.4 
mmol/l) and blood ammonia concentration was normal for a newborn (88 µmol/l). The first profile of 
amino acids in plasma and urine revealed elevated concentrations of lysine and hyperlysinemia was 
ruled out. Under suspicion of a metabolic defect the child was put on a low protein diet (1.4 g 
protein/kg/d) and improved remarkably. The follow-up investigation of the amino acid profile showed 
hyperglycinemia and hyperglycinuria. Accidental protein intake of 2 g/kg/d at 4 months of age led to a 
metabolic derailment which could be easily controlled by i.v. glucose application. Aged 8 month the 
urine was screened for organic acids and high concentrations of MMA were detected in urine (4.3 
mmol/d) and plasma (255 µmol/l) establishing the diagnosis of MMA-uria. Incorporation of label from 
(14C)propionate into cell proteins in cultured fibroblasts was severely deficient but showed a clear 
response to supplementation of the culture medium with high concentrations of hydroxocobalamin. A 
cblA defect was confirmed by somatic complementation and later by molecular genetic investigation 
which revealed a homozygous mutation in exon 2 of the MMAA gene (c.433C>T) predicting an amino 
acid change from arginine to a stop codon at position 145 (p.R145X). Vitamin B12 concentration was 
low (225 pmol/l) but within the normal range (220-730 pmol/l). Intramuscular injections of 
hydroxocobalamin for 5 days did not change the concentration of excreted MMA. Accordingly, no 
treatment was started initially. The patient was kept on a low protein diet (1.4 g/kg/d) and showed 
normal growth and psychomotor development (IQ 98 at age 4 years by J. Kramer intelligence test) 
(Fig. 1).  
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Figure 1: Summary of physical growth. The percentiles show stature and weight-for-age. CKD was diagnosed because of a decline in 
growth at 12 years of age as indicated by arrowhead. 
At age 12 years, the patient showed impaired growth and CKD stage III was discovered 
(glomerular filtration rate: 45 ml/min/1.73 m2, obtained by 24h urine collection, (Fig. 2)). Until this 
age, kidney function had not been documented so that the onset of CKD remains obscure. In addition, 
hyperuricemia (up to 778 µmol/l) due to reduced excretion of uric acid (19 µmol/kg/d, normal range 
91±50) was identified and subsequently treated with a xanthine oxidase inhibitor (Allopurinol). 
Generalized signs of proximal tubulopathy, like that seen in Fanconi syndrome described by D’Angio 
et al. in a patient with MMA-uria (4) were not found. Kidney size determined by ultrasound was 
within the normal range. According to a previous publication (5) the responsiveness of this patient to 
hydroxocobalamin was re-evaluated and, this time, found to be positive. Treatment with 
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hydroxocobalamin was re-introduced using a dosage of 2x10 mg/d p.o. from 1983-1995 and 1x10 
mg/7d i.m. from 1995 to 2006. Cofactor responsiveness was documented by impressive catch-up 
growth (Fig. 1) as well as long-term decline in urinary MMA excretion (Fig. 2), with mean MMA 
excretion decreasing from 3212 µmol/mmol creatinine before administration to 719 µmol/mmol 
creatinine (oral treatment) and further to 422 µmol/mmol creatinine (i.m. administration). Treatment 
included a low protein diet as well as carnitine (3x1 g/d) and bicarbonate. Neurodevelopment 
remained normal (IQ 97 at age 22, by Hamburg-Wechsler-Intelligenztest für Erwachsene, (HAWIE-
R)). 
Total kidney volume detected by ultrasound decreased during the following years and at 16 
years of age it was below two standard deviations compared to healthy peers. From 1988 she had 
arterial hypertension and in 1989 (age 18), at CKD stage III (GFR 54 ml/min/m2, determined by inulin 
clearance), a renal biopsy was performed (Fig. 2, nr. 1, Fig. 3). The main findings were areas with 
advanced tubular atrophy and interstitial fibrosis which were interspersed with mononuclear infiltrates. 
Immunohistochemistry and electron microscopy (EM) ruled out a glomerulonephritis or a hereditary 
glomerulopathy. Unfortunately, the material was not sufficient to examine the tubulointerstitium by 
EM in respect to mitochondrial pathologies as seen in the proximal tubules of a Mut knock-out mouse 
model (6). 
From 1996 (age 25), renal function deteriorated. Another biopsy was performed in 1999 (age 
28), (Fig. 2, nr. 2) showing a similar pattern as previously reported. However, additionally severe 
arteriolosclerosis was detected most probably due to arterial hypertension. One year later renal 
replacement therapy had to be started and the patient was dependent on hemodialysis the following 6 
years (Fig. 2). 
In 2006 (age35) the patient underwent kidney transplantation from a deceased donor. After the 
transplantation she remained on a low protein diet as well as supplementation with hydroxocobalamin 
(1x4 mg/14d i.m.) and carnitine (3x1 g/d). Immunosuppressive regimen consisted of tacrolimus 
(Prograf, Astellas), mycophenolate-sodium (Myfortic, Novartis) and prednisone. Prednisone was 
tapered and stopped three months after transplantation. The estimated glomerular filtration rate 
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(eGFR) according to Cockroft Gault was 90 ml/min/1.73 m2. Plasma MMA concentration decreased 
from 304 µmol/l to a baseline of 59 µmol/l (Fig. 2). Graft function remained stable and surveillance 
biopsies (Fig. 2, nr. 3, 4) were performed according to the transplant protocol three and six month after 
transplantation revealing borderline and moderate tubulitis, respectively, both consistent with 
interstitial rejection. The latter was treated with steroid pulses. In the second year after transplantation 
(eGFR 68 ml/min/1.73 m2) a third renal biopsy (Fig. 2, nr. 5) was performed. Besides minor 
arteriolosclerosis the morphology was well preserved and no further abnormalities were reported. 
Blood pressure was well controlled under antihypertensive treatment. At the last follow-up, six years 
after transplantation, serum creatinine concentration was 95 mol/l, the eGFR was 70 ml/min/1.73 m2 
and there was neither glomerular nor tubular proteinuria detectable.  
 
Figure 2: Course of glomerular filtration rate (GFR) and concentration of MMA in an individual with cblA MMA-uria in dependence of 
hydroxocobalamin (OHCbl) treatment. Values for GFR indicated as triangles were obtained as mean, each single value obtained from a 24 h 
urine collection (n=5 (1983), n=6 (1984), n=8 (1985), n=5 (1986), n=5 (1987), n=8 (1990), n=7 (1991), n=3 (1992), n=4 (1994), n=10 
(1995), n=5 (1996), n=7 (1997), n=4 (1998), n=3 (1999)). GFR values indicated as squares were measured by inulin clearance, values 
indicated as circles were obtained by Cockroft Gault estimation. Urinary MMA values (µmol/mmol creatinine) are depicted as a black line 
and plasma MMA (µmol/l) as a dotted line. Error bars are represented by vertical lines. Kidney biopsies are indicated with arrowheads and 
numbered. Boxes show 4 periods of treatment with hydroxocobalamin (n = number of independently performed measurements): No 
hydroxocobalamin treatment (n=47), 2x10 mg/d p.o. (n=21), 1x10 mg/7d i.m. (urine: n=42, plasma: n=6), post transplantation 1x4 mg/14d 
i.m. (urine: n=32, plasma: n=28). The significance has been determined by one-way ANOVA (*, **P <0.05) for MMA concentration in 
urine and (***P <0.05) for MMA concentration in plasma and is referring to the previous value. 
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Figure 3: Native kidney biopsy (1989, age 18 years) showing dense inflammatory interstitial infiltrate (), areas of tubular atrophy () and 
interstitial fibrosis (). Enrichment of protein casts close to the medulla-cortex region was reported as well as large areas with completely 
inconspicuously looking tubules (data not shown in the pictures). a) Periodic acid Schiff stain (PAS), LM, 200x; b) Masson’s Trichrome 
Stain (TRI), LM, 200x. 
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3. Discussion 
We present a long-term follow-up of a patient with vitamin B12-responsive cblA type MMA-
uria due to the STOP mutation p.R145X, which is the most common allele found in patients with CblA 
defects (representing 43% of pathogenic alleles) (7). The case illustrates progressive loss of kidney 
function finally leading to end stage kidney failure in a patient with a rather mild form of MMA-uria, 
in whom development and growth are normal and severe metabolic decompensations are lacking. It 
also underscores the importance of standardized testing for cofactor responsiveness and subsequent 
treatment with hydroxocobalamin in such patients. Our data clearly suggest improved metabolic 
control on i.m. application vs. oral supplementation. Given the risk of these patients for severe long-
term complications (e.g. end stage renal disease and optic nerve atrophy) it is important to study the 
effects of more aggressive management (8). 
Patients with isolated MMA-uria, even mildly affected, are thought to be at risk of developing 
CKD (3). High concentrations of MMA in urine are a known risk factor for the development of CKD 
in those patients (3). The administration of vitamin B12 in our patient resulted in a significant decrease 
in urinary MMA excretion (Fig. 2). Partial correction of the biochemical phenotype has slowed the 
progression from CKD III to end stage renal disease. Only after 17 years of vitamin B12 
supplementation, the patient necessitated hemodialysis. Nevertheless, these results should be 
interpreted with caution, since the urinary excretion of MMA and other putatively toxic metabolites of 
alternative propionate oxidation (e.g. 2-methylcitrate) diminish with decreasing kidney function and 
thus accumulating toxic compounds could foster the naturally occurring disease progression despite 
hydroxocobalamin supplementation. Unfortunately, only very few plasma MMA levels are available 
during the period before end stage renal disease. The drop of mean plasma as well as urinary MMA 
concentrations after renal transplantation (Fig. 2) is most likely due to the transplant, as the kidney is 
said to contribute to at least 18% of activity normally provided by the liver (9, 10). 
 Several mechanisms may explain the pathophysiology of cellular damage in MMA. First, 
disturbances of the tricarboxylic acid cycle and the respiratory chain as well as disturbances in the 
glutathione and dicarboxylate transport are thought to be involved in the pathomechanism (11). 
46 
Secondary to mitochondrial dysfunction, oxidative stress and disturbances in mitochondrial DNA 
equilibrium might occur (12, 13, 14). Second, accumulating dicarboxylic acids may be toxic, in 
particular in the brain. According to the “trapping hypothesis” impaired transport of dicarboxylic acids 
either at the blood-brain barrier or between astrocytes and neurons as well as de novo synthesis of 
dicarboxylic acids in brain is causing brain damage (13, 14). Sauer et al. (11, 15) suspect a similar 
pathomechanism of impaired function of dicarboxylic acid transporters and accumulating 
mitochondrial toxins to be responsible for kidney damage in MMA-uria.  
The performed native kidney biopsies showed areas with remarkable tubular atrophy and 
interstitial fibrosis interspersed with mononuclear infiltrates without other abnormal findings which 
might reflect the influence of MMA-uria in the kidney (Fig. 3). These observations fit with the 
description of kidney biopsies taken from other patients with MMA-uria due to mut- and cblA 
deficiency (10, 16). Similarly, the graft biopsies did not show any striking abnormalities which might 
be a hint at kidney damage caused by MMA-uria. This finding matches with the group of Lubrano et 
al. (17) who reported the case of a girl receiving a kidney transplant at the age of 17 years because of 
MMA-uria due to a cblA defect. In a 16.5 year follow-up study renal function remained stable and re-
biopsy did not show any striking abnormalities, even during pregnancy (18). In contrast to our case, 
this patient is on unrestricted diet and has not been on hydroxocobalamin treatment (18). 
Because of the small number of organ transplantations in a phenotypically highly variable 
patients’ population a clear recommendation for organ transplantation in MMA-urias cannot be made. 
Thirty-one patients with MMA-uria with kidney (n=10), liver (n=15) or combined liver/kidney 
transplantation (n=6) have been reported so far (10, 16, 20, 21, 22, 23, 24) most of them harboring a 
mut0 (n=16) defect. Some patients underwent episodes of severe metabolic decompensation, metabolic 
stroke or death (25) even after combined liver and kidney transplantation clearly demonstrating that 
severe complications may still occur. Nevertheless, the kidney seems to play an important role for 
metabolic stability and correction of MUT activity in the patients as kidney or combined kidney/liver 
transplantation seem to lower MMA concentration more efficiently and provide more metabolic 
stability than single liver transplantation (10, 17, 24, 26). This case report as well as the findings of 
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other groups (17, 24) in even more severe forms of MMA-uria suggests that elective kidney 
transplantation may be a form of “cell-therapy” and regarded as an alternative and safer strategy than 
liver or combined liver-kidney transplantation for it seems to restore sufficient enzyme activity and 
improves quality of life in patients. 
 Several cases of hyperuricemia in MMA-uria have been reported (10, 27) similar to the 
finding in our patient. As suggested by the reduced excretion of uric acid, one could speculate that the 
characteristically accumulating organic acids -and MMA in particular- may induce tubular damage 
and inhibit the tubular secretion of uric acid. Uric acid is known to induce gout nephropathy via 
chronic interstitial inflammation (28) and might be an additional toxic factor in the development of 
CKD in MMA-uria. 
 In conclusion, this case report illustrates that CKD is a long-term complication even in 
patients with mild defects leading to almost no metabolic derailment. High concentrations of MMA 
are suspected to be nephrotoxic and hydroxocobalamin can lower MMA concentration in responsive 
patients. Responsiveness to hydroxocobalamin treatment should therefore be carefully evaluated and 
responsive patients should be adequately treated by parental administration since this may slow down 
the progress of CKD. Elective kidney transplantation seems to be a valid option in selected patients. 
To date, no evidence of recurrence of MMA-specific changes in the transplanted kidney has been 
evidenced; however, it has to be kept in mind that it is neither curative nor protective against metabolic 
stroke.  
 
Conflict of interest 
The authors disclose any actual or potential conflict of interest including any financial, personal or 
other relationships with other people or organizations within three years after submission that could 
inappropriately have influenced, or be perceived to influence, their work. 
  
48 
4. References 
(1) Oberholzer VG, Levin B, Burgess EA, and Young WF, Methylmalonicaciduria. An inborn 
error of metabolism leading to chronic metabolic acidosis. Arch Dis Child. 42 (1967) 492–504. 
(2) Fowler B, Leonard JV, Baumgartner MR, Causes of and diagnostic approach to methylmalonic 
acidurias. J Inherit Metab Dis. 31 (2008) 350-60. 
(3) Hörster F, Baumgartner MR, Viardot C, Suormala T, Burgard P, Fowler B, Hoffmann GF, 
Garbade SF, Kölker S, Baumgartner ER, Long-term outcome in methylmalonic acidurias is 
influenced by the underlying defect (mut0, mut-, cblA, cblB). Pediatr Res. 62 (2007) 225-30. 
(4) D'Angio CT, Dillon MJ, Leonard JV, Renal tubular dysfunction in methylmalonic acidaemia. 
Eur J Pediatr. 150 (1991) 259-63. 
(5) Matsui SM, Mahoney MJ, Rosenberg LE, The natural history of the inherited methylmalonic 
acidemias. N Engl J Med. 308 (1983) 857-861.  
(6) Chandler RJ, Zerfas PM, Shanske S, Sloan J, Hoffmann V, DiMauro S, Venditti CP, 
Mitochondrial dysfunction in mut methylmalonic acidemia. FASEB J. 23 (2009) 1252-1261. 
(7) Lerner-Ellis JP, Dobson CM, Wai T, Watkins D, Tirone JC, Leclerc D, Doré C, Lepage P, 
Gravel RA, Rosenblatt DS, Mutations in the MMAA gene in patients with the cblA disorder of 
vitamin B12 metabolism. Hum Mutat. 24 (2004) 509-516. 
(8) Cosson MA, Benoist JF, Touati G, Déchaux M, Royer N, Grandin L, Jais JP, Boddaert N, 
Barbier V, Desguerre I, Campeau PM, Rabier D, Valayannopoulos V, Niaudet P, de Lonlay P, 
Long-term outcome in methylmalonic aciduria: a series of 30 French patients. Mol Genet Metab. 
97 (2009) 172-178. 
(9) Andrews E, Jansen R, Crane AM, Cholin S, McDonnell D, Ledley FD, Expression of 
recombinant human methylmalonyl-CoA mutase in primary mut fibroblasts and Saccharomyces 
cerevisiae. Biochem Med Metab Biol. 50 (1993) 135-44. 
49 
(10) Van Calcar SC, Harding CO, Lyne P, Hogan K, Banerjee R, Sollinger H, Rieselbach RE, 
Wolff JA, Renal transplantation in a patient with methylmalonic acidaemia. J Inherit Metab Dis. 
21 (1998) 729-737. 
(11) Morath MA, Okun JG, Müller IB, Sauer SW, Hörster F, Hoffmann GF, Kölker S, 
Neurodegeneration and chronic renal failure in methylmalonic aciduria--a pathophysiological 
approach. J Inherit Metab Dis. 31 (2008) 35-43. 
(12) De Keyzer Y, Valayannopoulos V, Benoist JF, Batteux F, Lacaille F, Hubert L, Chrétien D, 
Chadefeaux-Vekemans B, Niaudet P, Touati G, Munnich A, de Lonlay P, Multiple OXPHOS 
deficiency in the liver, kidney, heart, and skeletal muscle of patients with methylmalonic aciduria 
and propionic aciduria. Pediatr Res. 66 (2009) 91-95. 
(13) Kölker S, Sauer SW, Surtees RA, Leonard JV, The aetiology of neurological complications of 
organic acidaemias--a role for the blood-brain barrier. J Inherit Metab Dis. 29 (2006) 701-704. 
(14) Kölker S, Burgard P, Sauer SW, Okun JG, Current concepts in organic acidurias: 
understanding intra- and extracerebral disease manifestation. J Inherit Metab Dis. 20 March 2013, 
DOI 10.1007/s10545-013-9600-8, Epub ahead of print. 
(15) Sauer SW, Opp S, Haarmann A, Okun JG, Kölker S, Morath MA, Long-term exposure of 
human proximal tubule cells to hydroxycobalamin (c-lactam) as a possible model to study renal 
disease in methylmalonic acidurias. Inherit Metab Dis. 32 (2009) 720-727. 
(16) Coman D, Huang J, McTaggart S, Sakamoto O, Ohura T, McGill J, Burke J, Renal 
transplantation in a 14-year-old girl with vitamin B12-responsive cblA-type methylmalonic 
acidaemia. PediatrNephrol. 21 (2006) 270-273.  
(17) Lubrano R, Elli M, Rossi M, Travasso E, Raggi C, Barsotti P, Carducci C, Berloco P, Renal 
transplant in methylmalonic acidemia: could it be the best option? Report on a case at 10 years and 
review of the literature. PediatrNephrol. 22 (2007) 1209-1214.  
50 
(18) Lubrano R, Bellelli E, Gentile I, Paoli S, Carducci C, Carducci C, Santagata S, Pérez B, 
Ugarte M, Labriola D, Elli M, Pregnancy in a methylmalonic acidemia patient with kidney 
transplantation: a case report. Am J Transplant.13 (2013) 1918-1922.  
(19) Lubrano R, Perez B, Elli M. Methylmalonic acidemia and kidney transplantation, Pediatr 
Nephrol. 2013 Jun 22, DOI 10.1007/s00467-013-2536-2, Epub ahead of print. 
(20) Van't Hoff WG, Dixon M, Taylor J, Mistry P, Rolles K, Rees L, Leonard JV, Combined liver-
kidney transplantation in methylmalonic acidemia. J Pediatr. 132 (1998) 1043-1044. 
(21) Chakrapani A, Sivakumar P, McKiernan PJ, Leonard JV, Metabolic stroke in methylmalonic 
acidemia five years after liver transplantation. J Pediatr. 140 (2002) 261-263. 
(22) Morioka D, Kasahara M, Takada Y, Corrales JP, Yoshizawa A, Sakamoto S, Taira K, 
Yoshitoshi EY, Egawa H, Shimada H, Tanaka K, Living donor liver transplantation for pediatric 
patients with inheritable metabolic disorders. Am J Transplant. 5 (2005) 2754-2763. 
(23) Kaplan P, Ficicioglu C, Mazur AT, Palmieri MJ, Berry GT, Liver transplantation is not 
curative for methylmalonic acidopathy caused by methylmalonyl-CoA mutase deficiency. Mol 
Genet Metab.88 (2006) 322-326. 
(24) Brassier A, Boyer O, Valayannopoulos V, Ottolenghi C, Krug P, Cosson MA, Touati G, 
Arnoux JB, Barbier V, Bahi-Buisson N, Desguerre I, Charbit M, Benoist JF, Dupic L, Aigrain Y, 
Blanc T, Salomon R, Rabier D, Guest G, de Lonlay P, Niaudet P, Renal transplantation in 4 
patients with methylmalonic aciduria: A cell therapy for metabolic disease. Mol Genet Metab. 
2013 May 14, pii: S1096-7192(13)00149-2. doi: 10.1016/j.ymgme.2013.05.001. Epub ahead of 
print. 
(25) Kasahara M, Horikawa R, Tagawa M, Uemoto S, Yokoyama S, Shibata Y, Kawano T, Kuroda 
T, Honna T, Tanaka K, Saeki M, Current role of liver transplantation for methylmalonic acidemia: 
a review of the literature. Pediatr Transplant. 10 (2006) 943-947. 
51 
(26) Leonard JV, Walter JH, McKiernan PJ, The management of organic acidaemias: the role of 
transplantation. J Inherit Metab Dis. 24 (2001) 309-311. 
(27) Whelan DT, Ryan E, Spate M, Morris M, Hurley RM, Hill R, Methylmalonic academia: 6 
years clinical experience with two variants unresponsive to vitamin B12 therapy. CMA Journal 19 
(1979) 1230-1235. 
(28) Zhou Y, Fang L, Jiang L, Wen P, Cao H, He W, Dai C, Yang J, Uric acid induces renal 
inflammation via activating tubular NF-κB signaling pathway. PLoS One 7 (2012) e39738. 
  
52 
IV. Impaired Mitophagy Links Mitochondrial Dysfunction and Epithelial Cell Damage in 
Methylmalonic Aciduria  
Anke Schumann1,2, 3*, Alessandro Luciani1*, Marine Berquez1, Natsuko Tokonami1, Huguette Debaix1, 
Patrick Forny2, Stefan Kölker4, Francesca Diomedi Camassei5, Nourdine Faresse5, Andrew Hall6, Urs 
Ziegler7, Matthias Baumgartner2,3 and Olivier Devuyst1,3 
 
1Institute of Physiology, University of Zurich, Switzerland 
2Division of Metabolism and Children’s Research Center, University Children’s Hospital, Zurich, 
Switzerland 
3Center for Integrative Human Physiology, University of Zurich, Zurich 8057, Switzerland. 
4University Children’s Hospital, Division of Inherited Metabolic Diseases, Heidelberg, Germany 
5Division of Nephrology, Ospedale Pediatrico Bambino Gesu, Rome, Italy 
6Institute of Anatomy, University of Zurich, Switzerland 
7Center for Microscopy and Image Analysis, University of Zurich, Switzerland. 
 
 
 
 
* AS and AL contributed equally to this study. 
 
Correspondence: Prof. Dr. med. Olivier Devuyst ( Olivier.Devuyst@uzh.ch)  
University of Zurich, Institute of Physiology, Winterthurerstrasse 190, 8057 Zurich, Switzerland; 
Phone: +41 (0)44 635 50 82; Fax: +41 (0)44 635 68 14 
 
  
53 
Abstract 
The maintenance of mitochondrial integrity has a key role in preserving both the metabolic and 
cellular homeostasis in specialized cells. Mitochondrial disorders such as methylmalonic aciduria 
(MMA), due to inactivating mutations in the MUT gene coding for methylmalonyl-CoA mutase 
(MUT) cause epithelial cell damage resulting in renal tubular dysfunction and kidney disease. The 
mechanisms linking mitochondrial defects and epithelial cell damage remain unknown, preventing the 
development of disease-modifying therapies.  
By combining genetic and pharmacological approaches, we demonstrate that mitochondria are 
fragmented and dysfunctional in human and mouse renal cells lacking functional MUT. Through the 
dysregulation of the PINK1/Parkin pathway, disease-causing MUT mutations or Mut gene deficiency 
impair the autophagy-mediated clearance of dysfunctional mitochondria. In turn, the cells accumulate 
autophagy and ubiquitinated proteins and mitochondrial ROS, causing cell damage. Treatment of 
MMA patient-derived cells with the mitochondria-targeted antioxidant MitoTEMPO (MT) restored 
mitochondrial homeostasis and increased the ratio of uncleaved vs. cleaved PINK1, promoting 
autophagy degradation of dysfunctional mitochondria and reversing the cellular damage process. 
These data reveal the mechanism bridging mitochondrial dysfunction and epithelial cell damage in 
MMA and the importance of PINK1/Parkin dependent mitochondrial turnover in epithelial cell 
homeostasis. Targeting mitochondrial ROS production offers therapeutic perspectives to reduce 
epithelial damage downstream to primary mitochondrial defects.   
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1. Introduction 
The mitochondrial network performs diverse yet interconnected functions, producing energy and many 
biosynthetic intermediates while also contributing to the maintenance of homeostatic signaling 
pathways (Nunnari, 2012). The functioning of this dynamic and pleiotropic organelle is particularly 
relevant in the context of terminally differentiated cells (McWilliams, 2017). Defects in mitochondrial 
function potentially confer devastating vulnerability to many different cell types, contributing to 
severe clinical features of a wide range of human disorders (Anding, 2017). 
 Methylmalonyl-CoA mutase (MUT) is a mitochondrial enzyme which catalyzes the 
isomerization of methylmalonyl-CoA to succinyl-CoA using vitamin B12 as a cofactor. This reaction is 
crucial for the propionate catabolism, funneling metabolites of odd-chain fatty acids, branched-chain 
amino acids and cholesterol into the Krebs cycle (Baumgartner, 2014). The vital importance of MUT 
activity is demonstrated by methylmalonic aciduria (MMA, MIM# 251000), a severe inborn error of 
metabolism that is primarily caused by recessive mutations in the encoding MUT gene, resulting in 
complete (mut0) or partial (mut-) deficiency of the enzyme. Patients with MMA usually present during 
the first days of life with severe metabolic acidosis, lethargy, and failure to thrive, progressing to 
multi-systemic complications, coma and even death when untreated (Oberholzer, 1967; Baumgartner, 
2014). MUT is highly expressed in the kidney, where mitochondria fuel the important transport 
processes mediated by renal tubular cells (Emma, 2016). The most common complications observed in 
surviving MMA patients include renal tubular dysfunction and development of chronic kidney disease 
due to tubulointerstitial lesions (Hörster, 2007; Cosson 2009; Baumgartner, 2014). Treatment for 
MMA is limited to the reduction of circulating metabolites, symptomatic care of complications, and 
liver and/or kidney transplantation (Brassier, 2013; Kassahara, 2006). Thus, there is an urgent need to 
identify novel therapeutic targets for this devastating disorder.  
 Despite the genetic elucidation of MMA and the increasing knowledge of its clinical 
characteristics, the pathophysiology of the end-organ damage and the cellular mechanisms linking 
mitochondrial enzyme deficiency and epithelial dysfunction in MMA remain largely unknown. The 
Mut knock-out (KO) mouse models needed AAV-based gene therapy (Chandler, 2010) or transgenic 
expression in the liver (Manoli, 2013) to overcome the neonatal lethality, limiting their relevance for 
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the study of the human disease (Forny, 2016). Studies in transgenic Mut-/-; TgINS-Alb-Mut  mice showing a 
decreased glomerular filtration rate with tubulointerstitial damage revealed abnormal mitochondria, 
oxidative stress and increased renal damage markers, potentially attenuated by antioxidants (Manoli, 
2013). The generation of more clinically relevant mouse models of MMA using a constitutive Mut 
knock-in (KI) allele based on a typical MMA patient mutation (p.met700Lys) allowed us to confirm 
the metabolic relevance of the model, with manifestations of progressive kidney damage and markers 
of oxidative stress (Forny, 2016). 
 In most mammalian cells, a variety of mitochondrial quality control (MQC) systems operate to 
preserve the mitochondrial architecture and its bioenergetic function (Fischer, 2012). Through an 
evolutionary conserved, selective degradation of worn-out/damaged mitochondria by autophagy (a 
process called mitophagy), the cells remove the potential damage-promoting byproducts, safeguarding 
the homeostasis and cellular functions (Stolz, 2014). During mitophagy, the kinase PINK1 and the 
ubiquitin ligase Parkin cooperate to attach ubiquitin tags to proteins of outer membrane of damaged 
mitochondria, which mark them for disposal (Allyson, 2017; Kitada, 1998). Autophagy receptor 
proteins such as SQSTM1/p62 then assist in cellular degradation by binding to both the ubiquitinated 
proteins and to components of autophagy machinery, such as the protein LC3 (Stolz, 2014). This 
homeostatic process is particularly active in renal tubular cells, whose reabsorptive and secretory 
activities require the maintenance of mitochondria network (Fougeray, 2015). Moreover, the 
autophagy-mediated turnover of damaged mitochondria is required for protecting the tubular cells 
from acute injury (Isaka, 2011), whereas deletion of essential autophagy genes damages them through 
defective mitochondrial clearance and increased reactive oxygen species (ROS) (Yamamoto, 2016). 
Of note, accumulation of abnormal mitochondria with disorganized cristae has been described in 
kidney biopsies from MMA patients (Manoli, 2013), suggesting potential involvement of autophagic-
mediated clearance and MQC systems.  
 We therefore hypothesized that the MUT enzymatic deficienty may alter the integrity of the 
mitochondrial network by compromising mitochondrial autophagy and that such defects may 
contribute to the renal tubular dysfunction observed in patients with MMA. Here, we report that 
disease relevant inactivating mutations or genetic deletion of MUT impair the PINK/Parkin-mediated 
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autophagic degradation of fragmented and dysfunctional mitochondria, causing oxidative stress and 
dysfunction of renal tubule cells. Restoring mitochondrial homeostasis by applying mitochondria-
targeted antioxidant treatment in MMA patient-derived cells reverse cellular dysfunction, emphasizing 
a new therapeutic strategy for treating renal tubular dysfunction in MMA and mitochondrial disorders.  
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2. Results 
Defective mitochondrial homoeostasis, oxidative stress and damage in tubular cells from MMA 
patients 
Based on the high expression and specific distribution pattern of MUT in mouse and human kidney 
(Suppl. Figs. S1 and S2), we hypothesized that the MMA-associated mutations inactivating MUT 
impair mitochondria homeostasis and promote tubular/epithelial cell dysfunction.  
To tackle this hypothesis, we first analyzed the mitochondrial network in renal tubular cells obtained 
from the urine of MMA patients harbouring MUT mutations (MMA1-3) and three controls (WT1-3) 
(Table 1). The MMA-derived renal tubular cells displayed a marked decrease in MUT protein and 
activity at TOMM20-labelled mitochondria when compared to control cells (Fig. 1, A-C). 
Transmission electron microscopy (TEM) analyses revealed that mitochondria, which appear as an 
interconnected meshwork of elongated organelles in control cells, were characterized by a prominent 
fragmented/rod-like shape with an impaired cristae organization in MMA cells (Fig. 1D). The outer 
mitochondrial membrane protein TOMM20 and inner mitochondrial membrane protein prohibitin 
showed a marked decrease in mitochondrial content in MMA cells (Fig. 1E). These changes contrasted 
with no changes in segment markers (Suppl. Fig. S3A-B), morphological features (Suppl. Fig. S3C), 
viability (Suppl. Fig. S3D) and cell proliferation rates (Suppl. Fig. S3E) in MMA cells compared to 
controls. 
We next tested whether these MUT-induced changes in mitochondria network could have any impact 
on organelle function. Measurement of overall oxygen consumption rates in control and MMA patient-
derived cells based on Seahorse metabolic flux analyses revealed impaired mitochondrial 
bioenergetics, as evidenced by a reduction in baseline respiration, ATP turnover and total respiratory 
capacity (Fig. 1F; Suppl. Fig. S4 A-B). Quantitative confocal imaging of tetramethylrhodamine methyl 
ester (TMRM) dye revealed that the resting mitochondrial membrane potential (m, a key requisite 
for effective oxidative phosphorylation and energy production) of MMA cells was significantly lower 
than of control cells (Fig. 1G). These changes were paralleled by major mitochondrial oxidative stress, 
as indicated by elevated mtROS levels (MitoSOX, a live-cell permeant indicator of mitochondrial 
superoxide; Fig. 1H), increased anti-oxidant response (SOD1; Fig. 1I), and tubular cell damage, 
58 
indicated by the major increase in the kidney injury molecule 1 (KIM1) and lipocalin-2 (LCN2) (Fig. 
1I) in the MMA cells. These data suggest that an abnormal mitochondrial network triggers oxidative 
stress and epithelial damage in MMA patient-derived renal tubular cells. 
Table 1. Mutations and enzymatic activities in renal tubular cells obtained from wild-type controls and patients with MMA.  
Source 
 
Class of MUT 
mutation 
 
Nucleotide change Amino acid change 
Enzymatic activity 
(pmol/min/mg protein) 
 
Control 1 WT - - 3403 ± 136 
Control 2 WT - - 7406  
Control 3 WT - - 3738  
     
MMA1 mut- c.572C>A p.A191E 79 ± 9 
  (exon 3)   
MMA2 mut0 c.862T>C p.S288P 17 ± 10 
  (exon 4)   
MMA3 mut0 c.982C>T p.L328F 38 ± 25 
  (exon 4)   
      
Table 1: Enzymatic activity is given as mean  SEM of 3 independent measurements. WT, wild-type; MMA, methylmalonic aciduria; 
mut0, complete deficiency; mut- partial deficiency in methylmalonyl-CoA mutase (MUT).  
 
 
Figure 1. Impaired mitochondrial homeostasis, oxidative stress and cell damage in tubular cells derived from MMA patients.  
(A) Western blotting and densitometric analyses of MUT protein levels in control (n=3) and MMA cells (n=3). β-actin was used as a 
loading control. ***P<0.001 relative to control cells. (B) MUT enzymatic activity in crude cell homogenates obtained from control (n=3) 
and MMA cells (n=3). ***P<0.001 relative to control cells. (C) The control and MMA-derived renal tubular cells were immunostained 
with anti-TOMM20 (green) and anti-MUT (red) antibodies, and analysed by confocal microscopy. The MMA cells show a marked 
decrease in MUT protein and activity at TOMM20-labelled mitochondria when compared to control cells. (D) Electron microscopy 
showing filamentous mitochondria with preserved cristae in control cells vs. fragmented mitochondria with destroyed cristae in MMA 
cells. Dotted yellow squares. 
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Figure 1 (ctd.) (E) Western blotting and densitometric analyses of prohibitin, TOMM-20 and prohibitin protein levels in control (n=3) 
and MMA cells (n=3). β-actin was used as a loading control. **P<0.01 and ***P<0.001 relative to control cells (F) Mitochondrial 
function of controls (n=3) and MMA patient-derived renal tubular cells (n=3). Oxygen consumption rates (OCRs) were measured at basal 
level and after the sequential addition of oligomycin (Oligo, 1µM), FCCP (0.5µM) and Rotenone (ROT; 1.0µM) + antimycin A (ANT; 
1.0µM). The MMA patient-derived cells show a reduction in baseline respiration, ATP turnover and total respiratory capacity. (G) The 
cells were loaded with tetramethylrhodamine methyl ester (TMRM; 50nM for 30 min at 37°C) and analysed by live confocal microscopy 
to measure the resting mitochondrial membrane potential (m), which is significantly lower in MMA cells compared to control cells. 
Quantifications of TMRM fluorescence intensity obtained from 3 randomly selected fields per condition, with each containing ~10-15 
cells. **P<0.01 relative to control cells. (H) Cells were loaded with CellROX (cellular ROS probe; 5 µM for 10 min at 37°C) and 
MitoSOX (mitochondrial ROS probe; 2.5 µM for 10 min at 37°C) and analysed by live confocal microscopy. Quantification of CellROX 
or MitoSOX fluorescence intensity was obtained from 3 randomly selected fields per condition, with each containing ~10-15 cells. 
***P<0.001 relative to control cells. (I) Western blotting and densitometric analyses of SOD1, KIM1 and LCN2 protein levels in control 
(n=3) and MMA cells (n=3). ß-actin was used as a loading control. **P<0.01 and ***P<0.001 relative to control cells. The nuclei are 
counterstained with DAPI (blue). Yellow indicates co-localization in C and H. Scale bars: 10µm in C, 1µm in D and 10µm in G and H.  
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Autophagy is upregulated in renal tubular cells from MMA patients 
Because the clearance of damaged/dysfunctional mitochondria occurs via autophagy, we speculated 
that dysregulated autophagy may explain the mitochondrial abnormalities in tubular cells from MMA 
patients. To investigate the state of autophagy, the cells were transduced with adenoviral particles 
expressing the green-fluorescent protein (GFP)-tagged autophagosome marker MAP1LC3 (GFP-
LC3). We observed an increase in the number of autophagic vesicles in MMA cells when compared to 
controls (Fig. 2A). This observation was confirmed by quantifying the conversion of the LC3 (LC3I) 
to the autophagosome-associated lipidated form (LC3II; Fig. 2B) and by TEM (Fig. 2C).  
Higher numbers of autophagosomes may reflect increased biogenesis or reduced lysosomal clearance. 
We next used the autophagy flux inhibitor Bafilomycin A1 (BfnA1), which prevents lysosomal 
degradation and reveals changes in autophagosome synthesis (Klionsky, 2016). The inhibition of 
lysosome function by BfnA1 treatment further increased both the numbers of punctate GFP-LC3 and 
the levels of LC3II in MMA cells (Figs. 2A-B), implying an increase in autophagosome biogenesis. 
The abnormal autophagic flux was not due to a block in autophagosomal delivery or lysosomal 
clearance because neither changes in autophagosomal-lysosomal fusion (as indicated by the 
colocalization of LC3-marked autophagosomes in LAMP1-flagged lysosomes and by Rab7 GTPase 
protein regulating the fusion process) nor in lysosomal dynamics (as scored by abundance of 
lysosomal proteins LAMP2 and cathepsin-D) nor in lysosomal degradation capacity (as indicated by 
Bodipy-FL-PepstatinA (PepA), a fluorescence-tagged PepA which binds to the active site of 
cathepsin-D in acidic lysosomes) occurred in MMA cells (Suppl. Figs. 5A-C).  
When compared to control cells, MMA cells displayed increased levels of p62 (a protein regulating 
autophagic clearance of dysfunctional organelles), which was unrelated to increased mRNA levels 
(Fig. 2D; Suppl. Fig. 6 A-B). Consistently, ubiquitin (Ub)-positive inclusions accumulated in MMA 
cells (Fig. 2 E), substantiating a deregulation of autophagy. Similar to the changes in MMA patient 
derived renal tubular cells, there was a remarkable accumulation of LC3-marking autophagosomes and 
p62-forming aggregates in kidney biopsies from mut0 patient (Fig. 2 F-G). These findings show that 
the abnormalities in the mitochondrial network are associated with dysregulation of autophagy in 
MMA cells in vitro and in vivo.  
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Figure 2. Dysregulation of autophagy in tubular cells derived from MMA patients. 
(A) The cells were transduced with GFP-LC3B bearing adenoviral particles for 2 days and cultured in presence or in absence of 250 nM 
BfnA1 for 4h. Representative confocal micrographs (left panel)) and quantification of numbers of GFPLC3 structures in MMA and 
control cells (right panel; n=30 cells pooled from three control and MMA cells; each point representing the average number of GFPLC3+ 
vesicles in a cell). ***P<0.001 relative to control cells; **P<0.001 relative to untreated MMA cells. (B) Western blotting and 
densitometric analyses for LC3 protein levels in cells cultured in fed medium in presence or in absence of 250 nM BfnA1for 4h. *P<0.05 
relative to controls or to MMA cells and ***P<0.01 relative to controls, n=3 independent experiments. (C) Representative images of 
transmission electron microscopy (TEM) showing increased numbers of autophagic vacuoles in MMA cells in comparison to controls. 
Yellow arrow head indicates autophagic vacuoles. (D) Western blotting and densitometric analyses of p62 protein levels in control and 
MMA cells. β-actin was used as a loading control. **P<0.01 relative to control cells (n=3). (E) Control and MMA cells were cultured in 
presence and in absence of 26S proteasome subunit inhibitor MG132 (50µM for 12h). Western blotting and densitometric analyses of 
ubiquitin protein levels. β-actin was used as a loading control. ***P<0.01 relative to control cells (n=3); ns, not significant. (F-G) 
Representative confocal micrographs of LC3 (F, red) or p62 (G; red) in LTL (green)-positive proximal tubules of human kidneys from 
control and MMA patient. Nuclei counterstained with DAPI (blue). Scale bars: 10µm in A, F and G, and 2µm in C. 
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Impaired mitophagy in renal tubular cells from MMA patients 
The maintenance of the mitochondrial network is ensured through selective targeting of damaged 
mitochondria to autophagosomes via mitophagy (Pickrell, 2015). Given the higher LC3-fluxes in 
MMA cells experiencing mitochondrial dysfunction, we tested whether specific defects in mitophagy 
could account for the MMA-related alterations in mitochondrial network. The use of the mitochondrial 
stressor Rotenone, which leads to a rapid loss of m and a major increase of ROS in the cells (Suppl. 
Fig. S7 A-B), allowed us to investigate the mitophagy cascade in both control and MMA cells. The 
rates of mitophagy were quantified by the subcellular distribution of TOMM20-labeled mitochondria 
within LC3-flagged autophagic structures. In control cells, only a small fraction of LC3-vesicles co-
localized with mitochondria at baseline, whereas an increased number of mitochondria became coated 
with LC3 in response to rotenone (m depolarization) (Fig. 3A, top panel). Conversely, the 
mitophagic response was severely blunted in MMA cells even after treatment with rotenone, 
indicating impaired relocation of damaged mitochondria to the autophagosome (Fig. 3A, bottom 
panel). The initiation of mitophagy requires a molecular signal from damaged mitochondria. Loss of 
mitochondrial m inhibits the degradation of PINK1 and reroutes it to the surface of mitochondria, 
where it recruits parkin, tagging damaged mitochondria for autophagic degradation via ubiquitination 
(Youle, 2012). The baseline amount of PINK1and Parkin proteins were significantly decreased in 
MMA cells compared to controls (Fig. 3B), despite unchanged levels of mRNA transcripts (Suppl. 
Fig. S8).  
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When exposed to rotenone, the control cells showed a significant increase in the recruitment of PINK1 
to damaged mitochondria (colocalization with TOMM20), which was totally absent in MMA patient 
derived renal tubular cells (Fig. 3C).  
Because PINK1 is retained on the outer mitochondrial membrane of depolarized mitochondria and 
disease relevant inactivating mutations in MUT led to depolarization of the mitochondrial membrane, 
we next investigated the stability of the full-length PINK1 (Wang, 2011). In control cells, rotenone-
induced mitochondrial damage led to a major, 20-fold increase in the ratio of full-length to cleaved 
PINK1, which contrasted with the persistence of high level of cleaved PINK1 in the MMA cells (Fig. 
3D). These findings collectively suggest an impairment of PINK1/Parkin mediated degradation of 
damaged/dysfunctional mitochondria in tubular cells derived from MMA patients.  
 
Figure 3. Defective PINK1/Parkin dependent clearance of damaged mitochondria in tubular cells derived from MMA patients.  
(A, C-D) The cells were cultured in presence or in absence of Rotenone (10µM for 16 h). (A) Representative confocal micrographs and 
quantification of LC3/TOMM20 positive structures (in percentage of total mitochondria). Quantification obtained on 5 randomly selected 
fields per condition, with each containing ~10-15 cells; ***P<0.001 and *P<0.05 relative to untreated control cells; ***P<0.001 and 
relative to Rotenone-treated control cells; ns, not significant. (B) Western blotting and densitometric analyses of PINK1and parkin protein 
levels in control and MMA cells. β-actin was used as a loading control. **P<0.01 and ***P<0.01 relative to control cells (n=3). uc, 
uncleaved; c, cleaved.  Scale bar: 10µm in A. 
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Figure 3 (ctd.) (C) Representative confocal micrographs and quantification of PINK1/TOMM20 positive structures (in percentage of 
total mitochondria). Quantification obtained on 5 randomly selected fields per condition, with each containing ~10-15 cells; ***P<0.001 
relative to untreated control cells; ***P<0.001 relative to untreated-control cells; ***P<0.001 relative to Rotenone-treated control cells. 
ns, not significant. (D) Western blotting and densitometric analyses of PINK1protein levels in control and MMA cells. β-actin was used 
as a loading control. **P<0.01 and ***P<0.001 relative to control cells (n=3). uc, uncleaved; c, cleaved. Nuclei counterstained with 
DAPI (blue). Scale bar: 10µm in C. 
Impaired mitochondrial homeostasis due to MUT deficiency causes epithelial damage  
We next evaluated the direct link between the loss of MUT function, impaired mitochondrial 
homeostasis and dysfunction of renal tubular cells. We used primary proximal tubule cells (PTCs) 
derived from Mut flox/flox mice and an adenovirus-coding Cre-recombinase to investigate whether Mut 
deficiency may alter PINK1/Parkin-mediated mitophagy. The Cre-mediated loss of functional MUT, 
which was verified at both mRNA (Fig. 4A) and protein levels (Fig. 4B), lowered the mitochondrial 
mass (TOMM20 protein levels; Fig. 4B) and was reflected by an aberrant mitochondrial network with 
a prominent fragmented/rod-like shape evidenced by immunostaining for TOMM20 (Fig. 4C). These 
changes in mitochondrial mass and morphology were associated with a decrease in m (as evidenced 
by TMRM staining and quantitative confocal imaging; Fig. 4D) and increase in mitochondrial ROS 
generation (Fig. 4E). Paralleling mitochondrial dysfunction, Mut-deleted cells showed a striking 
accumulation of autophagic cargoes and substrates (quantitation of LC3-marking autophagosomes and 
aggregates-forming p62) (Figs. 4 F-G) and decreased levels of PINK1 and Parkin (Fig. 4G).  
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Figure 4. MUT deficiency impairs mitochondrial network and mitophagy, promoting cell damage in renal tubular cells.  
Primary cultures of mouse proximal tubule cells were transduced with either empty (Empty) or Cre-recombinase (Cre) bearing adenoviral 
particles for 5 days. (A) The mRNA levels of Mut were analysed by real-time PCR., (n=4). (B-C) Western blotting and densitometric 
analyses of MUT (B) and TOMM20 (C) protein levels. β-actin was used as a loading control, (n=4). (D) The cells were immunostained 
with anti-TOMM20 (green) and analysed by confocal microscopy. (E) The cells were loaded with tetramethylrhodamine methyl ester 
(TMRM; 50nM for 30 min at 37°C) or with MitoSOX (mitochondrial ROS probe; 2.5µM for 10 min at 37°C), and analysed by live 
confocal microscopy. Quantifications of TMRM or MitoSOX fluorescence intensities obtained from 4 randomly selected fields pooled 
from four independent experiments, with each containing ~10-15 cells. (F) Representative confocal micrographs and quantification of 
LC3 (left panel) and p62 (right panel) positive structures in MUT-deficient PT cells (n=50 cells pooled from four independent 
experiments; each point representing the average number of LC3+ or p62+ vesicles in a cell). (G) Western blotting and densitometric 
analyses of PINK1, Parkin, p62 and LCN2 protein levels. β-actin was used as a loading control. uc, uncleaved; c, cleaved. *P<0.05, 
**P<0.01, ***P<0.001 and #P<0.0001 relative to cells transduced with empty adenoviral particles. Nuclei counterstained with DAPI 
(blue). Scale bars: 10µm in D, E and F. 
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Additionally, the alterations in mitochondrial network homeostasis and mitophagy were mirrored by 
the increase in the renal tubular marker lipocalin-2 (LCN2; Fig. 4G), suggesting that the maintenance 
of mitochondrial network integrity is essential for preserving homeostasis in renal tubule cells. 
Impaired mitochondrial homeostasis leads to kidney damage in Mutko/ki mice 
To enhance the translational potential of the findings, we investigated the changes in mitochondrial 
network homeostasis and mitophagy in the kidneys of compound heterozygous Mutko/ki mice, a novel 
model of MMAuria (Forny, 2016). The protein expression of MUT was 5-fold reduced in the kidneys 
of the Mutki/ko mice (Fig. 5A), consistent with a major reduction in the MUT enzymatic activity in 
these kidneys (Forny, 2016). Immunofluorescence, TEM and western blotting analyses indicated that 
the mitochondrial network, which appeared fragmented and with disorganized cristae, was reduced in 
the epithelial cells lining the renal tubules of the Mutki/ko mice in comparison to control littermates 
(Figs. 5 A-C).  
 
Figure 5. Altered mitochondrial homeostasis and impaired mitophagy leads to kidney damage in Mutko/ki mice.  
(A) Western blotting and densitometric analyses of MUT and TOMM20 protein levels in whole kidney lysates from Mut mice. (B) 
Representative confocal micrographs of TOMM20 in Mut mouse kidneys. 
 
LC3-flagging autophagosomes or p62-positive aggregates accumulated in the kidneys of the Mutki/ko 
mice (Figs. 5 D-E) pointing at induction of autophagy. Similar to mitophagy defects observed in 
MMA patient-derived and Mut-deleted renal tubular cells, the mitophagy proteins PINK1and Parkin 
were strikingly lower in the kidneys from Mutko/ki mice when compared to control littermates (Fig. 5F). 
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These changes were paralleled by an increase in LCN2 (Fig. 5F) as well as by abnormal plasma and 
urine parameters (Table 2) indicating MMA-associated renal tubular damage.  
Consistent with in vitro findings (MMA cells and genetic deletion of Mut), these in vivo data suggest 
that MUT deficiency leads to renal tubule dysfunction by compromising PINK1/Parkin mediated 
mitophagy and mitochondrial homeostasis. 
 
Figure 5 (ctd.) (C) TEM micrographs showing filamentous mitochondria with preserved cristae organization in the kidneys of Mutwt/wt 
mice vs. fragmented mitochondria with destroyed cristae organization in the kidneys of Mutki/ko mice. (D-E) Representative confocal 
micrographs and quantification of the numbers of LC3 (left panel; red) or SQSTM1structures (right panel; red) per field in stained 
sections; n= 5 fields per kidney slices. (F) Western blotting and densitometric analyses of PINK1, Parkin, p62 and LCN2 protein levels in 
whole kidney lysates from Mut mice. uc, uncleaved; c, cleaved. *P<0.05, **P<0.01 and ***P<0.001 relative to control littermates. 
Nuclei counterstained with DAPI (blue). Scale bars: 10µm in B, D, and 1 µm in C. 
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Table 2. Clinical and biochemical parameters in Mutwt/wt and Mutko/ki mice. 
  Mutwt/wt Mutki/ko P value 
       
Body weight (g)  23.1 ± 0.34  21.4 ± 0.36 ≤ 0.01 
Food intake (per g BW)  0.16 ± 0.05  0.11 ± 0.01 ≤ 0.05 
Water intake (per g BW)  0.26 ± 0.05  0.11 ± 0.01 ≤ 0.01 
       
Plasma      
Creatinine (mg/dl)   0.11 ± 0.03    0.11 ± 0.03 ns 
BUN (mg/dl) 43.51 ± 4.98  61.99 ± 1.59 ≤ 0.001 
       
Urine      
Diuresis (µl/h/g BW) 10.47 ± 1.31    1.46 ± 0.24 ≤ 0.001 
Sodium (mM mM-1 creatinine) 32.85 ± 1.20  40.58 ± 2.22 ≤ 0.001 
Chloride (mM mM-1 creatinine) 51.97 ± 2.96  60.40 ± 3.81 ≤ 0.07 
Potassium (mM mM-1 creatinine) 71.08 ± 2.76  85.54 ± 2.88 ≤ 0.01 
Calcium (mg mg-1 creatinine)   0.02 ± 0.003    0.19 ± 0.03 ≤ 0.001 
Phosphate (mg mg-1 creatinine)   3.66 ± 0.30    6.29 ± 0.41 ≤ 0.01 
Magnesium (mg mg-1 creatinine)   1.59 ± 0.01    2.56 ± 0.16 ≤ 0.01 
       
Metabolic papameters      
C3 (mmol/l)  0.03 ± 0.002    0.25 ± 0.02 ≤ 0,001 
MMA excretion (mmol/mol creat)     10 ± 2.5 10000 ± 250 ≤ 0.001 
        
 
 
Table 2: Mutwt/wt (n=5) and Mutki/ko (n=5) female mice on C57BL/6 background at 16 weeks of age on normal diet. Values are given as 
mean  SEM. ns= non-significant.  
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Targeted antioxidant treatment restores mitochondrial homeostasis and attenuates cellular damage 
in MMA cells 
Finally, we explored the functional consequences of neutralizing the excess of mitochondrial oxidative 
stress by treating MMA patient-derived cells with the mitochondria-targeted anti-oxidant Mito-
TEMPO (MT, 10µM for 24h) (Lood, 2016). This treatment rescued the mitochondrial morphology and 
mass (Figs. 6 A-B), restored the mitochondrial membrane potential (m, Fig. 6C) and neutralized the 
excessive production of ROS (Fig. 6C).  
 
 
Figure 6. Mitochondria-targeted antioxidant restores 
mitochondrial homeostasis and attenuates cell 
damage in renal tubular cells from MMA patients.  
(A-F) Control and MMA cells were cultured in presence 
or in absence of MitoQ (MT, 10µM for 24 h). (A) The 
cells were immunostained with anti-TOMM20 (green) 
antibody and analysed by confocal microscopy. The 
nuclei counterstained with DAPI (blue). Scale bar, 10 
µm. (B) Western blotting and densitometric analyses of 
TOMM-20 protein levels. β-actin was used as a loading 
control. *P=0.03 relative to untreated control cells, 
**P<0.01 relative to untreated-MMA cells and 
***P<0.001 relative to untreated control cells, n=3. (C) 
The cells were loaded with tetramethylrhodamine methyl 
ester (TMRM; 50nM for 30 min at 37°C) or with 
CellROX (cellular ROS probe; 5µM for 10 min at 
37°C), and analysed by live confocal microscopy. 
Quantifications of TMRM or MitoSOX fluorescence 
intensities obtained from 4 randomly selected fields 
pooled from four independent experiments, with each 
containing ~10-15 cells. **P<0.01 and ***P<0.001 
relative to untreated control cells, and #P<0.001 relative 
to untreated MMA cells; n=3. 
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Importantly, treatment with MT decreased either the p62 protein amounts or ubiquitin-positive 
inclusions (Fig. 6C), and partially increased the levels of PINK1 (Fig. 6D), suggesting that MMA cells 
can effectively clear damaged/dysfunctional mitochondria targeted for mitophagy. Notably, the 
replenishment of mitochondrial network homeostasis by Mito-TEMPO (MT) was mirrored by a 
marked decrease in the protein levels of LCN2 (Fig. 6E), indicating that the excess of mitochondrial 
ROS production resulting from impaired targeting of damaged mitochondria to mitophagy is a 
decisive factor in epithelial damage associated with in MMA. 
 
 
 
 
 
 
Figure 6 (ctd.) (D) Western blotting and densitometric analyses of 
p62 and ubiquitin protein levels. β-actin was used as a loading 
control. **P<0.01 relative to untreated control cells and 
***P<0.001 relative to untreated MMA cells, n=3; ns, not 
significant. (E) Western blotting and densitometric analyses of 
PINK1 protein levels. β-actin was used as a loading control. 
**P<0.01 relative to untreated control cells and ***P<0.001 
relative to untreated MMA cells, n=3; ns, not significant, uc, 
uncleaved; c, cleaved. (F) Western blotting and densitometric 
analyses of LCN2 protein levels. β-actin was used as a loading 
control. ***P<0.01 relative to untreated control cells or to 
untreated MMA cells; n=3. 
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3. Discussion 
Mitochondria form a dynamic, interconnected network that integrate cell metabolism by regulating 
anabolic and catabolic functions (Nunnari, 2012). Congenital defects in mitochondria-localized 
proteins, as exemplified by MMA, cause epithelial cell damage resulting in end-organ dysfunction. By 
combining genetic and pharmacological approaches, we demonstrate that mitochondria are fragmented 
and dysfunctional in human and mouse renal cells lacking functional MUT. Through the dysregulation 
of the PINK1/Parkin pathway, disease-causing MUT mutations or Mut gene deficiency impair the 
autophagy-mediated clearance of dysfunctional mitochondria. In turn, the cells accumulate 
autophagy/ubiquitinated proteins and mitochondrial ROS, causing cell damage. These data reveal the 
mechanism bridging mitochondrial dysfunction and renal epithelial cell damage in MMA and the 
importance of PINK1/Parkin dependent mitochondrial turnover in epithelial cell homeostasis.  They 
also indicate that targeting mitochondrial ROS production offers therapeutic perspectives to reduce 
epithelial damage downstream to primary mitochondrial defects.   
Our findings show that MUT deficiency leads to a major alteration in mitochondrial integrity 
and function, as evidenced by decreased numbers of swollen mitochondria, which appear fragmented 
and with disorganized cristae; altered mitochondrial membrane potential-a key requisite for effective 
oxidative phosphorylation and energy production; and impaired bioenergetics profiling, as evidenced 
by a reduction in baseline respiration, ATP turnover and total respiratory capacity. These changes 
were mirrored by excessive mitochondrial ROS production, resulting in oxidative stress and renal 
epithelial damage in both Mut-depleted renal tubular cells and MMA patient-derived cells. Similar 
changes in the mitochondrial network were observed in the kidneys of the Mutko/ki mice, a novel mouse 
model recapitulating the kidney damage associated with MMA (Forny, 2016), extending earlier 
observations in transgenic Mut mice rescued from neonatal lethality (Manoli, 2013) and in a single 
kidney biopsy of a mut0 patient (Zsengellér, 2014). Taken together, these findings point to 
mitochondria as key actors in driving cellular damage in MMA. The question was how MUT 
deficiency impacts mitochondrial homeostasis and how mitochondrial dysfunction contributes to 
epithelial damage. 
73 
Mitochondrial homeostasis is crucial for generating the high, local energy demands which are 
requested for the maintenance of cellular function, particularly in tissues with high reabsorptive 
activities like the renal tubules (Emma, 2016). As a result, a variety of inter-connected mechanisms, 
known as MQC (MQC), have evolved to regulate mitochondrial morphology, content and function 
(Kotiadis, 2014; Fisher, 2012). The removal of damaged mitochondria by autophagy is an essential 
component of MQC (Ni, 2015; Fisher, 2012). In fact, autophagy-mediated turnover of damaged 
mitochondria is required for protecting renal tubules from injury (Isaka, 2011), whereas deletion of 
essential autophagy genes damages renal tubular cells through defective mitochondrial clearance and 
increased reactive oxygen species (ROS) (Yamamoto, 2016).  
In order to investigate MQC, we first assessed the state of autophagy in cells lacking MUT. 
Our studies reveal a robust, consistent increase in the number of autophagic vesicles and in the levels 
of autophagosome-associated LC3-II and autophagy substrate p62/SQSTM1 in the different models of 
MUT deficiency, including tubular cells from MMA patients, mPT cells from Mutflox/flox mouse 
kidneys, kidneys of Mutko/ki mice and kidney biopsies from a patient with MMA. We furthermore 
observed an excessive autophagic vacuole formation by TEM, sustaining the idea of an upregulated 
state of autophagy. Indeed, upregulated autophagy has been shown to be protective in models of 
acquired renal tubular injury (Liu, 2014; Isaka, 2011).  
Dysregulation of autophagy may occur at any steps involved in autophagosome formation 
and/or can be induced by factors that regulate autolysosomal trafficking or fusion between different 
subcellular compartments. For instance, accumulation of LC3-positive organelles unable to fuse with 
lysosomes has been observed in different lysosomal storage diseases (LSD), (Ballabio, 2009). 
However, when treating MMA cells with BfnAI, which accurately measures autophagy flux (Bento, 
2016), we observed a substantial co-localization of LC3-positive vesicles with the lysosome marker 
LAMP1, suggesting that the delivery and the autophagosome-lysosome fusion is not compromised in 
MMA cells. Therefore, we postulated that MUT deficiency is likely to affect autophagy either by 
increasing autophagosome biogenesis or by regulating the lysosomal degradation capacity. The latter 
hypothesis does not sound valid, because neither lysosomal dynamics (as scored by the abundance and 
positioning of the lysosomal proteins LAMP2 and CtsD) nor lysosomal activity (as measured by the 
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fluorescent tagged PepstatinA which binds active CtsD within mature lysosomes) appeared to be 
affected by MUT depletion. Instead, treatment with the lysosome inhibitor BfnAI increased the 
number of autophagosomes and the levels of the LC3-II in control and in MMA cells - clearly 
indicating that MUT deficiency may induce autophagosome synthesis rather than compromise their 
clearance.  
 Given the central role that autophagy plays in responding to cellular stresses, the higher LC3 
fluxes in MUT-deficient cells experiencing mitochondrial dysfunction support the concept that these 
cells need autophagic functions or products to cope with stress. In this scenario, damaged and 
dysfunctional mitochondria as observed in MUT-deficient cells should be removed by 
autophagosomal sequestration and subsequently degraded by lysosomes, clearing the cells of 
excessive dysfunctional mitochondria and their toxic byproducts (Twig, 2008). Particularly, the 
selective autophagic removal of damaged mitochondria (also known as mitophagy) relies on molecular 
sensors that detect potentially dangerous cues, converting them into signals that are ultimately relayed 
to the autophagic machinery. A recently identified paradigm pathway for mammalian mitophagy is 
mediated by the kinase PINK1 and the E3 ubiquitin ligase Parkin, which collaborate to sense and 
trigger the removal of damaged mitochondria (Valente, 2004; Kitada, 1998). Studies in Drosophila 
further suggested a role for PINK1 and Parkin in the regulation of mitochondrial integrity, since the 
loss of either protein results in mitochondrial dysfunction, driving degeneration of flight muscles and 
dopaminergic neurons (Greene, 2003; Park, 2005).  
 In healthy mitochondria, PINK1 is constitutively imported to the inner mitochondrial 
membrane, where it is cleaved by several proteases and proteolytically degraded (Greene, 2012). In 
case of impaired mitochondrial membrane potential, the degradation of PINK1 is inhibited and the 
protein is rerouted to the surface of the mitochondria, where it accumulates and recruits Parkin (Kim, 
2008; Nunnari, 2012). During mitophagy, PINK1 and Parkin cooperate to attach ubiquitin tags to 
proteins on the outer membrane of depolarized mitochondria, tagging them for autophagic removal 
and degradation. The use of Rotenone, a well-established toxin which depolarizes mitochondria and 
increases mitochondrial ROS levels, allowed us to track mitophagy events and autophagic 
sequestration of damaged mitochondria in renal tubular cells. Consistently, treatment with Rotenone 
75 
decreased the cleavage of PINK1 maintaining full-length PINK1 onto dysfunctional mitochondria (as 
marked by TOMM20) thus initiating the sequestration by autophagy (as shown by colocalization 
between damaged TOMM20 positive mitochondria and LC3-positive autophagosomes) in normal 
cells. However, this mitophagy signal was defective in MUT-deficient cells experiencing 
mitochondria dysfunction, with decreased protein levels of PINK1 and Parkin at baseline and a lack of 
proper recruitment of full-length PINK1 to the mitochondrial membrane upon Rotenone treatment. As 
a result, the damaged mitochondria are not flagged for disposal despite the abundant levels of p62, a 
stress-induced ubiquitin binding protein that targets damaged mitochondria to autophagosomes 
(Cohen-Kaplan, 2016). Taken together, these findings indicate that dysregulation of PINK/Parkin 
mediated mitophagy is explaining the abnormal accumulation of dysfunctional mitochondria in MMA 
and MUT-deficient systems.      
The link between defective mitochondrial homeostasis characterizing MMA and organ 
damage is supported by elevated levels of kidney damage markers (LCN2, KIM1) and disturbed 
metabolic and renal function parameters in the Mutki/ko mouse. A similar link between dysfunctional 
mitochondria, loss of PINK1 and tissue damage has recently been described in a human pulmonary 
fibrosis model (Bueno, 2014). Tubulointerstitial lesions frequently observed in kidney biopsies of 
MMA patients progressing to fibrosis underline the importance of that finding (Rutledge, 1993; 
Goyenechea, 2012). To substantiate the causal link between MUTdeficiency and the observed 
findings, we performed Cre mediated Mut deletion in renal tubular cells in vitro. The deletion of MUT 
was able to reproduce all observed findings including changes in mitochondrial homoeostasis, loss of 
PINK1 and Parkin expression, accumulation of autophagic marker proteins and elevated markers for 
kidney damage including LCN2. This strongly supports the importance of the MUT enzymatic activity 
for mitochondrial homoeostasis, regulation of autophagy and oxidative stress and provides causal 
evidence linking MMA to renal tubular damage. The carrier protein lipocalin-2 (LCN2) is of particular 
interest, since it has been shown as essential for chronic kidney disease progression in mice and 
humans (Viau, 2010), by mechanisms involving the mitogenic effects of the epidermal growth factor 
receptor (EGFR) and apoptosis through ROS generation (El Karoui, 2015). The fact that LCN2 is 
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upregulated by the inactivation of MUT in vitro and in vivo provides a strong candidate to mediate 
kidney damage in MMA. 
The potential importance of mitochondrial ROS production for cellular damage in MMA led 
us to investigate the beneficial effect of mitochondria-targeted antioxidant therapy in human renal cells 
from MMA patients and controls. MitoTEMPO (MT) is an orally bioavailable compound that 
predominantly accumulates within the mitochondria, due to the covalent binding of a lipophilic cation 
(triphenylphosphonium, TPP) to the endogenous antioxidant CoQ10. It exerts a direct antioxidant 
action, by scavenging peroxyl, peroxynitrites and superoxide in the mitochondria. Interest for 
mitochondria-targeted antioxidants, and MT in particular, has been triggered by in vivo studies 
showing protection in a number of clinical situations associated with oxidative stress, including sepsis, 
ischemia-reperfusion injury, liver disease, neurodegenerative diseases, and hypertension (Jin, 2014). 
Treatment of MMA patient-derived cells with MT, which efficiently neutralized the ROS production, 
restored mitochondrial morphology, normalized mitochondrial mass, and also increased the ratio of 
uncleaved vs. cleaved PINK1 ratio, promoting autophagic degradation of dysfunctional mitochondria. 
Importantly, the beneficial effects of treatment with MT were reflected by a robust reduction of LCN2 
levels, lending support to the idea that ROS play a major role in the development of MMA-associated 
kidney damage. Although these promising results should be confirmed in animal models, they provide 
new therapeutic perspectives for directly reducing the consequences of mitochondrial damage due to 
MUT deficiency. 
In conclusion, we identified a novel cascade connecting primary mitochondrial disease, 
impaired PINK/Parkin mediated autophagic degradation of dysfunctional mitochondria, oxidative 
stress and tubular cell damage in MMA. By identifying this mechanism and showing that 
mitochondria-targeted antioxidant treatment restores mitochondrial homeostasis and decreases 
mediators of tissue damage, we provide a novel strategy for treating renal tubular dysfunction in 
MMA and mitochondrial disorders. 
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4. Material and Methods 
Antibodies and reagents. The following antibodies were used in the study: mouse anti-Methylmalonyl 
Coenzyme A mutase antibody (67869 Abcam, Cambridge, UK), rabbit anti-Aquaporin 1 antibody 
(2219, Millipore, Billerica, USA), rabbit anti-Aquaporin 2 antibody (A7310, Sigma, Saint Louis, 
USA), rabbit- anti-Kidney injury molecule 1 (KIM1) antibody (76701, Novus Biologicals, Littleton, 
USA), rabbit anti-LC3 antibody (PM036, MBL, Woburn, USA), sheep anti-UMOD (K90071C, 
Meridian Life Science, Kampenhout, Belgium), rabbit anti-p62 antibody (PM045, PM036, MBL, 
Woburn, USA), rabbit anti-prohibitin (28172, Abcam, Cambridge, UK),rabbit anti-TOMM20 (11415, 
Santa Cruz Biotechnology, Dallas, USA)l, rabbit anti-Parkin (15954, Abcam, Cambridge, UK), goat 
anti-PINK1 (32584, Santa Cruz, CA, USA), rat anti-Lamp1 (sc-19992, Santa Cruz Biotechnology), 
goat anti-Cathepsin-D (sc-6486, Santa Cruz Biotechnology), rabbit anti-Rab7 (126712, Abcam, 
Cambridge, UK), mouse-anti-Ubiquitin (sc-8017, Santa Cruz Biotechnology), rabbit anti-Lipocalin-
2(ab63929, Abcam, Cambridge, UK), rabbit-anti superoxide dismutase (SOD)-1 (13498, Abcam, 
Cambridge, UK) and mouse anti--actin antibody (A5441, Sigma, Saint Louis, USA).  Compounds 
included Bafilomycin-A1 (ALX-380-030, Enzo Life Sciences, Zurich, Switzerland), Rotenone 
(R8875, Sigma, Saint Louis, USA), MG132 (474790, Merck Millipore, Zurich, Switzerland) and mito-
TEMPO (MT, ALX-430-150-M005, Enzo Life Sciences, Zurich, Switzerland). The adenovirus 
particles carrying green fluorescent protein (GFP) microtubule-associated protein light chain 3(LC3B) 
and Cre-recombinase were purchased from Vector Biolabs (USA). 
Human kidney biopsies. The human kidney biopsies were obtained from a 18 year old, female MMA 
patient harboring a mutation in the MUT gene and from one control (non-transplanted, normal control 
kidney). Informed consent was obtained and the use of the human biopsy samples was approved by 
the Ethical Review Board of Saint-Luc Academic Hospital (Brussels, Belgium) and the EURenOmics 
consortium (FP7, 2007–2013, grant agreement no. 305608).  
Cell culture. The renal tubular cells were obtained from urines of healthy donors or patients with mut0 
(Ruppert, 2015). The cells were cultured in DMEM GlutaMAX (Gibco, Luzern, Switzerland) and 
supplemented with 10% fetal calf serum (Biochrome, Berlin, Germany) and Pen/Strep (100 U/ml 
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penicillin, Gibco, Luzern, Switzerland). For inducing mitochondrial damage, the cells were cultured in 
media containing 10µM Rotenone for 16h and then processed as described above. For autophagy flux 
analysis, 250nM BafilomycinA1 or corresponding vehicle (that is water) were then added to cell 
medium for 4h. For proteasome inhibition, the cells were cultured in media containing 50µM 
Rotenone for 6h and then processed as described above. For neutralizing the excessive generation of 
mitochondrial oxidative stress, the cells were cultured in media containing 10mM MT for 24h and 
processed as described above. For expression studies, the cells were transduced using adenovirus 
constructs carrying mouse GFP-MAP1LC3B (Ad-GFP/mMAP1LC3B) and analysed by confocal 
microscopy.   
Enzymatic activity. The cells derived from human urine were classified as mut0 mutations by assessing 
MUT activity as previously described (Baumgartner, 1983). Briefly, the crude cell homogenates were 
sonicated and 1 mM DL-2-(methyl-14C)methylmalonyl-CoA (ARC; specific activity 7.03 MBq/mmol 
in assay) was added in absence (holo-MUT activity) and presence (total MUT activity) of the cofactor 
Adenosylcobalamin (AdoCbl) 50 µM)) in darkroom safelight red conditions. The reaction was 
terminated by the addition of 5N KOH (Merck, Darmstadt, Germany). The samples were enriched 
with succinic acid (Merck, Darmstadt, Germany) to visualize the succinate peak during HPLC 
separation. Succinate and methylmalonate peaks were detected at 210 nm by an UV detector. 
Quantification of the (14C) succinate fraction was performed with Optiphase HiSafe2 counting cocktail 
(PerkinElmer) in a Tri-Carc C1 900TR scintillator spectrometer (Packard). The protein concentration 
of the cell lysates was determined using the Lowry method. The MUT activity is given as pmol 
succinate which is formed per minute and mg protein (pmol/min/mg). Both holo-MUT (assay without 
AdoCbl) and total MUT (assay with 50–100 M AdoCbl) activities were strongly decreased in cells 
obtained from MMA patients whereas total MUT activity was normal in the cells derived from healthy 
controls. 
Cell viability assay. Cell viability was determined by the Cell Counting Kit-8 (CCK-8) assay 
(Dojindo, Rockville, USA). Cells were seeded at a density of 5000 cells/well of 96 well plate and 
grown until they reached 90% confluence. The cell medium was replaced by water-soluble tetrazolium 
79 
salt solution and incubated for 30 min at 37°C.according to the manufacturer’s protocol. The amount 
of formazan dye generated by dehydrogenase activity was measured at 450 nm in a TECAN infinite 
200 reader (Männedorf, Switzerland) in according to the manufacturer's specifications. 
Mice. The mice were maintained under temperature-and humidity-controlled conditions with 12-h 
light/12-h dark cycles with free access to appropriate standard diet in accordance with the institutional 
guidelines of National Institutes of Health Guide for the Care and Use of Laboratory Animals. The 
mice bearing Mutflox allele, in which exon 3of the Mut gene is flanked by 2 loxP sequences, and the 
mice carrying M698K point mutation in the Mut gene was performed by Polygene (Rümlang, 
Switzerland) using the C57Bl/6-derived embryonic stem cell targeting. To obtain Mutko/ki mice, 
females Mutko/wt were crossed to Mutki/ki males as previously described (Forny, 2016). Mouse 
genotyping was performed on genomic DNA from ear punch biopsies using the primers 5′-
GTGGGTGTCAGCACACTTG-3′ (forward) and 5′-CGTATGACTGGGATGCCT-3′ (reverse) for the 
KI allele and 5′-ACAACTCCTTGTGTAGGTC-3′ (forward) and 5′-CCTTTAGGATGTCATTCTG-
3′(reverse) for the KO allele. For mouse studies, no specific randomization or blinding protocol was 
used, the females (16-18 weeks) of both Mutwt/wt and Mutko/ki mice were used, and all the experiments 
were performed in accordance with National Institutes of Health guidelines for the care and use of 
laboratory animals and with the approval of the Committee for Animal Rights of the University of 
Zurich (Zurich, Switzerland). 
Metabolic cage studies and metabolic parameters. Long term monitoring of mice entailed weekly 
weight measurements and regular blood collections, as well as urine collections. The animals were 
single caged overnight to collect urine and measure individual chow and water intake; the urine was 
collected over ice in the morning and the diuresis was measured (Raggi, 2014; Luciani, 2016). 
Ammonia levels in whole blood were measured by the PocketChem blood ammonia meter (PA-4140; 
Arkray). The urine parameters were measured using a UniCel DxC 800 pro Synchron (Beckman 
Coulter, Fullerton, CA, USA), whereas MMA in mice urine was analyzed by liquid chromatography 
mass spectrometry (LC-MS/MS) on a Thermo Scientific UltiMate 3000 rapid separation LC coupled 
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to an AB Sciex 5500 TripleQuad mass spectrometer using a commercial kit (Recipe ClinMass® 
advanced).  
Kidney isolation and primary cultures of mouse proximal tubule cells. The kidneys were harvested 
from Mutflox/flox mice as previously described (Raggi, 2014; Luciani, 2016). One kidney was split 
transversally and one half was fixed and processed for immunostaining while the other half was flash-
frozen, homogenized by Dounce homogenizer in 1 mL of RIPA buffer that contains protease and 
phosphatase inhibitors and processed for western blot analysis. The contralateral kidney was taken to 
generate primary cultures of mPTCs as described (24). Freshly micro-dissected PT segments were 
seeded onto collagen-coated chamber slides (C7182, Sigma-Aldrich) and/or collagen-coated 6- or 24-
well plates (145380 or 142475, Thermo Fisher Scientific), and cultured at 37°C and 5% CO2 in 
DMEM/F12 (21041-025, Thermo Fisher Scientific) with 0.5% dialyzed FBS, 15mM HEPES (H0887, 
Sigma-Aldrich), 0.55 mM sodium pyruvate (P2256, Sigma-Aldrich), 0.1ml/L non-essential amino 
acids (M7145, Sigma-Aldrich), hydrocortisone, human EGF, epinephrine, insulin, triiodothyronine, 
TF, and gentamicin/amphotericin (Single Quots® kit, CC-4127, Lonza), pH 7.40, 325 mOsm/kg. The 
medium was replaced every 48 h. Confluent monolayers of mPTCs were expanded from the tubular 
fragments after 6–7 days, characterized by a high endocytic uptake capacity. All experiments were 
performed on confluent monolayers grown on chamber slides or plates.  
Adenovirus transduction. For expression studies, adenovirus constructs used include CMV (control 
vector, Ad-CMV-GFP, Vector Biolabs) or an individually carrying Cre-recombinase (Ad-Cre-GFP, 
Vector Biolabs). Briefly, the cells were plated onto collagen-coated chamber slides or 24-well or 6-
well tissue culture plates. Adenovirus transduction was performed 24h after plating when the cells 
reach approximately 70-80% confluence. The cells were subsequently incubated for overnight at 37°C 
with culture medium containing the virus at the appropriate concentration (0.2125×109 PFU/mL). The 
cells were afterwards provided with fresh medium every 2 days, cultured for 8 days and collected for 
analyses. Transduction efficiency was determined by viral GFP expression in live cells. GFP 
expression indicated that nearly 100% of cells were transduced after 8 days of transduction. The level 
of expression of mutase was determined by qPCR and proteins.  
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Quantitative real-time PCR.  
Total RNA was extracted from organs of 10 weeks old female wild type mice of C57BL/6 background 
using AurumTM Total RNA Fatty and Fibrous Tissue Kit (Bio-Rad, Hercules, USA), according to the 
manufacturers’ protocol. DNAse I treatment was performed to eliminate genomic DNA 
contamination. Total RNA was extracted from human urinary cells, mPTC and microdissected 
segments with RNAqueousR kit (Applied Biosystems Inc, USA), following the manufacturers 
protocol.  Real-Time PCR was performed as described previously (Jouret, 2007; Bustin, 2009). The 
reverse transcriptase reaction was performed with 1 µg of RNA using iScript TM cDNA Synthesis Kit 
(Bio Rad Laboratories, Hercules, CA). Changes in target genes mRNA levels were determined by 
relative RT-qPCR with a CFX96TM Real-Time PCR Detection System (Bio-Rad) using iQTM SYBR 
Green Supermix (Bio Rad) to detect single PCR product accumulation. Specific primers were 
designed using Primer3 (Rozen, 2000) (Suppl. Tables 1 and 2) PCR conditions were 94°C for 3 min 
followed by 40 cycles of 15 sec at 95°C, 30 sec at 60°C. The PCR products were purified and 
sequenced using an ABI3100 capillary sequencer (Perkin Elmer Applied Biosystems). The efficiency 
of each set of primers was determined by dilution curves (Suppl. Tables 1 and 2). The relative changes 
in target over GAPDH/Gapdh mRNAs were calculated using the 2-Ct formula (Pfaffl, 2001).   
Lysosomal activity. The detection of lysosomal activity was performed using Bodipy-FL-PepstatinA 
(P12271, Thermo Fischer Scientific) according to the manufacturer's specifications. Briefly, the cells 
were pulsed with 1µM Magic Red-(RR)2 in Live Cell Imaging (A14291DJ, Thermo Fischer Scientific) 
medium for 1h at 37°C followed by fixation and immunostaining with anti-LAMP-1 or anti-HA 
antibody, and subsequently analyzed by confocal microscopy. (Luciani, 2016).  
Extracellular Flux Analysis and Metabolic Assays.  
OCRs and extracellular acidification rates (ECAR) were measured in a XF-96 Extracellular Flux 
Analyzers (Seahorse Bioscience) in cells suspended in XF medium (non-buffered RPMI 1640 
containing either 25 mM glucose, 3,9 mM L-glutamine and 0,5 mM sodium pyruvate). Three 
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measurements were obtained under basal conditions and upon addition of oligomycin (2 µm), fluoro-
carbonyl cyanide phenylhydrazone (FCCP; 0,5 µm), and rotenone (1 µm) + antimycin A (1 µm). 
Mitochondrial membrane potential measurement. The mitochondrial membrane potential (m) was 
measured according to the manufacturer's specifications. Briefly, the cells were pulsed with 50nM 
Tetramethylrhodamine Methyl Ester Perchlorate (TMRM, T668 Thermo Fisher 
Scientific) for 30 min in live cell imaging at 37°C. After washing, the cells were subsequently 
analysed by confocal microscopy (Luciani, 2010).  
ROS detection. The cells were pulsed with 5 µM CellROX® Green Reagent (C10444, Thermo 
Fisher Scientific) or with 2.5 µM MitoSOX Red Mitochondrial Superoxide Indicator for 10 min in 
live cell imaging at 37°C. After washing, the cells were subsequently analysed by confocal 
microscopy (Luciani, 2010).  
Immunofluorescence and confocal microscopy 
Human and mouse tissue kidneys: Fresh mouse kidneys were fixed by perfusion with 500-700 µl of 
4% paraformaldehyde in PBS (158127, Sigma-Aldrich). The organs were dehydrated and embedded in 
paraffin at 58C°. Paraffin blocks of human and mouse kidney samples were sectioned into consecutive 
slices with a thickness of 6μm using a Leica RM2255 rotary microtome (Thermo-Fisher Scientific) on 
Superfrost Plus glass slides (12-550-15, Thermo-Fisher Scientific). Paraffin blocks were sectioned into 
consecutive 6µm-thick slices with a Leica RM2255 rotary microtome (Thermo-Fisher Scientific) on 
Superfrost Plus glass slides (Thermo-Fisher Scientific). Before staining, slides were deparaffinized in 
changes of CitriSolv (22-143-975, Thermo-Fisher Scientific) and 70% isopropanol. Antigen retrieval 
was accomplished by incubating in sodium citrate buffer (1.8% 0.1M citric acid, 8.2% 0.1M sodium 
citrate, in distillated water, pH 6.0) in a rice cooker for 30 minutes. The slides were quenched with 50 
mM NH4Cl, blocked with 0.5% BSA in PBS Ca/Mg (D1283, Sigma-Aldrich) for 30 min and stained 
with primary antibodies specific for LC3 and p62/SQSTM1 diluted in blocking buffer overnight at 
4°C. After two washes in 0.1% Tween 20 (v/v in PBS), the slides were incubated with corresponding 
fluorophore-conjugated Alexa secondary antibodies (Invitrogen) diluted in blocking buffer at room 
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temperature for 1 h and counterstained with 1µg Biotinylated Lotus Tetragonolobus Lectin (LTL) ( B-
1325 Vector Laboratories; marker of the PT apical membrane) and 10 µM Hoechst 33342 (H1399 
Thermo Fischer Scientific). The slides were mounted in Prolong Gold Anti-fade reagent (P36930, 
Thermo Fisher Scientific), acquired on Leica SP8 confocal laser scanning microscope (Center for 
Microscopy and Image Analysis, University of Zurich) equipped with a Leica APO 63x NA 1.4 oil 
immersion objective at a definition of 1,024 x 1,024 pixels (average of eight or sixteen scans), 
adjusting the pinhole diameter to 1 Airy unit for each emission channel to have all of the intensity 
values between 1 and 254 (linear range). The micrographs were processed with Adobe Photoshop 
(version CS5, Adobe System Inc., San Jose, USA) software. Quantitative image analysis was 
performed by selecting randomly 5 visual fields per each slide that included at least 3-5 PTs (LTL-
positive), using the same setting parameters (i.e. pinhole, laser power, and offset gain and detector 
amplification below pixel saturation). The numbers of LC3 or p62/SQSTM1 structures were counted 
per field in the kidneys by two people (blinded to the experimental groups) and the average of their 
scoring was used for each micrograph. 
Cultured cells. The cells were fixed for 10 min with 4% paraformaldehyde in PBS, quenched with 50 
mM NH4Cl and permeabilized for 30 min in blocking buffer solution containing 0.1% Triton X-100 
and 0.5% BSA dissolved in PBS. Subsequently, the cells were incubated overnight with the 
appropriate primary antibodies at 4°C. After repeated washing with PBS, the slides were incubated for 
30 min with the suitable fluorophore-conjugated Alexa secondary antibodies (Invitrogen), mounted 
with the Prolong Gold Anti-fade reagent, and analyzed by using a Leica SP8 confocal laser scanning 
microscope (Center for Microscopy and Image Analysis, University of Zurich) using the settings 
described above. Quantitative image analysis was performed by selecting randomly 3 visual fields 
pooled from biological triplicates, with each field including at least 10-15 cells, using the same setting 
parameters (i.e. pinhole, laser power, and offset gain and detector amplification below pixel 
saturation). The quantitative cell image analyses were performed using the open-source cell image 
analysis software CellProfilerTM (Carpenter, 2006). In particular, the pipeline “Speckle counting” was 
used to identify smaller objects (LC3 or SQSTM1 positive structures) surrounding larger objects and 
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to perform per-object aggregate measurements. The pipeline “Cell/particle counting, and scoring the 
percentage of stained objects” was used to score either the numbers of LC3/TOMM20 or 
TOMM20/PINK1 positive structures per cell.  
Transmission electron microscopy. Mouse kidney sections and cells were fixed in 4% 
paraformaldehyde/0.1% glutaraldehyde in 100 nM sodium cacodylate, at pH=7.43, dehydrated and 
embedded in LR-White resin (LADD Research Industries). The grids were viewed on a Philips 
CM100 transmission electron microscope at 80kV. 
 
Western blotting. Immunoblotting was performed as described previously (Raggi, 2014; Luciani, 
2016). Proteins were extracted from isolated kidneys or primary cultured cells, lysed in lysis buffer 
containing protease (1836153001, Roche) and phosphatase inhibitors (04906845001, PhosSTOP 
Sigma), followed by sonication and centrifugation at 12,000 rpm for 10 min at 4°C. The samples were 
thawed on ice, normalized for protein (20µg/lane), dissolved in Laemmli sample buffer and separated 
by SDS–PAGE in reducing conditions. After blotting onto PVDF and blocking with 5% non-fat milk 
(1706404, Bio-Rad Laboratories) diluted in PBS, the membranes were incubated overnight at 4°C 
with primary antibody, washed, incubated with peroxidase-labeled secondary antibody, and visualized 
with enhanced chemiluminescence (WBKLS0050, Millipore, Life technologies). For re-probing, the 
membranes were rinsed, incubated for 30 min at 55°C in a stripping buffer (62.5mmol/L Tris-HCl, 2% 
SDS, 100mM mercaptoethanol, adjusted to pH =7.4), before incubation with primary antibodies. 
Quantitative analysis was performed by scanning the blots and measuring the relative density of each 
band normalized to -actin, GAPDH or α- tubulin and using ImageJ software. 
 
Statistical analysis. The quantitative data were expressed as means ± standard error of the mean 
(SEM). Differences between experimental groups were evaluated using analysis of variance followed 
by Bonferroni post hoc test, when appropriate. When only two groups were compared, unpaired or 
paired two tailed Student’s t-tests were used as appropriate. The sample size of each experimental 
group is described in figure legends. The results are representative of at least three independent 
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experiments. GraphPad Prism software was used for all statistical analyses. Statistical significance was 
set at a P<0.05. 
  
86 
5. References  
Anding AL, Baehrecke EH. Cleaning House: Selective Autophagy of Organelles. Dev Cell. 2017 Apr 
10;41(1):10-22. doi: 10.1016/j.devcel.2017.02.016. 
Ballabio A, Gieselmann V. Lysosomal disorders: from storage to cellular damage. Biochim Biophys 
Acta. 2009 Apr;1793(4):684-96. doi: 10.1016/j.bbamcr.2008.12.001. Epub 2008 Dec 8. 
Baumgartner MR, Hörster F, Dionisi-Vici C, Haliloglu G, Karall D, Chapman KA, Huemer M, 
Hochuli M, Assoun M, Ballhausen D, Burlina A, Fowler B, Grünert SC, Grünewald S, Honzik T, 
Merinero B, Pérez-Cerdá C, Scholl-Bürgi S, Skovby F, Wijburg F, MacDonald A, Martinelli D, Sass 
JO, Valayannopoulos V, Chakrapani A. Proposed guidelines for the diagnosis and management of 
methylmalonic and propionic acidemia. Orphanet J Rare Dis. 2014 Sep 2;9:130. 014-0130-8. Review. 
Baumgartner R. 1983. Activity of the cobalamin‐dependent methylmalonyl‐CoA mutase In: Hall CA, 
editor. , editor. The cobalamins – volume 10 of methods in hematology. Churchill Livingstone, 
London, UK: p 181–193. 
Bento CF, Renna M, Ghislat G, Puri C, Ashkenazi A, Vicinanza M, Menzies FM, Rubinsztein DC. 
Mammalian Autophagy: How Does It Work? Annu Rev Biochem. 2016 Jun 2;85:685-713. doi: 
10.1146/annurev-biochem-060815-014556. Epub 2016 Feb 8. 
Brassier A, Boyer O, Valayannopoulos V, Ottolenghi C, Krug P, Cosson MA, Touati G, Arnoux JB, 
Barbier V, Bahi-Buisson N, Desguerre I, Charbit M, Benoist JF, Dupic L, Aigrain Y, Blanc T, 
Salomon R, Rabier D, Guest G, de Lonlay P, Niaudet P. Renal transplantation in 4 patients with 
methylmalonic aciduria: a cell therapy for metabolic disease. Mol Genet Metab. 2013 Sep-Oct;110(1-
2):106-10. doi: 10.1016/j.ymgme.2013.05.001. Epub 2013 May 14. 
Bueno M, Lai YC, Romero Y, Brands J, St Croix CM, Kamga C, Corey C, Herazo-Maya JD, Sembrat 
J, Lee JS, Duncan SR, Rojas M, Shiva S, Chu CT, Mora AL. PINK1 deficiency impairs mitochondrial 
homeostasis and promotes lung fibrosis. J Clin Invest. 2015 Feb;125(2):521-38. doi: 
10.1172/JCI74942. Epub 2014 Dec 22. 
Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, 
Shipley GL, Vandesompele J, Wittwer CT. The MIQE guidelines: minimum information for 
publication of quantitative real-time PCR experiments. Clin Chem. 2009 Apr;55(4):611-22. doi: 
10.1373/clinchem.2008.112797. Epub 2009 Feb 26. 
Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O, Guertin DA, Chang JH, 
Lindquist RA, Moffat J, Golland P, Sabatini DM. CellProfiler: image analysis software for identifying 
and quantifying cell phenotypes. Genome Biol. 2006;7(10):R100. Epub 2006 Oct 31. 
87 
Chandler RJ, Venditti CP. Long-term Rescue of a Lethal Murine Model of Methylmalonic Acidemia 
Using Adeno associated Viral Gene Therapy. Mol Ther. 2010 Jan;18(1):11-16. doi: 
10.1038/mt.2009.247. Epub 2016 Dec 6. 
Cohen-Kaplan V, Livneh I, Avni N, Fabre B, Ziv T, Kwon YT, Ciechanover A. p62- and ubiquitin-
dependent stress-induced autophagy of the mammalian 26S proteasome. Proc Natl Acad Sci U S A. 
2016 Nov 22;113(47):E7490-E7499. Epub 2016 Oct 17. 
 
Cosson MA, Benoist JF, Touati G, Déchaux M, Royer N, Grandin L, Jais JP, Boddaert N, Barbier V, 
Desguerre I, Campeau PM, Rabier D, Valayannopoulos V, Niaudet P, de Lonlay P. Long-term 
outcome in methylmalonic aciduria: a series of 30 French patients. Mol Genet Metab. 2009 
Jul;97(3):172-8. doi: 10.1016/j.ymgme.2009.03.006. Epub 2009 Mar 24.PMID: 19375370. 
El Karoui K, Viau A, Dellis O, Bagattin A, Nguyen C, Baron W, Burtin M, Broueilh M, Heidet L, 
Mollet G, Druilhe A, Antignac C, Knebelmann B, Friedlander G, Bienaimé F, Gallazzini M, Terzi F. 
Endoplasmic reticulum stress drives proteinuria-induced kidney lesions via Lipocalin 2. Nat Commun. 
2016 Jan 20;7:10330. doi: 10.1038/ncomms10330. 
Emma F, Montini G, Parikh SM, Salviati L. Mitochondrial dysfunction in inherited renal disease and 
acute kidney injury. Nat Rev Nephrol. 2016 May;12(5):267-80. doi: 10.1038/nrneph.2015.214. 
Review. 
Fischer F, Hamann A, Osiewacz HD. Mitochondrial quality control: an integrated network of 
pathways. Trends Biochem Sci. 2012 Jul;37(7):284-92. doi: 10.1016/j.tibs.2012.02.004. Epub 2012 
Mar 10. 
Fisher-Wellman KH, Neufer PD. Linking mitochondrial bioenergetics to insulin resistance via redox 
biology. Trends Endocrinol Metab. 2012 Mar;23(3):142-53. doi: 10.1016/j.tem.2011.12.008. Epub 
2012 Feb 2. 
Forny P, Schumann A, Mustedanagic M, Mathis D, Wulf MA, Nägele N, Langhans CD, Zhakupova 
A, Heeren J, Scheja L, Fingerhut R, Peters HL, Hornemann T, Thony B, Kölker S, Burda P, Froese 
DS, Devuyst O, Baumgartner MR. Novel Mouse Models of Methylmalonic Aciduria Recapitulate 
Phenotypic Traits with a Genetic Dosage Effect. J Biol Chem. 2016 Sep 23;291(39):20563-73. doi: 
10.1074/jbc.M116.747717. 
Fougeray S, Pallet N. Mechanisms and biological functions of autophagy in diseased and ageing 
kidneys. Nat Rev Nephrol. 2015 Jan;11(1):34-45. doi: 10.1038/nrneph.2014.201. Epub 2014 Nov 11. 
88 
Goyenechea E, Andrade F, de Las Heras J, Lage S, Prieto JÁ, Ruiz N, Aldámiz-Echevarría L: 
Expression of proinflammatory factors in renal cortex induced by methylmalonic acid. Ren Fail 
34:885-891, 2012. 
Greene AW, Grenier K, Aguileta MA, Muise S, Farazifard R, Haque ME, McBride HM, Park DS, Fon 
EA. Mitochondrial processing peptidase regulates PINK1 processing, import and Parkin recruitment. 
EMBO Rep. 2012 Apr;13(4):378-85. doi: 10.1038/embor.2012.14. 
Greene JC, Whitworth AJ, Kuo I, Andrews LA, Feany MB, Pallanck LJ. Mitochondrial pathology and 
apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci U S A. 2003 Apr 
1;100(7):4078-83. Epub 2003 Mar 17. 
Hörster F et al. Long-term outcome in methylmalonic acidurias is influenced by the underlying defect 
(mut0, mut-, cblA, cblB). Pediatr Res. Aug;62(2):225-30 (2007). 
Isaka Y, Kimura T, Takabatake Y: The protective role of autophagy against aging and acute ischemic 
injury in kidney proximal tubular cells. Autophagy 7:1085-1087, 2011. 
Jin H, Kanthasamy A, Ghosh A, Anantharam V1, Kalyanaraman B, Kanthasamy AG. Mitochondria-
targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes. Biochim 
Biophys Acta. 2014 Aug;1842(8):1282-94. doi: 10.1016/j.bbadis.2013.09.007. Epub 2013 Sep 20. 
Jouret F, Bernard A, Hermans C, Dom G, Terryn S, Leal T, Lebecque P, Cassiman JJ, Scholte BJ, de 
Jonge HR, Courtoy PJ, Devuyst O. Cystic fibrosis is associated with a defect in apical receptor-
mediated endocytosis in mouse and human kidney. J Am Soc Nephrol. 2007 Mar;18(3):707-18. Epub 
2007 Feb 7. 
Kasahara M, Horikawa R, Tagawa M, Uemoto S, Yokoyama S, Shibata Y, Kawano T, Kuroda T, 
Honna T, Tanaka K, Saeki M. Current role of liver transplantation for methylmalonic acidemia: a 
review of the literature. Pediatr Transplant. 2006 Dec;10(8):943-7. 
Kim WY, Nam SA, Song HC, Ko JS, Park SH, Kim HL, Choi EJ, Kim YS, Kim J, Kim YK. The role 
of autophagy in unilateral ureteral obstruction rat model. Nephrology (Carlton). 2012 Feb;17(2):148-
59. doi: 10.1111/j.1440-1797.2011.01541.x. 
Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, 
Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 
1998 Apr 9;392(6676):605-8. 
Kitada S, Kojima K, Shimokata K, Ogishima T, Ito A. Glutamate residues required for substrate 
binding and cleavage activity in mitochondrial processing peptidase. J Biol Chem. 1998 Dec 
4;273(49):32547-53. 
89 
Klionsky DJ et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd 
edition). Autophagy. 2016;12(1):1-222. doi: 10.1080/15548627.2015.1100356. 
Kotiadis VN, Duchen MR, Osellame LD. Mitochondrial quality control and communications with the 
nucleus are important in maintaining mitochondrial function and cell health. Biochim Biophys Acta. 
2014 Apr;1840(4):1254-65. doi: 10.1016/j.bbagen.2013.10.041. Epub 2013 Nov 6. 
Liu WJ, Luo MN, Tan J, Chen W, Huang LZ, Yang C, Pan Q, Li B, Liu HF. Autophagy activation 
reduces renal tubular injury induced by urinary proteins. Autophagy. 2014 Feb;10(2):243-56. doi: 
10.4161/auto.27004. Epub 2013 Nov 26. 
Lood C, Blanco LP, Purmalek MM, Carmona-Rivera C, De Ravin SS, Smith CK, Malech HL, 
Ledbetter JA, Elkon KB, Kaplan MJ. Neutrophil extracellular traps enriched in oxidized mitochondrial 
DNA are interferogenic and contribute to lupus-like disease. Nat Med. 2016 Feb;22(2):146-53. doi: 
10.1038/nm.4027. Epub 2016 Jan 18. 
Luciani A, Villella VR, Esposito S, Brunetti-Pierri N, Medina D, Settembre C, Gavina M, Pulze L, 
Giardino I, Pettoello-Mantovani M, D'Apolito M, Guido S, Masliah E, Spencer B, Quaratino S, Raia 
V, Ballabio A, Maiuri L. Defective CFTR induces aggresome formation and lung inflammation in 
cystic fibrosis through ROS-mediated autophagy inhibition. Nat Cell Biol. 2010 Sep;12(9):863-75. 
doi: 10.1038/ncb2090. Epub 2010 Aug 15. 
Luciani A, Sirac C, Terryn S, Javaugue V, Prange JA, Bender S, Bonaud A, Cogné M, Aucouturier P, 
Ronco P, Bridoux F, Devuyst O: Impaired Lysosomal Function Underlies Monoclonal Light Chain-
Associated Renal Fanconi Syndrome. J Am Soc Nephrol 27:2049-2061, 2016. 
Manoli I, Sysol JR, Li L, Houillier P, Garone C, Wang C, Zerfas PM, Cusmano-Ozog K, Young S, 
Trivedi NS, Cheng J, Sloan JL, Chandler RJ, Abu-Asab M, Tsokos M, Elkahloun AG, Rosen S, Enns 
GM, Berry GT, Hoffmann V, DiMauro S, Schnermann J, Venditti CP. Targeting proximal tubule 
mitochondrial dysfunction attenuates the renal disease of methylmalonic acidemia. Proc Natl Acad Sci 
U S A. 2013 Aug 13;110(33):13552-7. doi: 10.1073/pnas.1302764110. Epub 2013 Jul 29. 
McWilliams TG, Muqit MM. PINK1 and Parkin: emerging themes in mitochondrial homeostasis. Curr 
Opin Cell Biol. 2017 Apr;45:83-91. doi: 10.1016/j.ceb.2017.03.013. Epub 2017 Apr 22. 
Ni HM, Williams JA, Ding WX. Mitochondrial dynamics and mitochondrial quality control. Redox 
Biol. 2015;4:6-13. doi: 10.1016/j.redox.2014.11.006. Epub 2014 Nov 20. Review. 
Nunnari J, Suomalainen A. Mitochondria: in sickness and in health. Cell. 2012 Mar 16;148(6):1145-
59. doi: 10.1016/j.cell.2012.02.035. 
90 
Oberholzer VG, Levin B, Burgess EA, Young WF (1967). Methylmalonicaciduria. An inborn error of 
metabolism leading to chronic metabolic acidosis.Arch Dis Child. 42(225): 492-504. 
Park J, Kim SY, Cha GH, Lee SB, Kim S, Chung J. Drosophila DJ-1 mutants show oxidative stress-
sensitive locomotive dysfunction. Gene. 2005 Nov 21;361:133-9. Epub 2005 Oct 3. 
Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids 
Res. 2001 May 1;29(9):e45. 
Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. 
Neuron. 2015 Jan 21;85(2):257-73. doi: 10.1016/j.neuron.2014.12.007. 
Raggi C, Luciani A, Nevo N, Antignac C, Terryn S, Devuyst O: Dedifferentiation and aberrations of 
the endolysosomal compartment characterize the early stage of nephropathic cystinosis. Hum Mol 
Genet 23:2266-2278, 2014. 
Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. 
Methods Mol Biol. 2000;132:365-86. 
Ruppert T, Schumann A, Gröne HJ, Okun JG, Kölker S, Morath MA, Sauer SW. Molecular and 
biochemical alterations in tubular epithelial cells of patients with isolated methylmalonic aciduria. 
Hum Mol Genet. 2015 Dec 15;24(24):7049-59. doi: 10.1093/hmg/ddv405. Epub 2015 Sep 29. 
Rutledge SL, Geraghty M, Mroczek E, Rosenblatt D, Kohout E: Tubulointerstitial nephritis in 
methylmalonic acidemia. Pediatr Nephrol 7:81-82, 1993. 
Stolz A, Ernst A, Dikic I. Cargo recognition and trafficking in selective autophagy. Nat Cell Biol. 
2014 Jun;16(6):495-501. doi: 10.1038/ncb2979. 
Twig G, Elorza A, Molina AJ, Mohamed H, Wikstrom JD, Walzer G, Stiles L, Haigh SE, Katz S, Las 
G, Alroy J, Wu M, Py BF, Yuan J, Deeney JT, Corkey BE, Shirihai OS. Fission and selective fusion 
govern mitochondrial segregation and elimination by autophagy. EMBO J. 2008 Jan 23;27(2):433-46. 
doi: 10.1038/sj.emboj.7601963. Epub 2008 Jan 17. 
Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Ali Z, Del Turco D, 
Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, González-Maldonado R, Deller T, Salvi S, 
Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, Wood NW. Hereditary 
early-onset Parkinson's disease caused by mutations in PINK1. Science. 2004 May 
21;304(5674):1158-60. Epub 2004 Apr 15. 
91 
Viau A, El Karoui K, Laouari D, Burtin M, Nguyen C, Mori K, Pillebout E, Berger T, Mak TW, 
Knebelmann B, Friedlander G, Barasch J, Terzi F. Lipocalin 2 is essential for chronic kidney disease 
progression in mice and humans. J Clin Invest. 2010 Nov;120(11):4065-76. doi: 10.1172/JCI42004. 
Wang X, Winter D, Ashrafi G, Schlehe J, Wong YL, Selkoe D, Rice S, Steen J, LaVoie MJ, Schwarz 
TL: PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial 
motility. Cell 1474:893-906, 2011 
Yamamoto T, Takabatake Y, Kimura T, Takahashi A, Namba T, Matsuda J, Minami S, Kaimori JY, 
Matsui I, Kitamura H, Matsusaka T, Niimura F, Yanagita M, Isaka Y, Rakugi H. Time-dependent 
dysregulation of autophagy: Implications in aging and mitochondrial homeostasis in the kidney 
proximal tubule. Autophagy. 2016 May 3;12(5):801-13. doi: 10.1080/15548627.2016.1159376. Epub 
2016 Mar 17. 
Youle RJ, van der Bliek AM: Science337:1062-1065, 2012 
Zsengellér ZK, Aljinovic N, Teot LA, Korson M, Rodig N, Sloan JL, Venditti CP, Berry GT, Rosen S: 
Methylmalonic acidemia: a megamitochondrial disorder affecting the kidney. Pediatr Nephrol 
29:2139-46, 2014. 
  
92 
6. Supplementary tables 
Suppl. Table 1. Human primer pairs for gene expression analysis. 
Gene name Forward primer (5’-3’) Reverse primer (5’-3’) PCR products (bps) Efficiency 
GAPDH GGGGCTCTCCAGAACATCAT TCTAGACGGCAGGTCAGGT 162 0.99 ± 0.02 
MUT CAATGGCAGCAGTATTTGGA GATCAGCCACTTTGGGAATC 150 0.99 ± 0.03 
NPHS2 TGGGGAATCAAAGTGGAGAG CCTCAGGGACTCAGAAGCAG 153 1.01 ± 0.03 
AQP1 GGACACCTCCTGGCTATTGA GGCCAGGATGAAGTCGTAGA 162 1.02 ± 0.02 
AQP2 GAAGCTCTTCCTGACACTG TAGAGCAGCCGGTGTAATGG 149 1.03 ± 0.03 
KCNJ1 CCAAGTCCGGACATCCTATG CAGTGAGGGGTCTCCACTTC 141 0.99 ± 0.02 
SLC38A3 AAGGACCCCTCCAAGAAGAA TCCACCTTGCTGTAGGTGTG 149 0.98 ± 0.03 
UMOD CGAGTGTCACCTGGCGTAC TGTGCTCCAGGAGGGAGATA 155 1.02 ± 0.03 
SQSTM1 TGTGGGGAAGATTCTTGGAC AGTGGGCATATTTGGGGTCT 152 1.01 ± 0.03 
PCNA ACGTCTCTTTGGTGCAGCTC GCGTTATCTTCGGCCCTTAG 157 0.97 ± 0.03 
 
Suppl. Table 2. Mouse primer pairs for gene expression analysis. 
Gene name Forward primer (5’-3’) Reverse primer (5’-3’) PCR products (bps) Efficiency 
Gapdh TGCACCACCAACTGCTTAGC GGATGCAGGGATGATGTTCT 176 1.04 ± 0.03 
Pink1 ATATGCTGCCCCCACACTAC CAACTGCAAGGTCATCATGG 149 1.02 ± 0.04 
Park2 TTGACACGAGTGGACCTGAG GGGCCTTTGCAGTAGATGAA 152 0.98 ± 0.03 
Npsh2 GTCTAGCCCATGTGTCCAAA CCACTTTGATGCCCCAAATA 162 1.03 ± 0.03 
Slc12a3 CATGGTCTCCTTTGCCAACT TGCCAAAGAAGCTACCATCA 148 1.01 ± 0.03 
Slc12a1 CCGTGGCCTACATAGGTGTT GGCTCGTGTTGACATCTTGA 154 0.99 ± 0.04 
Aqp2 TCACTGGGTCTTCTGGATCG CGTTCCTCCCAGTCAGTGT 147 1.03 ± 0.04 
Slc5a2 TTGGGCATCACCATGATTTA GCTCCCAGGTATTTGTCGAA 164 1.01 ± 0.03 
Slc38a3 GTTATCTTCGCCCCCAACAT TGGGCATGATTCGGAAGTAG 109 0.99 ± 0.02 
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7. Supplementary Figures  
 
Fig. S1. Tissue expression of MUT in mouse and human. (A) Gene (Mut) and (B) protein (MUT) expression in different whole 
tissue lysates obtained from mouse by RT-qPCR and immunoblotting analyses. The graphs represent mean ± SEM, n=4. The gels 
were stained overnight with Protoblue. Data are normalized to those obtained from liver. (C) Expression profile of MUT in human 
tissues using RT-qPCR. The graphs represent mean ± SEM. (D) Protein levels of MUT in human tissues ((C), (D) (Data compiled 
from the Human Protein Atlas (www.proteinatlas.org).)). 
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Fig. S2. Segmental expression of MUT in mouse kidney. (A) Expression profile of Mut in kidney segments by using RT-qPCR. 
Segment specific markers (e.g. Nphs2 for glomerulus (GLOM); Scl5a2 or Slc38a3 for proximal convoluted (PCT) or proximal straight 
tubule (PST), respectively; Slc12a1 for thick ascending limb (TAL); Slc12a3 for distal convoluted tubule (DCT) and Aqp2 for 
collecting duct (CD)) were used to score the purity of each tubule segment fractions. The graphs represent mean ± SEM, n=4. (B) 
Representative confocal micrographs of MUT in LTL (green, left)-positive proximal tubules or uromodulin-positive thick ascending 
limb (green, middle) or in aquaporinn-2 positive collecting duct segments (green, right panel) of mouse kidneys. The nuclei 
counterstained with DAPI (blue). Scale bars, 30µm. (C) Distribution of MUT in various tubular segments of the human kidney. (Data 
compiled from the Human Protein Atlas (www.proteinatlas.org).) 
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Fig. S3. Characterization of renal tubular cells derived from control and MMA patients. (A) Gene expression profile of MUT, 
NPSH2, AQP1, SLC83A3, UMOD, KCNJ1 and AQP2 in control and MMA patient-derived cells by RT-qPCR. (B) Western blotting 
and densitometric analyses of AQP1, UMOD and AQP2 protein levels in control and MMA cells. β-actin was used as a loading 
control. (C) Morphology of control and MMA cells was assessed by phase-contrast microscopy. Scale bar, 200 μm (D) Cellular 
viability and (E) PCNA gene expression of control and MMA cells monitored by Cell Counting Kit-8 assay and by RT-qPCR, 
respectively. Mean ± SEM; n=3, ns, not significant. 
 
 
  
96 
 
Fig. S4. Mitochondrial respiration is impaired in renal tubular cells derived from MMA patients. (A) Averaged values of 
different domains of mitochondrial function in control and MMA patientderived renal tubular cells. Bars are mean ± SEM. 
***P<0.001, n=6 measurements per condition. (B) E t Extracellular acidification rates (ECAR) were measured in real time in control 
and MMA cells. The graphs represent mean ± SEM, n=6 measurements per each condition. 
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Fig. S5. Autophagosome-lysosome fusion and lysosomal degradation capacity are not altered in renal tubular cells from MMA 
patients. (A) The cells were transduced with GFP/mMAP1LC3B bearing adenoviral particles and cultured in presence of BfnA1 (50 
nM for 1h), fixed and immunostained with anti-LAMP1 antibody, and analysed by confocal microscopy. Yellow indicates the 
colocalization. Nuclei are counterstained with DAPI (blue). Scale bar, 10µm. (B) Western blotting and densitometric analyses of 
LAMP2, Cathepsin-D and RAB7 protein levels in control and MMA cells. β-actin was used as a loading control. **P<0.01 relative to 
control cells (n=3); ns, not significant. (C) The cells were loaded with MR-CtsB peptide (1mM, for 1h), fixed and analysed by 
confocal microscopy. Quantifications of MR-CtsB structures (n=30 randomly selected cells, each point representing the average 
number of in a cell; graphs represent mean ± SEM (n=3; ns, not significant). Nuclei are counterstained with DAPI (blue). Scale bar, 
10µm. 
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Fig. S6. Autophagy is dysregulated in renal tubular cells derived from MMA patients. (A) Representative confocal micrographs 
(left) and quantification of numbers of p62 structures (red) in MMA and control cells (n=30 cells pooled from three control and MMA 
cells; each point representing the average number of p62+ structures in a cell; graphs represent mean ± SEM). ***P<0.001 relative to 
control cells. Scale bar, 10 µm. (B) The mRNA levels of Sqstm1 were analysed by real-time PCR in controls (n=3) and in MMAcells 
(n=3). Bars are mean ± SEM. ns, not significant. 
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Fig. S7. Damaged mitochondria and mitochondrial oxidative stress in control cells exposed to Rotenone. (A-B) The cells were 
cultured in presence or in absence of Rotenone (10mM for 16 h). (A) The cells were loaded with tetramethylrhodamine methyl ester 
(TMRM; 50nM for 30 min) and analysed by live confocal microscopy. Quantifications of TMRM fluorescence intensity obtained 
from 3 randomly selected fields per condition, with each containing ~10-15 cells. ***P<0.01 relative to untreatedcontrol cells. (B) 
Cells were loaded with CellROX (cellular ROS probe; 5 mM for 10 min) and MitoSOX (mitochondrial ROS probe; 2.5 mM for 10 
min) and analysed by live confocal microscopy. Quantifications of CellROX or MitoSOX fluorescence intensity was obtained from 3 
randomly selected fields per condition, with each containing ~10-15 cells. **P<0.01 relative to untreated control cells. 
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Fig.S8. The mRNA levels of Mut, Pink1 and Park2 were analysed by real-time PCR. The graphs represent mean ± SEM. (n=4 
independent experiments). (A) Gene expression in control vs. MMA patient-derived cells; ns, not significant. (B) Gene expression in 
Empty vs. Mut-deleted mPTC. #P=5,52×10-6 relative to cells transduced with empty adenoviral particles. 
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V. DISCUSSION AND PERSPECTIVES 
This thesis investigated the influence of MUT deficiency leading to MMA and its impact on renal 
disease using a multi-level approach based on in vitro and in vivo models of human (renal tubular 
epithelial cell lines, kidney tissue) and murine (Mutki/ko mouse model, mPTC cells from the Mutflox/flox 
mouse model) origin. Our data indicate the mitochondrion as key disease-driving organelle in MMA. 
Due to defective PINK1/parkin-mediated mitophagy, the autophagic removal of dysfunctional 
mitochondria is impaired. This results in accumulation of autophagic products and mitochondrial ROS 
causing cellular damage. Mitochondria-targeted anti-oxidant treatment restored mitochondrial integrity 
and homeostasis, rescued the mitophagy machinery and promoted clearance of dysfunctional 
mitochondria by autophagic degradation thus revising the cellular damage process. The data provide 
the mechanism linking mitochondrial dysfunction and renal epithelial cell damage and highlight the 
importance of PINK1/parkin-mediated clearance for mitochondrial degradation and renal epithelial 
homeostasis. Targeted mitochondrial treatment with anti-oxidant provides a novel strategy to treat 
renal tubular dysfunction in mitochondrial disorders such as MMA. 
The epithelial cells lining the kidney tubules are particularly active in terms of active transport. 
Primarily the PT (Hall, 2013) and TAL (Emma, 2016) segments are involved in the reabsorption of 
essential nutrients and solutes and therefore need mitochondria to provide energy for ATP-consuming 
transport-mechanisms mainly provided by the basolateral Na+/K+-ATP-ase. Mitochondria are not only 
extremly vulnerable to ROS, but also a main source of ROS production. Un-balanced mitochondrial 
ROS levels will have a direct negative influence on renal cellular and kidney function. 
Recent studies have shown that MMA leads to deficiency of the respiratory chain (Morath, 2008) and 
highly elevated ROS levels (Manoli, 2013) point at mitochondrial dysfunction to be involved in the 
onset and progression of kidney disease in MMA (Manoli, 2013). Patients present with renal tubular 
dysfunction and finally develop CKD due to tubulointerstitial lesions as evidenced by bioptic 
investigations (Haarmann, 2013). MUT is expressed in every tissue and organ, but the kidney is -
besides the brain- the only organ suffering from early and chronic long-term complications. Hardly 
any organ specific studies have been conducted so far for a lack of appropriate models and tools. The 
investigation of tissue specific alterations caused by MUT deficiency in novel in vitro but also in vivo 
models is challenging and crucial to unravel disease associated mechanisms. This might lead to a 
better understanding of the underlying pathomechanisms causing CKD in MMA and reveal new 
treatment options. 
In the first part of the thesis we illustrated the long-term follow up of a patient suffering from a 
vitamin B12 responsive CblA type MMA-uria due to the relatively common p.R145X nonsense 
mutation. Despite metabolic stability and normal development and growth, the patient developed CKD 
at the age of 12 years. She was re-tested at this time for vitamin B12 responsiveness. Of note, kidney 
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function could be stabilized by the administration of vitamin B12 for a period of 17 years before she 
had to undergo renal replacement therapy and finally kidney transplantation. This study highlights the 
importance of early and adequate vitamin B12 supplementation in responsive patients and underlines, 
that renal failure is the consequence even in relatively mild forms of MMA with excellent metabolic 
stability. 
High concentrations of methylmalonic acid in the urine are a known risk factor for early and rapid 
development of CKD in MMA (Hörster, 2007). Regular application of high doses of vitamin B12 were 
able to reduce significantly the urinary excretion of MMA in our patient and probably prolonged the 
progression from CKD III to end stage renal disease for 17 years. After renal transplantation, plasma 
and urinary methylmalonic acid levels dropped pointing at the high MUT activity of ~20% provided 
by the transplanted kidney (van Calcar, 1998; Morath, 2008).  
Several kidney biopsies were performed showing impressive tubular atrophy and interstitial fibrosis 
interspersed with mononuclear infiltrates. Despite the biopsies reflect different states of renal 
insufficiency in the patient’s kidney, no MMA specific pattern could be detected, which fits well to 
previous reports (Lubrano, 2007). 6 years after kidney transplantation the graft biopsy did not reveal 
any striking abnormalities or hints at a relapse of kidney disease. 
However, organ transplantation in MMA has to be interpreted with care: The limited amount of 
transplantations (kidney, liver or combined liver kidney) conducted were performed in a 
phenotypically highly heterogeneous group, most of them suffering from a mut(0) defect (Kaplan, 
2006; Brassier, 2013; Kashahara, 2006). Although organ transplantation was able to improve 
metabolic stability in some patients, others were facing severe metabolic crisis, metabolic-stroke like 
episodes and death. A Japanese group (Sakamoto, 2016) recently underlined the importance of liver 
transplantation for metabolic stability in a cohort of MMA patients for growth and metabolic stability 
but clearly states that transplantation is neither a cure nor allows following a normal diet. The kidney 
seems to play a key role in the context of MMA: Patients receiving a kidney or a combined kidney 
liver transplant had lower levels of MMA and a better metabolic stability (Brassier, 2013; Kashahara, 
2006) than compared to liver only transplanted patients. 
In conclusion, the long-term follow up clearly underlines that CKD is a long-term consequence even 
in (almost) optimal metabolic conditions with only few and mild metabolic derailments. Vitamin B12 
treatment significantly lowered MMA levels and CKD progression and should therefore be carefully 
evaluated in every MMA patient. Organ transplantation and kidney transplantation in particular can 
give metabolic stability but does not cure MMA nor solve the dietary issue.  
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For this reason, it is obvious that an in-depth investigation of the causal pathophysiology of CKD is 
crucial for a better understanding of mechanisms induced by MMA. This might in the long run lead to 
novel, more targeted treatment options. 
In the second part of the thesis we investigated the subcellular changes leading to renal cellular 
damage in MMA in vitro and traced back key findings in the novel Mutki/ko mouse model and a human 
kidney biopsy in vivo. The aim was to provide multilevel evidence that disruption of the MUT gene is 
associated with changes in the dynamic equilibrium of renal mitochondrial metabolism and the 
pathway leading to epithelial damage. We showed in different in vitro (human renal tubular epithelial 
cell lines, Cre mediated Mut deletion in mPTC from Mutflox/flox mice) and in vivo (Mutki/ko mouse 
model, human kidney biopsy) systems that mitochondria are fragmented and dysfunctional in models 
lacking functional MUT. Dysregulation of the PINK1/parkin pathway causes impaired autophagic 
clearance of defective mitochondria resulting in increased autophagic flux with accumulation of 
autophagic products. Even after challenge with the mitochondrial toxin Rotenone the PINK1/parkin 
pathway remained down-regulated, indicating a defective mitochondrial targeting mechanism in 
MMA. Elevated markers for kidney damage suggested that these changes might be causal for CKD 
pointing at the importance of mitochondrial homeostasis in the pathogenesis of cellular damage in 
MMA. Cre mediated Mut deletion in mPTC from the Mutflox/flox mouse model was able to reproduce 
the observed findings underlining the importance of MUT activity for mitochondrial homeostasis. 
Treatment of human renal epithelial cells with mitochondria-targeted anti-oxidant therapy had a 
beneficial effect on the observed events. These results shed new light on the mechanisms leading to 
CKD in MMA and indicate that targeting mitochondrial ROS production restores mitochondrial 
homeostasis and reduces kidney damage. 
MUT is expressed in all human tissues (Uhlén, 2015). Highest MUT activity is detected in the liver 
and the kidney followed by heart and brain (Wilkemeyer, 1997). Expression studies in female wild 
type mice of C57BL/6 background confirmed this data rendering mice a suitable model for in vivo 
studies. Microdissection of Mutwt/wt mouse kidneys revealed that MUT is expressed in all kidney 
segments with exception of the glomerulus. MUT deficiency might therefore not only affect specific 
kidney sections but the kidney as an entire organ. 
To investigate the role of MUT and the impact of MUT deficiency on a subcellular, tissue specific 
level, we characterized immortalized cell lines derived from the urine of healthy controls and MMA 
patients harboring a Mut(0) mutation (Ruppert T, 2015). While expression of kidney specific markers 
of all tubular segments were comparably high in all cell lines, MUT activity was significantly reduced 
in MMA cells, rendering the cell lines a robust model.  
MUT is a mitochondrial enzyme as indicated by its mitochondrial target-sequence (Fenton, 1982). 
Due to its energetic needs the kidney is rich in mitochondria which lead us to closely investigate this 
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organelle in the context of MMA. Our findings revealed remarkable alterations of mitochondrial 
morphology and function: MUT deficiency leads to decreased numbers of swollen, fragmented 
mitochondria with severe defects of their christae structure. Energetic profiling revealed a reduction of 
mitochondrial membrane potential as well as a reduction of baseline respiration, total respiration 
capacity and ATP turnover. The findings were paralleled by massive elevation of mitochondrial 
oxidative stress levels and renal epithelial damage in both MMA in vitro models. The findings could 
be confirmed in kidneys of the novel Mutki/ko mouse model (Forny, 2016). These results are in line with 
Manoli et al. describing ultrastructural changes and respiratory chain dysfunction in a Mutko/ko mouse 
model rescued from neonatal lethality by transgene expression in the liver (Manoli, 2013). Morath et 
al. (Morath, 2008) summarize the inhibition of mitochondrial energy metabolism by metabolites of 
alternative propionate oxidation leading to ROS generation in different in vitro settings and MMA 
patients’ fibroblasts. These findings highlighted the mitochondrium as key organelle in promoting 
cellular damage in MMA. The mechanisms by which MUT deficiency disturbes mitochondrial 
homeostasis and how mitochondrial dysfunction is linked to cellular damage, remained, however, 
unclear. 
Mitochondria are highly dynamic and metabolically active organelles. In renal tubular cells 
performing intense reabsorption and excretion processes at high energy costs, intact mitochondrial 
function is crucial for the maintenance of cellular health (Emma, 2016). Excess production of ROS 
leads to cellular dysfunction and tissue damage. Mitochondria themselves are a source of excessive 
ROS production as a side product of oxidative phosphorylation along the respiratory chain (Sena LA, 
2012). To maintain mitochondrial integrity and homeostasis, MQC by the tightly inter-connected 
processes autophagy and mitophagy is essential (Ni, 2015; Kotiadis, 2014). Particularly in the kidney 
activation of autophagy has been associated with renal protective mechanisms, while pharmacological 
or genetic deletion of important autophagic proteins induced elevated ROS levels and cellular damage 
(Liu, 2014; Yamamoto, 2016). 
In a next step, we investigated MQC and tested whether MUT deficiency leads to induction of altered 
autophagic flux in our different MMA models. Up-regulation of the autophagy machinery, evidenced 
by elevated levels of the autophagic proteins p62 and LC3-II going in hand with vast amounts of p62 
and LC3-II positive vesicles could be detected in all in vitro and in vivo models. These findings were 
sustained by excessive accumulation of autophagic vacuole formation documented by EM 
investigation. Activation of the autophagy machinery has recently been described as a renal-protective 
mechanism in acute kidney injury by different groups (Isaka, 2011; Liu, 2014). 
Autophagy is a tightly orchestrated process and accumulation of autophagic proteins can be induced at 
any step down-stream towards lysosomal degradation: Autophagosome formation and trafficking can 
be impaired as well as autolysosomal fusion or lysosomal degradation. Defective autolysosomal 
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fusion, e.g., is a hallmark of many lysosomal storage diseases (Ballabio, 2009). We tested this 
hypothesis by treating MMA cells with Bafilomycin (BfnAI), a drug accurately measuring autophagic 
flux (Bento, 2016). BfnAI treatment increased the levels of LC3-II in both control and MMA cells. 
Co-localization with the lysosomal marker LAMP-1 suggested undisturbed delivery of LC-3 positive 
cargo to the lysosome releaving that autolysosomal fusion is not compromised in MMA cells. The 
results pointed at either increased autophagosome synthesis or decreased lysosomal degradation 
capacity. The latter hypothesis could be ruled out since the lysosomal proteins LAMP2 and cathepsin 
D (CtsD) were present in equal amounts as compared to control cells and lysosomal activity measured 
by fluorescent tagged Pepstatin A binding active CtsD was comparably high in both groups. The fact 
that BfnAI treatment increased LC3-II levels in control and MMA cells strongly supports the 
hypothesis, that MUT deficiency indeed induces autophagosome synthesis rather than their clearance. 
Autophagy plays a key role in cellular stress response. Increased LC3 fluxes in the MUT deficient 
models suffering from mitochondrial dysfunction underline the hypothesis that autophagy is crucial to 
counter-act stressful conditions. The accumulation of dysfunctional mitochondria and their toxic 
byproducts leads to potentiation of cellular stress and further impairment of cellular function (Twig, 
2008). The selective removal of dysfunctional mitochondria (=mitophagy) is mediated by molecular 
mechanisms detecting potentially dangerous cargo and converting them into signals which lead to 
initiation of autophagic degradation. A well-described pathway for mammalian mitophagy is governed 
by the kinase PINK1 and the E3 ubiquitin ligase parkin whose close interaction allows the sensing and 
removal of dysfunctional mitochondria (Valente, 2004; Kitada, 1998). The importance of PINK1 and 
parkin for mitochondrial integrity and homeostasis is underlined by the fact that loss of either protein 
leads to mitochondrial dysfunction inducing muscular and neuronal dysfunction in drosophila models 
(Greene, 2003; Park, 2005). In healthy mitochondria, PINK1 is constantly cleaved from the OMM and 
degraded by several proteases (Greene, 2012). In stressful conditions leading to a loss of 
mitochondrial membrane potential, PINK1 is not longer processed but accumulates on the OMM 
recruiting parkin. This step allows the attachment of ubiquitin tags which label dysfunctional 
mitochondria for autophagic degradation (Valente, 2004). Rotenone is a well-known mitochondrial 
toxin inducing mitochondrial membrane depalorization. Treatment with Rotenone allowed us to track 
mitophagy events and concomitant autophagic sequestration. Indeed, Rotenone treatment led to 
accumulation of full length PINK1 on the OMM of dysfunctional mitochondria (counter-stained by 
TOMM20) and initiated autophagosomal degradation (as shown by co-localization of defective 
mitochondria (TOMM20) and LC-3 positive autophagosomes) in control cells. MMA cells were 
unable to react comparably to the rotenone stimulus depicting a lack of PINK1 and parkin already at 
baseline conditions and absence of PINK1 recruitment to the OMM after the rotenone challenge. 
Consequently, mitochondria of MUT-deficient models are not correctely labelled for autophagic 
degradation despite abundant expression of p62, a stress induced ubiquitin binding protein involved in 
the process of autophagosomal degradation (Cohen-Kaplan, 2016). Deficiency of the mitophagy 
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machinery might thus explain the defective clearance of dysfunctional mitochodnria and explain 
excessive accumulation of autophagic products. 
Elevated levels of kidney damage markers (LCN2, KIM1) and disturbed renal function in the Mutki/ko 
mouse model suggest a link between disturbed mitochondrial integrity and renal damage in MMA. 
Bueno et al (Bueno, 2014) recently related deficiency of PINK1/parkin mediated mitophagy and 
mitochondrial dysfunction to tissue damage and fibrosis induction in a pulmonary fibrosis model. 
Tubulointerstitial lesions transiting to fibrosis are frequently found in MMA patients’ kidney biopsies 
underlining the importance of that finding (Rutledge, 1993; Goyenechea, 2012). 
The question arising from the previous findings was whether the observed alterations in vitro and in 
vivo are related to MMA caused by monogenic MUT deficiency. To address this point, we performed 
Cre mediated Mut deletion of mPTC derived from a Mutflox/flox model. Cre mediated Mut deletion 
reproduced all observed findings including substantial changes of mitochondrial integrity and 
homeostasis, deficiency of the mitophagy machinery, accumulation of autophagic marker proteins and 
elevation of markers of kidney damage. These findings emphasize the role of MUT activity for 
mitochondrial homeostasis and link ROS and activation of autophagy to renal tubular damage. 
Elevation of LCN2 in the context of MUT deficiency plays a key role, since elevated LCN2 levels 
have been identified to play a disease driving role in CKD in mice and humans (El Karoui K, 2016; 
Viau, 2010). 
Our findings suggested excessively elevated ROS levels to be a major complication in all MMA 
models. ROS is a well-known inducer of cellular and tissue damage. This is why we applied targeted 
anti-oxidant treatment with MitoTEMPO (MT) to control and MMA patients cell lines. Because of 
covalent binding of a lipophilic cation (triphenylphosphonium) to endogenous anti-oxidant CoQ10 the 
drug accumulates preferentially in the mitochondria, where it exerts a direct anti-oxidant reaction by 
neutralizing peroxyl, peroxynitrites and superoxide. Taking advantage of its oral bioavailability and 
targeted anti-oxidant effects, the efficiacy of MT treatment has been demonstrated in different disease 
models associated with excessive ROS production such as sepsis models, neurodegenerative disease 
and ischemia reperfusion injury (Jin, 2014). 
MT treatment rescued mitochondrial morphology and function, restored mitochondrial mass levels and 
increased the ratio of uncleaved vs. cleaved PINK1 in MMA cells, allowing autophagic degradation as 
evidenced by reduced levels of autophagic proteins. Finally, LCN2 levels were markedly reduced in 
MMA cells pointing at a beneficial effect for cellular damage in treatment conditions. Altough MT 
treatment provided promising results in restoring mitochondrial homeostasis and cellular function 
further studies in animal models are necessary before translating these findings to the patient. 
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To conclude, MMA inevitably leads to CKD and end stage renal disease despite optimal metabolic 
management and cofactor supplementation, which is a major burden and live-time risk on all MMA 
patients. We identified in a multi-level approach the mitochondrion to be the key disease driving 
organelle in MMA. Mitochondrial integrity is severely hampered due to MUT deficiency. MQC is 
defective in MMA, as indicated by a highly active autophagy but deficient mitophagy machinery 
leading to a loss of mitochondrial homeostasis. These changes are paralleled by elevated LCN2 levels 
linking MUT deficiency to cellular and tissue damage. Targeted anti-oxidant treatment is able to 
reverse the above findings on a subcellular level highlighting the deleterious effect of excessive ROS 
production for disease progression. Further studies in vitro and in vivo will provide evidence whether 
anti-oxidant supplementation is a new therapeutic option to treat renal tubular dysfunction in MMA 
and other mitochondrial disorders.  
Inborn errors of metabolism represent a monogenic group of defects with primary and secondary 
impacts on whole body metabolism. Characterization of metabolic changes and implications on human 
health and disease therefore are challenging. Understanding of the consequence of monogenic disease 
might be fundamental to draw conclusions for multifactorial, complex diseases in a next step. 
However, most of the studies on monogenic diseases like MMA have been narrowly focussed on the 
affected pathways neglecting involved pathways and possible targetable aims up- or down-stream. A 
main goal of physicians dealing with patients suffering from rare metabolic disease is to provide them 
with therapeutic interventions significantly improving their acute and chronic complications. As 
discussed for MMA, therapeutic interventions are limited and chronic complications a severe burden 
on MMA patients. 
In this context, MMA as a monogenic disease is a prime candidate for an in-silico modeling approach. 
MMA qualifies in particular, since 1) the mitochondrial enzyme is highly expressed in the kidney, the 
most important target organ, 2) MUT does not have an impact on structural changes which might 
secondarily affect metabolic functions and 3) well-characterized in vitro and in vivo models of murine 
and human origin presented in this thesis allow a rapid and robust testing of the obtained hypothesis. 
In the aera of “omic” approaches, non-invasive investigation of human body fluids (e.g. blood, urine) 
by large sacle screening approaches (proteomics, metabolomics) can be used to confirm the relevance 
for affected individuals (Fig. 9). Algorithms to predict changes in metabolic flux and metabolites 
between controls and MUT deficient individuals will result in a ranked- list of prime candidates 
allowing for systematic and rapid evaluation as novel biomarkers or potentially targetable aims. 
Another important point is the identification of possible “by-pass” candidates whose activation might 
lead to a circumvention of the metabolic block. The efficiency and importance of in silico modeling in 
the metabolic field has recently been demonstrated by Pagliarini et al. (Pagliarini, 2016).  
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Figure 9: In silico model predicting alterations in metabolix flux caused by MUT deficiency. Loss of MUT activity is simulated in a 
computational model allowing to predict changes in metabolites and metabolix flux. Investigation of different in vitro and in vivo MMA 
models discussed in the thesis could be used for translation of the findings. Omic approaches of human body fluids will test the revevance 
of newly identified candidates. (Adapted from Pagliarini, 2016). 
 
However, understanding of complex metabolic networks might only be one piece of the puzzle leading 
to new therapeutic options. New computational tools (Mode of Action by NeTwoRk 
Analysis=MANTRA, Iorio, 2016) are capable to analyze the mode of action of novel drugs and able to 
identifiy approved candidates for “drug-repositioning”. The algorithm relies on a genome wide ranked 
expression list of genes sorted according to their expression after drug-treatment. To explore approved 
drugs to identify “repositionable-drugs” the system is ready to use. Based on our findings in this 
thesis, MANTRA could be used to predict the efficacy and possible side effects of treatment with e.g. 
autophagy inducers (e.g. Rapamycin), stimulators of mitochondrial biogenesis via PGC-1-α (fibrates, 
glitazones) or evaluate the advantages/disadvantages of targeted (MT) and un-targeted (e.g. N-
acetylcysteine) anti-oxidant treatment. Exploration of the reference-drug neighbourhood might reveal 
more favourable candidates imposing less side effects. 
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This thesis demonstrates that MUT deficiency severly impacts mitochondrial homeostasis and that 
impaired PINK1 and parkin mediated clearance of dysfunctional mitochondria generate ROS leading 
to tubular cell damage. Targeting ROS to ameliorate kidney damage is the logical consequence. The 
advantage of targeting ROS is the fact that a large variety of different compounds acting at different 
aims (lipid membrane, cystosol, glutathione system, mitochondria) is already available on the market 
and FDA-approved (e.g. vitamin E, N-acetylycsteine, allopurinol, CoQ10) (Fig. 10, Small, 2012). 
However, the systemic effects as well as the advantages of targeted vs. untargeted treatment in the 
context of MMA have never been studied. The Mutki/ko mouse model characterized by a renal 
phenotype will serve as a valid model to invatigate the effect of anti-oxidant treatment on kidney 
function in a next step before translation to bedside. 
 
Figure 10: Cellular sites of ROS reduction mediated by different anti-oxidant compounds. Vitamin E acts on phospholipid bilayers. 
Allopurinol inhibits xanthine oxidase to reduce ROS production. N-acetylcysteine (NAC) acts on glutathione metabolism and CoQ10 
enhances respiratory chian activity. (Adapted from Small, 2012). 
 
However, studies in mice bear the disadvantage that breeding is costly and generation time is long 
compared to other models. The zebrafish has recently become a promising vertebrate disease model 
for phenotype based drug screening. Its genome shares 82% of human disease-causing proteins 
rendering the fish a suitable model organism. A reliable MMA zebrafish-model reproducing all 
metabolic hallmarks of MMA has recently been generated in the Devuyst group. The big advantage of 
the zebrafish would be that the assay output would provide a whole organism phenotype integrating 
multiple biochemical pathways. Unlike worms or flies, the zebrafish possesses organ systems 
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comparable to man (e.g. kidney) and organ function could be a direct read out. Phenotypic screens 
provide i) discovery of drugs in the absence of a validated target, ii) identification of compounds 
producing effects through activation of multiple targets and iii) identification of beneficial and 
unpleasant side effects in the same screen. The findings could be immediately applied to our in vitro 
and in vivo models and later translated to the patient. 
The combination of highly focused tissue specific in vitro and in vivo studies on the one hand and 
highly predictive computational in silico models in combination with large-scale screening approaches 
will add substantial information to the understanding of MMA and its involvement in CKD onset and 
progression and might provide new therapeutic options. 
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